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ABSTRACT 
THE ROLE OF O-GlcNAc SIGNALING IN ACUTE MYOCARDIAL 
ISCHEMIA 
Gladys Afor Ngoh 
October 21, 2009 
O-linked ~-N-acetylglucosamine (O-GlcNAc) is an inducible, dynamically cycling, 
and reversible post-translational modification of serine/threonine amino acid 
residues of nucleocytoplasmic and mitochondrial proteins. O-GlcNAc transferase 
(OGT) adds, while O-GlcNAcase (GCA) removes O-GlcNAc from proteins. 
Albeit being a recruitable stress-induced signal in other tissues, the role of 0-
GlcNAc in the heart is unknown. Therefore, we hypothesized that O-GlcNAc is 
recruited in the heart during acute stress, and enhanced O-GlcNAc is 
cardioprotective. Subjecting neonatal rat cardiac myocytes (NRCMs) to hypoxia, 
or mice to myocardial ischemia reduced O-GlcNAc signaling. Augmented 0-
GlcNAc signaling attenuated, while diminished O-GlcNAc signaling exacerbated 
post-hypoxic cardiomyocyte death. To determine how O-GlcNAc protects, we 
identified numerous proteins including voltage dependent anionic channel 
(VDAC) to be O-GlcNAc-modified via mass spectrometry and 
immunoprecipitation. Since VDAC is a putative member of the mitochondrial 
VlI 
permeability transition pore (mPTP), we hypothesized that one mechanism of 0-
GlcNAc-mediated cardioprotection is by blocking mPTP formation. We 
ascertained if O-GlcNAc signaling affects key players in ischemic/hypoxic injury, 
Ca2+ overload and oxidative stress, both inducers of mPTP. Enhanced 0-
GlcNAc significantly mitigated, while, reduced O-GlcNAc aggravated post-
hypoxic Ca2+ overload and ROS generation. Furthermore, augmented 0-
GlcNAc reduced, while, diminished O-GlcNAc sensitized mitochondria to mPTP 
formation according to Ca2+-induced swelling. Since mPTP formation induces 
loss of mitochondrial membrane potential (Lll.jJm) , we evaluated whether 0-
GlcNAc signaling affects post-hypoxic Lll.jJm recovery. Enhanced O-GlcNAc 
significantly improved, while reduced O-GlcNAc minimized post-hypoxic Lll.jJm 
recovery. Because ER stress contributes to ischemia-reperfusion injury, we 
evaluated whether inhibiting maladaptive ER stress reponse maybe another 
mechanism through which O-GlcNAc signaling cardioprotects. Indeed, 
augmented O-GlcNAc reduced maladaptive ER stress response according to 
diminished CHOP levels and PI positivity. To determine if such in vitro protection 
could be translated in vivo, we augmented O-GlcNAc levels (with PUGNAc) in 
adult, wild-type C57BL6 mice, subjected them to 40 minutes of left anterior 
descending coronary artery ligation, then reperfused for 24 hours, and assessed 
infarct size. Augmented O-GlcNAc levels significantly decreased infarct size. 
We conclude that O-GlcNAc mediates cardioprotection in vitro and in vivo via 
attenuating maladaptive ER stress response and recruitment of early events in 
the mitochondrial death pathway leading to mPTP formation. 
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CHAPTER I 
INTRODUCTION 
According to the World Health Organization (WHO), ischemic heart 
disease is one of the leading causes of death worldwide, with about 3.8 million 
men and 3.4 million women dying yearly from this disease. In the United States, 
ischemic heart disease resulting from coronary artery disease is devastating, with 
1.5 million US citizens developing myocardial infarctions that account for nearly 
200,000 deaths per year (1, 2). The National Heart Lung and Blood Institute 
estimate that an average 14.2 years of life is lost due to a heart attack. 
Nine easily measured and potentially modifiable risk factors account for 
over 90% of the risk of an initial acute myocardial infarction (MI). The effect of 
these risk factors is consistent in men and women, across different geographic 
regions, and by ethnic group, making the study applicable worldwide. These 
nine risk factors include cigarette smoking, abnormal blood lipid levels, high 
blood pressure, diabetes, abdominal obesity, a lack of physical activity, low daily 
fruit and vegetable consumption, alcohol overconsumption, and psychosocial 
index (329). Extensive clinical and statistical studies by the American Heart 
Association reveal that in addition to these nine factors, aging, gender, race, and 
stress also increase the risk of developing ischemic heart disease. 
Despite prevalence of ischemic heart disease, better treatments for 
minimizing post-ischemic cardiac injury remain limited. A primary limitation to 
such advances may be our incomplete understanding of why cardiac myocytes 
die. Moreover, few ongoing efforts address the metabolic aspect of myocardial 
ischemia-reperfusion injury. The heart is an energy omnivore with energy 
requirements exceeding that of any of the body's other organs (274, 275). 
Despite its huge energy requirements, the heart has limited energy reserves and 
must therefore continually produce large amounts of ATP to sustain its function. 
In order to sustain this enormous energy demands, energy metabolism of the 
myocardium is coupled to ATP hydrolysis. It is widely accepted that alterations 
in cardiac energy substrate availability have significant effects on the energetic 
status of the heart. Therefore, it is likely that any imbalances to this tightly 
regulated system may contribute to the development and, perhaps exacerbate 
ischemic heart disease. Hence, a clear understanding of cardiac metabolism 
and its regulation under normal and pathological conditions is essential for the 
determination of how any potential treatment could be targeted in an attempt to 
alleviate the morbidities associated with ischemic heart disease. 
Finally, an ongoing debate is whether the irreversible cardiomyocyte injury 
occurs primarily during ischemia or upon reperfusion. Understanding when 
irreversible myocardial injury occurs is relevant, because this would aid in the 
development of drugs and clinically allow the administration these 
cardioprotective drugs. 
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CHAPTER II 
BACKGROUND AND LITERATURE REVIEW 
1. Acute myocardial infarction (Mil 
Commonly known as heart attack, MI is a manifestation of ischemic heart 
disease. It results from decreased or complete blockade of blood flow to the 
heart muscle. The resulting hypoxia decreases both aerobic fatty acid and 
glucose oxidation causing damage and potential death of heart tissue. Hypoxia 
reduces the oxygen supply to the myocardial cells leading to inhibition of 
oxidative reactions, diminished rate of ATP production by oxidative 
phosphorylation, modulation of protein kinase activities, and changes in the 
expression of specific genes (177). Because it is difficult to completely mimic the 
in vivo ischemic environment in isolated heart and/or cultured cardiomyocyte 
studies, hypoxia combined with procedures that inhibit aerobic glycolysis are 
frequently used, so that the main mechanical features of ischemia can be 
observed (235). 
One hallmark of MI is a reduction in myocardial oxygen supply, i.e. there is 
a mismatch between oxygen supply and demand (Figure 1). This is manifested 
in a switch of myocardial energy substrate preference from fatty acid to glucose. 
Hence, there is a shift in heart metabolism from aerobic fatty acid metabolism to 
anaerobic glycolysis, which provides energy for critical myocardial cellular 
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processes (235). This alteration in substrate utilization results in the uncoupling 
between glycolysis and glucose oxidation. In aerobic glycolysis, glucose is 
broken down to pyruvate generating ATP and NADH in glycolysis. This pyruvate 
is further converted to acetyl GoA and more reducing molecules are generated in 
a process called glucose oxidation. Acetyl GoA then enters Krebs cycle, making 
more reducing molecules (NADH and FADH2) through several enzyme catalyzed 
reactions. These reducing equivalents then enter the electron transport chain 
where they are utilized to generate electrons to reduce oxygen as well as a 
proton motive force necessary for ATP synthesis. However, in anaerobic 
metabolism, glucose oxidation is inhibited and glycolytic pyruvate is no longer 
converted to acetyl GoA. Instead glycolytic pyruvate is reduced to lactic acid 
which accumulates in the cytosol causing intracellular acidosis (99). This 
decrease in myocardial intracellular pH alters the sensitivity of contractile 
proteins and sarcoplasmic Ga2+ pump to Ga2+. Decrease in glucose oxidation 
also diminishes oxygen-dependent oxidative phosphorylation. Therefore, the 
switch in substrate preference coupled with the change in substrate availability 
inhibits mitochondrial oxidative metabolism, forcing the heart to be more 
dependent on anaerobic glycolysis for energy its energy requirement (274). 
Another consequence of myocardial ischemia is increased glucose 
utilization in cardiac tissues (235). The ischemia-mediated increase in glucose 
utilization is characterized by enhanced rates of exogenous glucose uptake in 
vivo (99, 266) due to increased GLUT 1 (26) expression, GLUT 4(281) 
translocation to the plasma membrane, and increased hexokinase activity (212). 
4 
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Because glucose transport is an essential metabolic function necessary for cell 
survival, alteration in glucose flux through the disruption of blood flow to the 
myocardium exerts profound metabolic dysfunction and intricately affects 
intracellular physiologic processes. Thus, MI may be considered an acute and 
direct metabolic insult. 
During reperfusion (or reoxygenation), cardiac myocytes are subjected to 
abrupt biochemical and metabolic changes such as mitochondrial reenergization, 
generation of reactive oxygen species, intracellular and mitochondrial Ca2+ 
overload, restoration of cellular pH and activation of inflammation due to 
immediate resumption of oxidative functions as shown in Figure 1 (245). During 
reoxygenation, damage of sarcolemmal membrane, reverse functioning Na+ -
Ca2+ exchanger, and ROS-mediated sarcoplasmic reticulum dysfunction mediate 
further Ca2+ influx into the already Ca2+ -overloaded cardiac myocytes causing 
cardiomyocyte death via hypercontracture. Moreover, restoration of 
mitochondrial membrane potential drives Ca2+ entry into the mitochondria. This, 
together with the loss of the inhibitory effects of acidic pH on mitochondrial 
permeability transition pore (mPTP) and the generation of ROS, mediate mPTP 
opening (Figure 1). Opening of mPTP causes cardiac myocyte death by 
dissipating mitochondrial membrane potential, uncoupling oxidative 
phosphorylation, and inducing mitochondrial swelling. 
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Ischemia 
Reperfusion 
Substrate switch from FA to 
Glc 
Loss of 
membrane 
Cell death 
Figure 1. Molecular events occurring during myocardial ischemia-reperfusion 
injury. During myocardial reperfusion, the ischemic myocardium is subjected to 
abrupt biochemical and metabolic changes which adds to the changes generated 
during myocardial ischemia. These changes include mitochondrial reenergization 
(j.D.ljJm), generation of reactive oxygen species (ROS), intracellular ([Ca2+]i) and 
mitochondrial ([Ca2+]m) calcium overload and the restoration of intracellular pH. 
These factors interact with each other and mediate cardiomyocyte death via 
mitochondrial permeability transition pore (mPTP) formation. mPTP formation 
results in loss of mitochondrial membrane potential (.D.ljJm), massive matrix 
swelling, outer mitochondrial membrane rupture, and the release of the apoptotic 
signaling protein, cytochrome c, all culminating in cell death. 
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1. A. What causes cardiomyocyte death following MI? 
1. A. I. Calcium Overload 
Ca2+ primarily enters cardiac myocytes through L-type Ca2+ channels. 
Once in the cell, it induces Ca2+-induced-Ca2+ release from the sarcoplasmic 
reticulum (SR). This increased intracellular calcium leads to cardiac myocyte 
contraction during systole. The Na+-Ca2+ exchanger (NCX) and sarcolemmal 
Ca2+-ATPase are responsible for removal of the cytosolic Ca2+ post contraction 
during diastole. NCX removed most of the Ca2+ that entered the myocyte via L-
type Ca2+ channels while SR/Endoplasmic Reticulum ATPase (SERCA) removes 
the Ca2+ released by the SR (18, 77). 
Ischemia causes intracellular ([Ca2+]i) and mitochondrial ([Ca2+]m) calcium 
overload (Figure 1 )(94, 143, 218, 219, 224, 244, 260, 276-278). The primary 
source of the rise in [Ca2+]j is via reverse functioning NCX. Ischemia causes 
metabolic acidosis that in turn activates the sodium-hydrogen exchanger (NHE) 
which facilitates the extrusion of H+ in exchange for Na + thus, leading to high 
intracellular Na + ([Na +]i)(219). Moreover, ischemia induces depolarization of the 
plasma membrane. Both the increased [Na+]i and the depolarization of the 
plasma membrane result in the reversal of NCX to bring Ca2+ into the myocyte. 
Studies have shown that interventions that directly (via inhibition of L-type Ca2+ 
channel or NCX) or indirectly (blocking increased [Na+]j via inhibition of NHE) 
attenuate the rise in [Ca2+]i' and reduce ischemia-reperfusion injury (37, 143, 
162, 219, 224, 308). In the mitochondria, Ca2+ uptake is via the mitochondrial 
Ca2+ uniporter and it is driven by the mitochondrial membrane potential (~ljJm). 
7 
---------.--~ 
Hence, [Ca2+]m uptake dissipates b.4Jm and unless electron transport continually 
resynthesizes this gradient, there will be no driving force for ATP synthesis in the 
mitochondria. Ca2+ is removed from the mitochondria primarily via the 
mitochondrial NCX. The rise in [Ca2+]m observed during ischemia is mainly due 
to reverse functioning mitochondrial NCX (94). In fact, blocking mitochondrial 
NCX attenuates ischemia-induced [Ca2+]m overload (94). 
During reperfusion, there is a transient early increase in [Ca2+]1 as shown 
in Figure 1. This is because the slow return of intracellular pH to normal, 
facilitates [Na+]j accumulation and subsequently [Ca2+]j increase via reverse 
functioning NCX. If cardiac myocytes are not permanently damaged, [Ca2+]j 
returns to near normal levels. But if cardiac myocytes are irreversibly damaged 
either due to dysfunction of Ca2+ handling proteins (262, 271), abnormal [Na+]j 
levels (262), or abnormal ATP levels (229), [Ca2+]j continues to rise throughout 
reperfusion. Since the reintroduction of oxygen during reperfusion, and 
resumption of oxidative metabolism regenerates b.4Jm, one might expect 
significant [Ca2+]m uptake. Indeed, studies have shown an additional rise in 
[Ca2+]m during reperfusion (94). 
1. A. II. Reactive Oxygen Species (ROS) generation 
Reactive oxygen species are a class of radical and non-radical oxygen-
containing molecules that display high reactivity with lipids, proteins and nucleic 
acids. Consequently, ROS are very unstable and highly reactive, and they tend 
to initiate chain reactions that result in irreversible chemical changes in lipids or 
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proteins. These potentially deleterious reactions can result in profound cellular 
dysfunction and even cytotoxicity. High levels of ROS can trigger cell death, 
whereas lower levels drive diverse and important cellular functions. The primary 
source of ROS in cardiac myocytes is the mitochondrial electron transport chain 
(ETC)(67, 142). Cardiac myocytes are rich in mitochondria, which in addition to 
providing the large amount of energy required to maintain cardiac output, can 
produce ROS that contribute to ischemia-reperfusion injury (183). The 
mitochondrial ETC produces ROS by the transfer of unpaired electrons from 
complex I and from ubisemiquinone of complex III to molecular oxygen (100, 
159). Also, "electron leakage" may contribute to ROS generation. It is 
estimated that approximately 5% of the oxygen consumed by myocytes are 
transformed into ROS. Because of this, mitochondria are targets for ROS 
damage. Additional sources of ROS generation include neutrophils, oxyradical 
generation from xanthine oxidase, autooxidation of catecholamines, activation of 
various NAD(P)H oxidases and reactive nitrogen species. These additional 
sources become the primary source of ROS generation when prolonged 
ischemia irreversibly disrupts ETC (75, 87). Basally generated ROS are 
efficiently detoxified by endogenous enzymatic antioxidants, such as superoxide 
dismutase, glutathione peroxidase, and catalase (211, 314). However, under 
conditions associated with excess ROS generation, such as ischemia-
reperfusion injury, the flux of ROS generated by tissues can exceed the capacity 
of endogenous oxidant defense mechanisms to detoxify ROS and prevent 
deleterious ROS-mediated reactions. 
9 
Ischemia/hypoxia augments ROS generation in the intact myocardium and 
isolated cardiac myocytes (9, 14, 166). In fact, Zweier et al. demonstrated using 
electron spin resonance of frozen ground hearts that 20 minutes of ischemia 
increased ROS production (340). Interventions that prevent ischemia-mediated 
rise in ROS regeneration reduce myocardial ischemia-reperfusion injury. 
Indeed, Lesnefsky et al. showed that inhibition of electron transport during 
ischemia protects cardiac mitochondria and reduces ischemia-reperfusion injury 
(186). 
During reperfusion, a large burst of ROS has been consistently shown to 
occur (Figure 1 )(166, 302, 339). This burst in ROS generation during 
reoxygenation has been attributed to damage of electron transport chain 
components resulting in inefficient electron transfer. Several studies have shown 
that addition of antioxidants or scavengers delay irreversible myocardial damage 
or attenuate ischemia-reperfusion injury (7, 43, 168). Overexpression of 
manganese superoxide dismutase reduces infarct size in mice (157). Moreover, 
treatment of in vivo or in vitro hearts with antioxidants reduced ROS generation 
(22). 
1. A. III. Mitochondrial permeability transition pore (mPTP) formation 
The mPTP is a non-specific pore spanning both the outer mitochondrial 
membrane (OMM) and inner mitochondrial membrane (IMM) shown in Figure 2. 
This pore allows molecules <1.5kDa to enter and exist the mitochondria. Even 
though the molecular composition of mPTP is still debatable, mPTP may reflect 
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interaction of several proteins that would connect the mitochondrial matrix to the 
cytosolic space. A relatively simple model was first proposed to constitute 
cyclophilin D (CyP-D) in the matrix, adenine nucleotide translocase (ANT) in the 
IMM and voltage dependent anionic channel (VDAC) in the OMM (104, 259). 
This simplistic model was later made complex by the addition of several other 
proteins such as the benzodiazepine receptor (BdR), hexokinase (HK) and 
creatine kinase (CK) to accommodate the variety of effectors acting on the mPTP 
(205, 259). An alternative model of mPTP proposes that mPTP would be formed 
by clusters of misfolded proteins. 
mPTP 
1 
IMM 
Figure 2. Mitochondrial permeability transition pore complex (mPTP). mPTP is a 
non-specific pore that allows molecules <1.5kDa to pass in and out of the 
mitochondria. As described in the text, mPTP is thought to constitute cyclophilin 
D (CyP D) in the matrix, adenine nucleotide translocase (ANT) in the inner 
mitochondrial membrane (IMM) and voltage dependent anionic channel (VDAC) 
in the outer mitochondrial membrane (OMM). Other components thought to 
regulate mPTP include benzodiazepine receptor (BdR), Hexokinase (HK) and 
creatine kinase (CK). IMS refers to the intermembranous space. 
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Voltage dependent anionic channel (VDAC) proteins are the most 
abundant protein in the OMM (Figure 2) and exist as three isoforms (VDAC-1, 
VDAC-2, and VDAC-3). VDAC was first discovered over 30 years ago as a 
channel protein more permeable to cr than to K+ (263). Later, VDAC was shown 
to be a single channel with ion selectivity that reacts to membrane potential (51). 
Recently, VDAC was shown to transport ATP and interact with molecules that 
need to be in close proximity to ATP (258). VDAC interacts with hexokinase 
(206), creatine kinase (265) and members of the Bcl family (BcI-2, Bak and 
Bax)(269, 270, 304). Hence, VDAC serves as a binding partner for proteins that 
mediate and regulate the integration of mitochondrial functions with other cellular 
activities. VDAC is thought to play a critical role in mitochondrial death 
pathways. The role of VDAC in mPTP and mitochondrial-mediated apoptosis is 
still being debated. Earlier reports indicated that VDAC might be required for 
cytochrome c release from the mitochondria during apoptosis (269, 270). 
Indeed, there is evidence that VDAC-2 plays an important role in suppressing 
apoptosis in mice by sequestering Bak and that VDAC-2 null MEFs are more 
susceptible to apoptosis (38). Additionally, several lines of evidence suggested 
that the OMM protein involved in mPTP formation might be VDAC: purified VDAC 
incorporated into planar phospholipid bilayers formed a channel with 
electrophysiological properties similar to those of mPTP; VDAC channel 
properties changed in the presence of NADH, glutamate or Ca2+; and finally 
chromatography of mitochondrial extracts on a CyP-D matrix allowed for the 
purification of VDAC and ANT, which in the presence of CyP-D catalyzed the 
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CsA-sensitive permeabilization of liposomes to solutes. Recently, work by 
Krauskopf et al (171) and Baines et al (11) dispute the role of VDAC in mPTP 
and apoptosis. Baines et al. showed that VDACs are dispensable for mPTP 
formation (11). Moreover, eliminating VDAC isoforms by genetic knockout or 
knockdown using small interfering RNAs, did not affect mPTP formation. 
Furthermore, VDAC-deficient mouse embryonic fibroblast exhibited similar 
cellular response and mitochondrial response to Ca2+ overload, oxidative stress 
and Bax-Bid activation as control cells (11). 
In addition to their normal physiological function of exchanging 
mitochondrial ATP for cytosolic ADP, ANTs has been implicated in cell death. 
There exist three ANT isoforms (ANT1, ANT2, and ANT3) in humans and two 
isoforms (ANT1 and ANT2) in mice. ANTs operate as gated pores located in the 
inner mitochondrial membrane (Figure 2) such that when occupied by 
transportable substrates, they alternate between two conformations in which the 
ADP/ATP-binding site is either on the matrix side of the IMM (m-state) or on the 
cytoplasmic side (c-state). ANT ligands that bind to the m-state (e.g. bongkrekic 
acid, BKA) inhibit mPTP formation while c-state ligands (e.g. 
carboxyatractyloside (CAT), pyridoxal phosphate) activate mPTP. The 
involvement of ANT in mPTP formation was first demonstrated in studies in 
which ATP and BKA inhibited opening of the mPTP by decreasing its sensitivity 
to Ca2+ while CAT and adenine nucleotide depletion both triggered pore opening 
by sensitizing the pores to Ca2+. This notion is now questionable following a 
recent study by Kokoszka et al. showing that liver mitochondria from mice lacking 
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ANT were sensitive to CsA inhibitable mPTP (169). Moreover, Konkoszka and 
Wallace studies revealed that the mPTP in ANT-null mitochondria were 
insensitive to opening by atracyloside and to closure by ADP, all compounds that 
affect PTP opening through ANT (102, 169). 
CyP D, a product of the Ppif gene, is a member of the cyclophilin family. 
CyP-D is located in mitochondrial matrix (Figure 2) and exhibits peptidyl-prolyl 
cis-trans isomerase (PPlase) activity. The involvement of CyP-D in mPTP 
formation was first suggested when similar concentration of CsA was found to 
inhibit mitochondrial cyclophilin activity and block mPTP opening (106, 213). 
Moreover, mitochondrial cyclophilin and mPTP showed comparable sensitivities 
to CsA analogues (93, 231). CyP-D favors mPTP opening by facilitating the 
Ca2+ -induced conformational change. Such earlier findings were later confirmed 
by studies using CyP-D knockout mice from several groups (10, 12,58, 106,223, 
264, 267). These studies revealed that CyP-D regulates mPTP, CyP-D null 
mitochondria were not responsive to Ca2+, and CyP-D is a relevant factor for 
mPTP modulation but not required for its formation and opening. Additionally, 
mPTP formation in CyP-D null mitochondria is not inhibited by the mPTP blocker 
cyclosporine A (CsA) and mPTP opening is essential for mitochondrial-mediated 
necrotic cell death but dispensable for mitochondrial-mediated apoptotic cell 
death (10,12,58,106,223,264,267). 
Factors that regulate mPTP can be classified as matrix or membrane 
effectors (Table 1). Matrix effectors such as mitochondrial Ca2+ overload (16, 
17), oxidized pyridine nucleotides (40, 61, 63), high inorganic phosphate and 
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increased mitochondrial ROS (31, 40, 60, 61, 107) favor PTP, while GsA (24, 
64), bongkrekate (140, 180), and matrix pH below 7(16, 17, 104, 141) inhibit 
mPTP formation. Membrane effectors including amphipathic anions (like fatty 
acids produced by phospholipase A2) favor mPTP (25, 242), while polycations 
(spermine)(179), amphipathic cations (sphingosine, trifluoperazine)(25) and 
positively charged peptides (253) inhibit mPTP opening. 
Table 1: Known inducers and inhibitors of mPTP 
Matrix Effectors Membrane Effectors 
Mitochondrial calcium 
overload 
Oxidized pyridine 
nucleotides 
Favor mPTP High inorganic Amphipathic anions 
phosphates 
Increased mitochondrial 
ROS generation 
carboxyatractyloside 
Gyclosporine A (GsA) Polycations e.g. Spermine 
Inhibit mPTP Bongkrekate Amphipathic cations e.g. 
spingosine 
Matrix pH < 7 Positively charged peptides 
Agents that prevent mPTP formation attenuate ischemia-reperfusion 
injury. In fact, known mPTP inhibitors, cyclosporine A (GsA) and it analog 
sanglifehrin A, have been shown to protect cardiac myocytes against 
reoxygenation injury (95, 227, 320) and decrease infarct size in various species 
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(122, 123) . CsA has also recently been shown to reduce infarct size in humans 
during percutaneous coronary intervention procedure (243). Furthermore, 
cardioprotective interventions such as ischemic preconditioning, ROS 
scavengers, inhibitors of the Na + -H+ exchanger and Ca2+ antagonists have been 
shown to inhibit mPTP formation as part of the mechanisms through which they 
confer cytoprotection (68, 101, 104). In addition, mice lacking CyP-D, a putative 
mPTP component are less susceptible to ischemia-reperfusion injury (10, 223). 
The inhibitory effect of CsA and its analogs involves interaction with CyP-D that 
reduces sensitivity of pore opening to Ca2+. 
1. A. IV. Endoplasmic Reticulum (ER) stress 
Proper protein synthesis, folding, and transport are essential for cell 
survival. The rough endoplasmic reticulum (ER) is involved with maintaining 
proper synthesis, folding, and transport of proteins targeted to membranes and 
organelles (20). Conditions that alter the ionic balance, molecular chaperones, 
protein glycosylation machinery, and/or redox status of the ER lumen cause ER 
stress and trigger an intracellular signaling system called the unfolded protein 
response (UPR, Figure 3)(23, 36, 163, 195, 261). Initially, the UPR promotes 
adaptation to reestablish normal ER function. Such adaptation occurs by 
reducing the quantity of protein synthesized in the ER, inducing the expression of 
genes that enhance protein folding capacity of the ER, promoting ER-associated 
protein degradation to remove misfolded proteins, and reestablishing the ER 
luminal environment to that suitable for new protein synthesis and folding (Figure 
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3). Such initial responses are designed to resolve the stress and ultimately 
enhance the chances of survival, but if the ER stress is prolonged, the 
maladaptive arm of the UPR is activated causing cell death as shown Figure 3 
(284). 
ER stress has been implicated in the pathogenesis of several diseases 
including ischemia-reperfusion injury (249, 293). One study showed that 
numerous UPR genes are induced within 24 hours of myocardial infarction in 
mice (117). Moreover, several studies have shown that interventions that inhibit 
ER stress in the heart attenuate ischemia-reperfusion injury in mice or hypoxic 
injury in cultured cardiac myocytes (230, 249, 286, 289). 
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Figure 3. Unfolded protein response (UPR). Under non-stressed conditions, 
proteins synthesized in the ER are efficiently folded. Stressors that perturb the 
ER protein glycosylation machinery, ER Ca2+ levels, and/or redox status results 
in accumulation of misfolded proteins in the ER and initiates the unfolded protein 
response (UPR). The initial action of the UPR is geared towards restoring normal 
ER environment via increased synthesis of ER chaperones (e.g. glucose 
regulated peptides 94(Grp 94) and 78 (Grp 78)), calcium binding proteins 
(e.g.calreticulin) and protein disulfide isomerases (PDI)). If ER stress is not 
resolved during the prosurvival phase, maladaptive UPR is activated leading to 
apoptosis. CHOP/GADD153 - growth arrest and DNA damage 153. 
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1. B. Cardioprotective mechanisms 
1. B. I. Ischemic Preconditioning 
Inducing brief non-lethal episodes of ischemia and reperfusion to the heart 
prior to an episode of sustained lethal myocardial ischemia has the capacity to 
dramatically reduce myocardial ischemia-reperfusion injury. This phenomenon, 
termed ischemic preconditioning (I PC), is a transient, self-defense mechanism 
present in the heart and many other organs including the kidney, liver, and brain 
(220). IPC significant and reproducible and serves as the gold standard for 
studies of cardioprotection (152). IPC reduces myocardial infarct size, lactate 
generation and rate of fall of ATP. There are two "windows" of protection 
afforded by preconditioning, "early" and "late" preconditioning. The protective 
effect of early IPC is mediated by posttranslational modification and is lost if the 
time between the initial IPC protocol and the sustained ischemia is greater than 
one hour (292). The late or second window of preconditioning involves gene up 
regulation and occurs 24 hours after preconditioning. 
Intense investigation of the mechanisms responsible for the protective 
effects of preconditioning has revealed numerous potential mediators and 
downstream effectors of preconditioning (Figure 4), but cause and effect 
relationships have not been fully delineated. However, Tong et al. and others 
have successfully demonstrated that ischemic preconditioning enhances glucose 
uptake (147, 296, 309). Moreover, preconditioned hearts have less anaerobic 
glycolysis, hence make less lactate and have less acidic pH during ischemia 
(221, 278). Interestingly, the rate of ATP consumption is slower for PC hearts 
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(221, 278). Two hypotheses have been put forward to explain why PC hearts 
have reduced ATP hydrolysis: 1. IPC might inhibit ATP breakdown by reverse 
mode functioning of mitochondrial ATP synthase confirmed by in vitro and in vivo 
data from several groups (69, 97, 149, 187,207,328). 2. The ATPase inhibitor 
subunit might bind to and inhibit the mitochondrial ATPase during IPC. Data 
from several groups show that IPC and diazoxide enhance early binding of 
ATPase inhibitor subunit to mitochondrial ATPase (6, 52, 59). Contrarily, 
Grover's (89) and Jennings' (303) groups found no evidence supporting inhibition 
of ATP synthase in PC hearts. IPC has also been shown to decrease Ca2+ 
overload (218), oxidative stress (301), and PTP formation (123, 148). 
Recent studies suggest that IPC also activates several signaling pathways 
(Figure 4). The most prominent is the activation of G-protein coupled receptors. 
Activation of GPCRs leads to activation of the phosphoinositide-3-kinase (PI3K) 
pathway. The action of PI3K is attributed to the generation of 
phosphatidylinositol 3,4,5-phosphate (PIP3). PIP3 facilitates phosphoinositide-
dependent protein kinase 1 (PDK1) phoshorylation and activation of substrates 
like Akt (PKB), p70S6K, Protein Kinase C (PKC), extracellular regulated kinase 
(ERK), p38 MAPK, JNK, PKC-E, and eNOS/NO to mediate cardioprotection. In 
fact, Tong et a/ showed PC induced Pl3K-mediated cardioprotection was via 
activation of targets upstream of PKC (297). Moreover, phosphatase and tensin 
homolog deleted chromosome ten (PTEN) which regulates PIP3, is degraded 
during PC and might be involved in GPCR recycling (30, 73, 298). 
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Figure 4. Summary of signaling pathways activated by ischemic preconditioning 
and postconditioning. IPC leads to release of agonists that activate G proteins 
coupled receptor (GPCR), leading to activation of phosphoinositide 3-kinase 
which in turn activates protein kinase B (PKB or AKT), PKA, PKC, and 
extracellular regulated kinase (ERK) signaling pathways. These pathways 
converge on the mitochondrial where they inhibit mitochondrial permeability 
transition pore (mPTP) formation. PIP2 - phosphatidylinositol 3,4-diphoshpate, 
PIP3 - phosphatifylinositoI3,4,5-triphoshate, PDK1 - protein dependent kinase 
1, PTEN - phosphatase and tensin homolog deleted on chromosome ten, GSK-
glycogen synthase kinase, eNOS - endothelial nitric oxide synthase. 
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1. B. II. Reperfusion Injury Survival Kinases (RISK pathway) 
The RISK pathway refers to a group of protein kinases that when activated 
during myocardial reperfusion confers cardioprotection (126, 327). Extensive 
preclinical data have amassed showing that pharmacologic preconditioning (126, 
127), IPC, or postconditioning(124) activation of RISK pathway reduces infarct 
size by up to 50%. Indeed, Hausenloy et al. showed that ERK and Akt were 
activated at the start of reperfusion and blockade of ERK and Akt at the start of 
reperfusion blocks PC-mediated protection in PC hearts (124). RISK pathway is 
thought to reduce myocardial ischemia-reperfusion injury by inhibiting mPTP 
formation(66), improving SR calcium uptake (3, 246) and by activation of 
antiapoptotic pathways (327). 
1. B. III. Postconditioning 
Interrupting myocardial reperfusion with brief cycles of myocardial 
ischemia and reperfusion reduces infarct size. This phenomenon, termed 
ischemic postconditioning, was first reported by Zhao et al in 2003 (335). In this 
study, after 45 minutes of sustained myocardial ischemia in dogs, the interruption 
of reperfusion with three 30 second cycles of ischemia and reperfusion reduced 
myocardial infarct size from 47% to 11 % (335). Thus, the myocardial reperfusion 
phase could be a target of cardioprotection. Although the exact mechanisms 
through which postconditioning confers protection are not fully understood, 
postconditioning has been shown to inhibit lethal reperfusion injury through the 
same mechanisms as IPC (Figure 4)(124). Postconditioning activates PI3K 
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pathway which results in the activation of downstream targets like PKC, 
PKG/NO, and MAPK to mediate cardioprotection. Ischemic postsconditioning 
also targets important mediators of ischemia-reperfusion injury such as oxidative 
stress, [Ca2+]j overload, neutrophil accumulation (336) and cellular pH (49). 
Moreover, ischemic postconditioning activates the RISK pathway (126) and 
blocks opening of the mPTP (125). 
2. Hexosamine Biosynthetic Pathway (HBP) 
Intracellular glucose normally provides substrate for metabolic processes. 
In general, upon entering the cell, glucose is rapidly phosphorylated by 
hexokinase to glucose-6-phosphate which either enters glycogen metabolism or 
reversibly converted to fructose-6-phosphate for primarily glycolysis (Figure 5). 
Thus, glycogen synthesis and glycolysis uses ==90-95% of cellular glucose. Less 
than 5% of the remaining cellular glucose is shunted to a unique accessory 
pathway, the hexosamine biosynthetic pathway (208). This pathway involves a 
series of enzyme catalyzed reactions ending with the formation of uridine 
diphosphate-N-acetylglucosamine (UDP-GlcNAc, Figure 5). HBP begins with the 
rate limiting conversion of fructose-6-phosphate to glucosamine-6-phosphate by 
L-glutamine: fructose-6-phosphate amidotransferase (GFAT) using glutamine as 
the amide donor (Figure 5). The next critical reaction involves the modification of 
the hexosamine core in the conversion of glucosamine-6-phosphate to N-
acetylglucosmaine-6-phosphate by glucosamine-6-phosphate acetyltranseferase 
(Emeg32) using acetyl-coenzyme A (CoA, Figure 5). The final step involves 
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exergonic pyrophosphorylation of glucosamine-1-phosphate to uridine 
diphosphate-p-N-acetylglucosamine (UDP-GlcNAc) by UDP-GlcNAc 
pyrophosphorylase (Figure 5). Once formed, UDP-GlcNAc serves as the 
glycosidic precursor for glycoproteins, glycolipids, proteoglycans, and more 
germane to this research project, serves as the nucleotide sugar for the post-
translational glycosylation of nuclear, cytoplasmic and mitochondrial proteins (0-
GlcNAc). Despite using less than 5% of cellular glucose, UDP-GlcNAc, is 
second only to ATP in terms of the intracellular concentration of high energy 
compounds (209). Flux through HBP can be increased by adding exogenous 
glucosamine. Glucosamine enters the cell via a glucose transporter and is 
phosphorylated by hexokinase to glucosamine-6-phosphate, thus by-passing 
GFAT and rapidly increasing UDP-GlcNAc levels(204). 
Data on how the critical enzymes of the HBP are regulated is 
unexpectedly very limited. GFAT activity is glutamine-dependent and can be 
inhibited by the glutamine analogues 6-azido-5-oxo-L-norleucine (DON) and 0-
diazoacetyl-L-serine (azaserine)(215). There are two isoforms of GFAT; GFAT1 
and GFAT2 transcribed from separate genes. GFAT1 is highly expressed in the 
pancreas, placenta and testes while, GFAT2 is more abundant in the heart and 
central nervous system. Eukaryotic GFAT is highly conserved and regulated 
transcriptionally (241), post-translationally by cAMP-dependent protein 
kinase(35, 136) and by UDP-GlcNAc feedback inhibition (88). Phosphorylation 
of GFAT1 decreases its activity while phosphorylation of GFAT2 increases its 
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activity. Emeg32, another critical enzyme of the HBP, is important for 
maintaining proper intracellular UDP-GlcNAc concentration (21). 
The diverse nature of the precursors of UDP-GlcNAc potentially links HBP 
to several metabolic pathways (Figure 5). First, less than 5% cellular glucose 
siphoned to the HBP (203). Second, glutamine, a nonessential amino acid highly 
abundant in muscle cells enters the HBP at the rate limiting step, potentially 
linking HBP to amino acid metabolism. Third, acetyl-CoA, produced primarily 
from fatty acid and pyruvate oxidation in the mitochondria, enters HBP during the 
acetylation of the glucosamine core to form N-acetylglucosamine-6-phosphate, 
possibly links HBP to fatty acid metabolism. Finally, ATP enters the HBP at the 
final step i.e. the conversion of N-acetylglucosamine-1-phosphate to UDP-
GlcNAc by UDP-GlcNAc pyrophosphorylase, linking HBP to nucleotide 
metabolism. Therefore, UDP-GlcNAc and hence O-GlcNAc might act as a 
nutrient and/or metabolic sensor. 
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Figure 5. Hexosamine biosynthetic pathway (HBP). Once cells take up glucose, 
it is first phosphorylated by hexokinase. This phosphorylated glucose either 
enters glycogen synthetic pathway or is further converted to fructose-6-
phosphate by glucose-6-phosphate isomerase. The majority of fructose-6-
phosphate is channeled to glycolysis. Of the remainder, between <5% is 
channeled to an accessory pathway for glucose metabolism, the hexosamine 
biosynthetic pathway (HBP). This pathway begins with the rate limiting 
conversion of fructose-6-phosphate to glucosamine-6-phosphate by L-
glutamine:D-fructose-6-phosphate amidotransferase (GFAT). The next critical 
reaction involves acetylation of gluocsamine-6-Phosphate by glucosamine-6-
phosphate acetyltransferase (Emeg32) to for N-acetylglucosamine-6-phosphate 
(GlcNAc-6-P). Next are two reversible reactions: first the conversion of GlcNAc-
6-P to GlcNAc-1-P by phosphate-acetylglucosamine mutase, and then the 
formation uridine diphosphate- GlcNAc (UDP-GlcNAc) by UDP-GlcNAc 
pyrophosphorylase. 
26 
1 
3. What is O-GlcNAc 
3. A. O-GlcNAc biology 
Beta-O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational 
sugar modification of eukaryotic proteins (Figure 6) first described in 1984 by 
Torres and Hart in a study in which soluble ~-1-4 galactosyltransferase was used 
to probe lymphocyte plasma membrane for surface glycans (300). This study 
was ground breaking at that time because not only were glycosylated proteins 
thought to exist only in luminal compartments and on cell surfaces, but, also all 
glycosylation processes were thought to be largely static. The addition of 0-
GlcNAc to proteins from UDP-GlcNAc stores is a metabolic post-translational 
modification occurring in the cytoplasm, nucleus, and potentially mitochondria. 
OH OH 
HO-,:--~ __ _ 
o o 
AcNH I t OGT, GCA AcNH f t 
Tyr-Ser-Pro-Thr-Ser-Pro-Thr 
Figure 6. O-GlcNAc transferase (OGT) adds, while O-GlcNAcase (GCA) 
removes GlcNAc molecule from Ser/Thr residues of mature nuclear, cytoplasmic 
and mitochondrial proteins. 
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O-GlcNAcylation is in many ways distinct from the "classical" protein 
glycosylation in that: 1. O-GlcNAc modified proteins are found mostly within the 
nucleus, cytoplasm or mitochondria versus cell surfaces, the lumen of 
membranous organelles, the endoplasmic reticulum and Golgi apparatus for N-
glycosylation (118, 138). 2. O-GlcNAc is not elongated into complex structures 
or further modified (with the exception of nuclear pore protein) unlike the 
extraordinarily complex array of glycans found on extracellular glycoproteins 
(131, 132, 300). 3. O-GlcNAc rapidly cycles on and off proteins on a time scale 
similar to that for phosphorylation/dephosphorylation, unlike extracellular 
complex glycans, which are static (70, 79, 176, 255). 4. There is no obvious 
consensus sequence for the addition of O-GlcNAc to proteins while N-
glycosylation has Asn-X-Ser/Thr sequence (where X could be any amino acid 
other than proline or aspartic acid). 5. GlcNAc is added to proteins through an 0-
linkage on the hydroxyl group of Ser/Thr while in N-glycosylation the 
monosaccharide is added through an N-linkage on the amide group of Asn. 
Akin to phosphorylation, O-GlcNAcylation is one of the most common 
post-translational modifications. O-GlcNAc is similar to a protein phosphorylation 
in that: 1. Both O-GlcNAcylation and phosphorylation post-translational 
modifications are found on serine and threonine residues (119, 120). 2. Both 
modifications are dynamically added and removed from proteins in response to 
cellular signals (44, 45, 160). 3. Both alter the functions and associations of the 
modified protein. Conversely, O-GlcNAc differs from protein phosphorylation in 
that only two enzymes control the addition and removal of the O-GlcNAc post-
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translational modification from proteins, while over 600 genetically distinct 
kinases and phosphatases exist in mammalian cells. 
O-GlcNAc modified proteins do not have a consensus sequence, but most 
of the sites of O-GlcNAc addition mapped so far have a Pro-Val-Ser motif similar 
to that recognized by proline-directed kinases. Moreover, many phosphorylation 
sites are also known glycosylation sites (44, 45). O-GlcNAc and O-phosphate 
site-mapping studies so far suggest that there are at least four different types of 
dynamic interplay between O-GlcNAc and O-phosphate. There is evidence of 
competitive occupancy at the same site; for example, that which occurs in the 
transcription factor c-Myc(46, 47, 160), estrogen receptor-j3(39), oncoprotein SV-
40 large T-antigen(214) and endothelial nitric oxide synthase(74). In competitive 
occupancy, O-GlcNAcylation and O-phosphorylation compete for the same site 
and have antagonistic effects. Next, there exist competitive and alternative 
occupancy occurring at adjacent sites, such as in tumor suppressor p53(323) 
and synapsin 1(50). Hence, it is possible that O-GlcNAcylation can inhibit 
phosphorylation at adjacent sites by steric hindrance or modulation of protein 
structure. Another, interplay between O-GlcNAc and O-phosphate described is a 
complex interplay whereby some O-phosphate attachment sites on a given 
protein are the same as some O-GlcNAc sites, whereas others are adjacent to, 
or even distant from each other, as on the C-terminal domain of RNA polymerase 
11(53) and on cytokeratins 8 and 18(45). The finally type of interplay involves 
proteins in which this relationship has yet to be clearly defined. The interplay 
between O-GlcNAc and O-phosphate is also underscored by the recent finding 
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that OGT transiently forms complexes containing the catalytic subunit of protein 
phosphatase 1 (PP1 c)(311), hence there may exist a single enzyme complex for 
the addition of GlcNAc and removal of phosphate. Additionally, many known 0-
GlcNAc sites have the PEST sequence (Pro-Glu-Ser-Thr), a sequence 
associated with rapid degradation suggesting that O-GlcNAcylation at these sites 
might slow or prevent protein degradation(113). O-GlcNAcylation affects protein 
trafficking and localization for example c-Myc (160), Tau(182), and Stat5a(85, 
225) have a larger portion of the O-GlcNAcylated form located in the nucleus 
than cytoplasm. 
3. B. Enzymatic regulation of O-GlcNAc cycling 
Modulation of protein O-GlcNAcylation is achieved by the concerted action 
of two highly evolutionarily conserved enzymes, a uridine diphospho-N-
acetylglucosamine: peptide J3-N-acetylglucosaminyl transferase (OGT) and 0-J3-
N-acetylglucosaminidase (O-GlcNAcase aka GCA, OGA, or MGEA5). 
O-GlcNAc transferase (OGT) is a soluble, ubiquitously expressed, and 
highly conserved enzyme in all multicellular eukaryotic organisms involved with 
the addition of a single J3-N-acetylglucosamine (GlcNAc) moiety (from UDP-
GlcNAc) via an O-linkage to serine/theronine amino residues of mature nuclear, 
cytoplasmic and mitochondrial proteins as shown in Figure 6( 110, 112, 173, 
199). OGT is expressed in all examined tissue types and is most abundant in the 
glucose-sensing cells of the pancreas and in the brain. OGT is primarily located 
in the nucleus and has an optimum pH of about 6(173, 199). OGT is encoded by 
a single copy X-linked gene in mammals while plants have two OGT homologs 
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spy and secret agents (121, 173, 199, 268). Even though OGT is coded by a 
single gene in mammals, alternative splicing of OGT mRNA leads to three 
potential isoforms, nucleocytoplasmic OGT (ncOGT), mitochondrial OGT 
(mOGT) and short OGT (sOGT)(173, 199, 232). These isoforms share an 
identical C-terminal catalytic domain but have distinct N-terminal domains 
contributing to their differential localization and unique targeting sequences (115, 
198, 232). Structurally, OGT contains an N-terminal tetratricopeptide repeat 
(TPR), a linker region and C-terminal catalytic domains (173,199). TPR domain 
consists of a 34 amino acid repeat varying from 3-12 involved in inter-subunit 
interaction, protein-protein interaction, subcellular targeting, substrate 
recognition, cell cycle regulation and transcriptional control (13, 144, 145, 151, 
174, 199, 326). The linker region is the least conserved sequence of OGT. The 
catalytic domain of OGT is thought to have a UDP-GlcNAc binding site and is 
involved with the glycosylation of proteins (319). Post-translational modification 
of OGT by tyrosine phosphorylation and O-GlcNAc modification, UDP-GlcNAc 
concentration and protein-protein interaction are thought to regulate OGT activity 
(42, 173, 199). Recently, insulin signaling was shown to regulate OGT (316, 
324). In these studies, insulin increased post-translational OGT phosphorylation 
and O-GlcNAcylation, OGT activity and transient translocation from nucleus to 
the cytoplasm (316, 324). In neuro-2a neuroblastoma cells, OGT mRNA and 
protein expression are regulated in an AMP-activated protein kinase-dependent 
manner, whereas OGT enzymatic activity is regulated in a p38 MAPK-dependent 
manner (41). Moreover, activated p38 has been shown to interact with OGT and 
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recruit it to specific substrates, such as neurofilament H during glucose 
deprivation in neuroblastoma cells (41). Tissue specific OGT mutation causes 
disturbance in somatic cell function(234) while OGT deletion is embryonically 
lethal(268), hence O-GlcNAc is important for cellular viability. 
O-~-N-acetylglucosaminidase (O-GlcNAcase, aka GCA, OGA, or MGEA5) 
is a soluble, highly conserved enzyme, expressed in all eukaryotic organisms 
involved with the removal of O-GlcNAc modification from proteins (Figure 6)(84). 
O-GlcNAcase is primary located in the cytoplasm with an optimum pH of 5.5-7 
and coded for by a single gene. Structurally, O-GlcNAcase is a 917 amino acid 
protein with an N-terminal hexosaminidase and a C-terminal histone 
acetyltransferase domain (HAT)(56, 78, 84, 130, 295). The N-terminal domain is 
similar to hyaluronidase and was originally identified as a meningioma expressed 
antigen 5(56, 78, 84, 130). While there may be some activity against hyaluronan, 
the preferred substrate for O-GlcNAcase is O-GlcNAc (84, 310). The C-terminal 
histone acetyltransferase domain acetylates free histones and nucleosomal 
histone proteins (295). O-GlcNAcase is cleaved by caspase 3 into HAT and 
hexosaminidase domains with no change in the activity of each domain. Protein-
protein interaction and phosphorylation are thought to regulate O-GlcNAcase 
activity (84, 310). Two splice variants of O-GlcNAcase have been reported in 
rats, both lacked O-GlcNAcase activity but retained HAT activity. The spliced 
variant detected in Goto-Kakizaki rats (-90kDa) lacks exon 8 while the spliced 
variant in Sprague-Dawley (-84kDa) lacks both exons 8 and 9. 
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The fact that OGT is known to associate with histone deacetylase 
complexes(326) and promote transcriptional silencing (326), while O-GlcNAcase 
has a HAT domain(295), has led to the hypothesis that O-GlcNAcylation plays a 
role in the regulation of transcription. Such hypothesis has been supported by 
studies identifying numerous transcription factors to be regulated by O-GlcNAc-
modification (146, 165, 178, 325). O-GlcNAcylation can either suppress or 
enhance transcription, depending on the promoter involved and other associated 
proteins. The transcription factor ST AT5A is known to alter gene activation by 
preferentially binding to the co-activator of transcription, CREB-binding protein 
when O-GlcNAc modified (85). O-GlcNAc modification of Sp1 has multiple effects 
on the function of the transcription factor (146). Augmented O-GlcNAc 
modification of SP1 has been shown to drive the transcription of plasminogen 
activator and extracellular matrix proteins that have an important role in diabetic 
cardiovascular disease while reduction of Sp1 glycosylation led to an increase in 
Sp1 proteasome susceptibility (113). 
3. C. Pharmacologic regulation of O-GlcNAc cycling 
Pharmacological approaches to beUer understand the role of enzymes 
controlling the presence of O-GlcNAc on proteins in biological and pathological 
processes have been limited due to lack of specific high-affinity inhibitors (Table 
2). Alloxan, a uracil and UDP-GlcNAc analog, may be an irreversible inhibitor of 
OGT (170). The drawbacks of this compound include its ability to inhibit many 
other enzymes using uridine as substrate, its reactivity with many cellular 
33 
components like DNA (285) and also, its ability to inhibit O-GlcNAcase(181}. 
Compounds "4" (aka TT04) and "5" (aka TT40) inhibit OGT by competing with 
UDP-GlcNAc for the same site on OGT(96}; however, there are relatively few 
reports of their use in biological systems. O-GlcNAcase, unlike OGT, has 
several known pharmacologic inhibitors. Streptozotocin (STZ), a diabetogenic 
compound and GlcNAc analog, inhibits O-GlcNAcase by binding to its active site, 
leading to the formation of energetically more stable transition state ligands (254, 
294). Results from studies using STZ as an O-GlcNAcase inhibitor should be 
interpreted with caution because of its cytotoxic effects on pancreatic cells and its 
ability to reduce cellular NAD levels (27). Whether the STZ-mediated increase in 
O-GlcNAc levels is due to secondary or other toxic effects remains debatable. 
Furthermore, Macualey et al. showed that STZ had no effect on O-GlcNAcase 
activity in vitro (200). PUGNAc, a GlcNAc analog, prevents the binding of 0-
GlcNAcase to GlcNAc (134). Even though PUGNAc lacks the cytotoxic effects of 
STZ(111}, it inhibits other lysosomal hydrolases and shows little specificity for 0-
GlcNAcase over hexosaminidase (200). 1,2-dideoxy-2-methyl-D-
glucopyranoso[2,1-d]-2-thiazoline (NAG-thiazoline) and its derivatives inhibit 0-
GlcNAcase and have 1500-fold greater specificity for O-GlcNAcase over 
hexosaminidase than PUGNAc(200}. GlcNAcstatin, a glucoimidazole-based 
inhibitor, has been shown to inhibit O-GlcNAcase in the picomolar range with 
100,OOO-fold selectivity over lysosomal hexosaminidase in human embryonic 
kidney 293 and SH-SY5Y neuroblastoma cell lines but has not been as widely 
studied as PUGNAc (71). This may be more selective and potent than PUGNAc 
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and NAG-thiazoline. Thiamet-G, another O-GlcNAcase inhibitor, has also 
recently been developed (330). Again, few studies have addressed the role of 0-
GlcNAcase inhibition beyond the use of PUGNAc or NButGT. As with inhibitors 
of OGT, concern remains regarding the off-target effects of PUGNAc, ST2, and 
other putative inhibitors of O-GlcNAcase. Thus, the use of other approaches, 
such as RNA interference or adenoviruses, could clarify some of the off-target 
effects of the aforementioned pharmacologic approaches. 
Table 2: Common pharmacologic inhibitors of OGT and GCA 
O-GlcNAc Transferase (OGT) O-GlcNACase (GCA) 
Alloxan (Konrad et aI., 2002) PUGNAc (Horsch et aI., 1991) 
Compound 4 (Gross et aI., 2005) Streptozotocin (Roos et aI., 1998) 
Compound 5 (Gross et aI., 2005) Alloxan (Lee et aI., 2006) 
NButGT (Macauley et aI., 2005) 
GlcNAcstatin (Dorfmueller et aI., 2006) 
Thiamet-G (Yuzwa et aI., 2008) 
3. D. Detection tools and methods 
Despite its abundance and discovery two decades ago, few protein targets 
have been unequivocally and site-specifically identified as carrying an O-GlcNAc 
modification. This is due to the lack of specific and sensitive methods, which are 
further limited by the relatively labile nature of the modification, its limited mass, 
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its fast turnover(45, 255) and its lack of charge(315). One of the earlier 
developed approaches relied upon enzymatic labeling of terminal O-GlcNAc 
residues with radioactive uridine diphospho-galactose (UDp[3H]Gal) using 
galactosyltransferase (114, 133, 256, 299). Since O-linkage of GlcNAc to 
protein is resistant to peptide/N-glycosidase F (PNGase F), nonspecifically 
UDp[3H]Gal tagged N-linked oligosaccharides were cleaved by PNGase F 
treatment. The main limitation of this technique was that O-GlcNAc is not readily 
accessible to galactosyltransferase. Hence, galactosyltransferase will recognize 
any terminal GlcNAc residue, such as those found in many N-linked 
oligosaccharides. Consequently, definitive identification of O-GlcNAc 
modification requires further carbohydrate characterization. In addition, the 
donor sugar UDP-[3H]galactose has a very low specific activity (17-20 Cilmmol), 
making this method insensitive compared to radiolabeling techniques with other 
isotopes, such as [32P]phosphate, with specific activities as high as 6000 
Ci/mmol. Such a low specific activity of the sugar donor may require several 
weeks of exposure to detect O-GlcNAc. 
Plant lectins like wheat germ agglutinin (WGA) or succinylated WGA have 
also been used for the detection and purification of O-GlcNAc-containing proteins 
(41, 288, 321). WGA does not recognize GlcNAc in a linkage-specific manner 
and therefore, samples must first be treated with peptide: N-glycosidase F 
(PNGase F) to remove the N-linked sugars. Another disadvantage of this 
method is that sWGA is less sensitive and only proteins with multiple O-GlcNAc 
residues are readily detected. Sensitivity may be improved by using sWGA-
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conjugated sepharose column to isolate and enrich O-GlcNAc-modified proteins 
from cell extracts. Thus, the identification of O-GlcNAc by this existing method 
requires further carbohydrate analysis for confirmation. 
Several monoclonal antibodies that recognize O-GlcNAc are commercially 
available, the most commonly used of these antibodies are referred to as 
RL2(133, 239, 272) and CTD110.6(S4). RL2, generated against nuclear pore 
glycoproteins, recognizes a limited subset of O-GlcNAc proteins and requires 
protein determinants in addition to O-GlcNAc. CTD110.6, a murine monoclonal 
IgM raised against the O-GlcNAc-modified C-terminal domain of the RNA 
polymerase II large subunit, specifically recognizes single O-GlcNAc residues in 
~-O-glycosidic linkage to serine and threonine. CTD110.6 shows no apparent 
cross-reactivity with peptide determinants and apparently does not react with 
other closely related carbohydrate antigens. All of the antibodies are somewhat 
restrictive in their target specificity and may require more than one site of 
modification. Despite their limitations, these antibodies have proven invaluable in 
both early and ongoing studies of O-GlcNAc biology. 
Several chemical approaches have also been developed to analyze 0-
GlcNAc residues(31S). Alkaline l1-elimination can be used to generate 
radiochemically labeled O-GlcNAc moieties (114, 299) and introduce a 
radiochemical label if borotritide is used instead of borohydride in the reduction 
stage of the reaction. Another more recent approach, mild l1-elimination followed 
by Michael addition with dithiothreitol (BEMAD), is useful for mass spectrometry 
(312). Bertozzi's group (306) recently developed a purely chemical means of 
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detection involving the incorporation of an azido derivative of GlcNAc (GlcNAz) 
into protein targets of O-GlcNAc. Because the enzymes of O-GlcNAc 
modification (OGT and O-GlcNAcase) tolerate analogs of their natural substrates 
in which the N-acyl side chain has been modified to a bio-orthogonal azide 
moiety (GlcNAz), cells can be metabolically labeled or the reaction can be 
performed in vitro with recombinant galactosyltransferase. These 0-
azidoacetylglucosamine-modified proteins can be covalently derivatized with 
various biochemical probes at the site of protein glycosylation using Staudinger 
ligation. This strategy should have general application for both the identification 
of O-GlcNAc-modified proteins and mapping protein target sites that bear 0-
GlcNAc modification. Because UDP-GlcNAc is incorporated into several classes 
of glycoconjugates, specificity must be demonstrated with properly controlled 
experiments. Tagging-via-substrate (TAS)(226) and Click-chemistry(98) also use 
the same principle. These techniques are highly sensitive and especially useful 
for lower molecular weight proteins. Despite the development of such 
techniques, the lack of a recognizable consensus motif somewhat complicates 
the analyses of O-GlcNAc function and limits predictive capabilities. 
3. E. How does O-GlcNAc signaling affect cellular function in disease? 
Since its discovery two decades ago, O-GlcNAc has been implicated in a 
variety of pathological processes such as neurological diseases, cancer, 
diabetes, and insulin signaling. Genes encoding both OGT and O-GlcNAcase 
map to chromosomal regions associated with neurodegenerative diseases. 
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Neurodegenerative disorders result from disease-specific protein aggregates due 
to accumulation of certain major proteins (116, 161, 287). This protein 
accumulation may be due to defects in these proteins, accelerated rate of 
synthesis or defects in protein degradation. Since the ubiquitin-proteosome 
system (UPS) disposes of some of these protein aggregates (185, 202, 233), it is 
plausible that failure of the UPS would contribute to the pathogenesis of 
neurodegenerative disorders. Numerous studies have shown that proteosomal 
function is controlled by post-translational modification of its cap by O-GlcNAc 
(113, 279, 280, 334). Moreover, augmented O-GlcNAc modified proteosome is 
less active proteosome(334). Recently, Kan et al. showed that augmented 0-
GlcNAc modification in the brain (with streptozotocin) reduced cerebral function 
and induced neuronal apoptosis (192). Alzheimer's disease, a neurodegenerative 
disease is characterized by the aggregation of ~-amyloid and microtubule-
associated protein, tau in affected neurons. ~-amyloid and tau proteins are 0-
GlcNAc-modified and the degree of O-GlcNAcylation has been shown to change 
in Alzheimer's disease(8, 90, 91). Moreover, the gene encoding O-GlcNAcase, 
the enzyme involved with the removal of O-GlcNAc modification, has been 
mapped to a region on chromosome 10q24.1 linked to Alzheimer's disease (55). 
Altered protein glcosylation is known to correlate with tumorigenesis, but 
the role of O-GlcNAc in the pathogenesis of tumors is still to be determined. 
Many oncogene and tumor suppressor gene products, such as c-Myc, SV40 
large T antigen, and p53, have been shown to be modified by O-GlcNAc. The 
oncogen, c-Myc is O-GlcNAc-modified at Thr-58, a known phosphorylation site. 
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O-GlcNAcylation of tumor suppressor gene p53 is known to increase DNA 
binding and transcriptional activity. The O-GlcNAcylation of oncogenes and 
tumor suppressor proteins emphasizes the critical roles of O-GlcNAcylation in 
cancer. 
The vast majority of the data amassed so far on O-GlcNAc and cellular 
function are in the context of diabetes and dysregulation of insulin signaling. 
There is significant evidence suggesting that prolonged augmentation of 0-
GlcNAc levels either via increasing HBP flux(129, 257), overexpression of 
OGT(324), or inhibition of 0-GlcNAcase(307), impair insulin signaling a hallmark 
of type II diabetes. Flux through HBP can be regulated by cellular glucose levels, 
GFAT or glucosamine. Adipocytes and muscles cells exposed to chronic high 
levels of glucose in the presence of insulin develop insulin resistance. Moreover, 
inhibition of GFAT (with DON) blocked the hyperglycemia-mediated insulin 
resistance while glucosamine treatment (enters HBP down stream of GFAT) 
restored the insulin resistant phenotype (129, 203, 208, 210, 257). Blockade of 
insulin-stimulated GLUT4 translocation and subsequent glucose uptake have 
been proposed as possible mechanisms through which hyperglycemia and 
glucosamine induce insulin resistance (29, 129). Direct manipulation of OGT and 
GCA, the enzymes involved with the regulation of O-GlcNAc modification, is 
associated with the pathogenesis of diabetic complications and insulin 
resistance. Interestingly, genetic studies reveal that mutation of GCA gene is 
associated with susceptibility to the development of diabetes in the Mexican 
American population (139, 184). In addition, nematodes (C. e/egans) expressing 
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GCA null allele exhibited a phenotype metabolically similar to that of human type 
II diabetes (SO). Overexpression of OGT in cardiac myocytes impaired calcium 
cycling via inhibition of SERCA, a phenotype reversed by ectopic overexpression 
of GCA(4S). Also, pharmacologic augmentation of O-GlcNAc signaling (via GCA 
inhibition with PUGNAc) causes insulin resistance in 3T3-L 1 adipocytes (307). 
Hence, alteration of post-translational protein glycosylation is influential in the 
pathogenesis of insulin resistance and the development of other diabetic 
complications. 
This project explores the role of O-GlcNAc signaling in the pathogenesis 
of acute myocardial ischemia. It provides evidence that O-GlcNAc signaling is 
endogenously recruited during acute stress events in the heart. Moreover, it 
highlights O-GlcNAc signaling as an emerging cardioprotective signal and 
identifies potential mechanisms of O-GlcNAc-mediated cardioprotection. 
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CHAPTER III 
HYPOTHESIS AND SPECIFIC AIMS 
Physiological or chemical stress normally induces signal transduction events that 
end with the activation and/or production of molecules and proteins that diminish 
the effects of deleterious signaling pathways (167, 172). Protein phosphorylation 
is typically the mechanism associated with these signal transduction pathways 
but in 2004, Zachara et al. showed that the post-translational sugar protein 
modification, O-GlcNAc, may be a stress induced signal. In this study, exposing 
multiple cell lines to diverse stressors (heat shock, ethanol, UV, hypoxia, 
reductive, oxidative and osmotic stress), results in a rapid and global increase in 
O-GlcNAc levels (332). This response was one of the earliest responses. 
Moreover, interventions that reduced O-GlcNAc levels resulted in post-stress 
lethality while interventions that augmented O-GlcNAc levels resulted in more 
stress tolerant cells raising the possibility that increasing O-GlcNAc modification 
acts as a short-term survival signal (331, 332). In addition, it has been proposed 
that stress-induced glucose uptake results in elevated pools of UDP-GlcNAc and, 
hence, increased O-GlcNAc in cells(216). 
O-GlcNAc is intricately linked to glucose because its donor, UDP-GlcNAc 
is the end product of HBP which uses less than 5% of cellular glucose. Several 
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Studies have shown that cells subjected to stress rapidly take up glucose (188, 
201, 217). Moreover, this increased glucose uptake has been associated with 
increased tolerance to stress either by maintaining membrane potential, 
stabilizing redox state and/or maintaining cellular ATP levels(109, 188, 201, 240, 
282). 
In a healthy functioning adult heart, about 60-70% of myocardial energy is 
obtained from the metabolism of fatty acids, while the remainder comes from 
non-lipid sources like carbohydrates, ketone bodies, and amino acids (196, 247, 
248). This is supported by data showing that cardiomyocytes remain viable and 
beat synchronously when cultured in glucose-free media for several days(248). 
Nevertheless, during ischemia or hypoxia, the primary source for maintenance of 
myocardial viability is glucose (251, 252, 273). Hypoxia/ ischemia induced the 
translocation of the major glucose transporter GLUT-4(281), increased GLUT-1 
expression (26), and increased hexokinase activity(212). Multiple studies have 
suggested that augmented glucose uptake and glycolytic flux can reduce 
ischemic/hypoxic injury in cardiomyocyte in vivo or in vitro (15, 76, 236). In fact, 
Malhotra et al. showed that glucose uptake and metabolism through glycolysis 
protected cardiomyocytes from hypoxia-induced apoptosis(201). Taken together, 
these events serve to enhance glucose uptake and metabolism. 
More interesting is the fact that glycolysis is not the only glucose metabolic 
pathway implicated in glucose-mediated protection. Studies have shown that 
blocking glucose flux via the hexosamine biosynthetic pathway (HBP) using 
azaserine (a GFAT inhibitor), reduced glucose-induced JNK1 activity(193), and 
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ablated hyperglycemia-mediated decrease in angiotensin II induced hypertrophy 
(237) resulting in decreased cell survival. The end product of HBP serves as the 
monosaccharide donor for the post-translational glycosylation of proteins, 0-
GlcNAc, raising the possible involvement of O-GlcNAc signaling in glucose-
mediated cytoprotection. 
Knowing that ischemia/hypoxia is a stress event, we sought to determine if 
O-GlcNAc signaling is involved with the lethality associated with neonatal cardiac 
myocytes subjected to oxidative stress, hypoxia-reoxygenation, ER stress and 
adult mice subjected to myocardial ischemia. Hence I proposed the general 
hypothesis that O-GlcNAc signaling confers cardioprotection against acute stress 
(Figure 6). After identifying potential proteins O-GlcNAc-modified in the heart, I 
further hypothesized that one potential mechanism of O-GlcNAc-mediated 
cardioprotection is attenuating mitochondrial death pathway. Moreover, since ER 
stress is known to contribute to the pathogenesis of post-hypoxic or post-
ischemic injury, I hypothesized that mitigating the activation of maladaptive ER 
stress response is another possible mechanism through which O-GlcNAc 
mediates cardioprotection. To test this hypothesis, I addressed the following 
specific aims. 
Specific Aim I: Determine if O-GlcNAc modification is protective in the heart 
a. Determine the role of O-GlcNAc transferase in cardiomyocytes following 
hypoxia-reoxygenation and ER stress. 
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b. Determine the role of O-GlcNAcase in cardiomyocytes following oxidative 
stress, hypoxia-reoxygenation, and ER stress. 
Specific Aim II: To identify metabolic proteins modified by O-GlcNAc in the heart 
a. Use a gel based approach to discover potential candidate proteins in 
card iomyocytes 
b. Incorporate a focused approach to interrogate discrete protein subsets 
within mitochondria 
Specific Aim III: To evaluate the influence of O-GlcNAc on mitochondrial 
mediated death pathway. 
a. Determine whether manipulation of O-GlcNAc signaling affects post-
hypoxic ROS generation 
b. Determine whether manipulation of O-GlcNAc affects post-hypoxic Ca2+ 
overload. 
c. Determine whether manipulation of Q-GlcNAc affects post-hypoxic 
recovery of mitochondrial trans inner membrane potential. 
d. Characterize potential modulation of mitochondrial permeability transition 
pore. 
45 
Oxidative Stress 
Enhanced O· 
Myocardial Ischemia· 
Reperlusion Injury 
Ca2+ Overload 
ER Stress 
GlcNAc Signaling Unfolded Protein 
? Mitochondrial 
I 
Permeability Transition 
Pore formation (mPTP) 
? 
I 
Loss of Mitochondrial 
membrane potential 
(~~ ) 
? 
I 
Figure 7. Hypothesis scheme 
Cardiomyocyte 
Death 
46 
Response 
Apoptosis 
Necrosis 
? 
I 
Enhanced O· 
GlcNAc Signaling 
CHAPTER IV 
MATERIALS AND METHODS 
All animals were used in compliance with the Guide for the Care and Use of 
Laboratory Animals, published by the National Institutes of Health (Department of 
Health and Human Services, publication NO. [NIH] 86-23). The experimental 
protocol for the present study was reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of Louisville. 
Neonatal rat cardiac myocyte isolation and culture: Neonatal rat cardiac 
myocytes (NRCMs) were isolated from 1-2 day old Sprague-Dawley rats and 
cultured according to a well characterized protocol (4, 158, 290, 291). Mice were 
decapitated, hearts removed, rinsed and minced in calcium- and bicarbonate-free 
Hank's buffer with HEPES. The tissue fragments were digested by stepwise 
trypsin (10 mL) dissociation. The dissociated cells were mixed with 7mL FBS, 
and centrifuged at 180g at room temperature for 5 minutes. The pellet was 
resuspended in 30mL of warm fortified DMEM containing 5% fetal bovine serum, 
penicillin/streptomycin, and vitamin B12 , and centrifuged at 180g for 5 minutes. 
Pellet was then resuspended in 50 mL of warm fortified DMEM, and then 
preplated in 100mm dishes for one hour to allow fibroblast to adhere and enrich 
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culture with myocytes. The nonadherent myocytes were then plated at a density 
of 0.8-1.0x 106 cells/mL. BrdU (0.1 mmol/L) was added to the medium the first 
four days of culture to inhibit fibroblast growth. The cells were maintained at 37°C 
in the presence of 5% CO2 in a humidified incubator. Twenty-four hours prior to 
experimentation, medium was changed to serum-free DMEM. 
Mouse genotyping: At 6-8 weeks of age, mice were ear tagged and tail snips 
were taken. Total DNA was isolated from tail snips using the Qiagen DNAeasy 
Tissue Kit. The DNA was stored at -20°C until PCR was performed. PCR was 
performed using the Taq PCR Core Kit from Qiagen. Mixes were created as 
follows: tube 1 contained 1 IJL DNTP, 1ul of 20 IJmoi/L Primer 0lMR3203 (5'-CAT 
CTC TCC AgC CCC ACA AAC Tg-3'), 1 IJL of 20 IJmollL Primer 0lMR3204 (5'-
gAC gAA gCA ggA ggg gAg AgC AC-3'), 10 IJL Enzyme Q, and 7 IJL water per 
sample. Tube 2 contained 5 IJL 10X buffer, 0.5 IJL Taq, and 14.5 IJL water per 
sample. 20 uL of each tube were added to PCR tube containing 10 IJL of purified 
DNA. PCR was performed at the following conditions: 1 cycle of 94°C for 3 min, 
35 cycles of 94°C for 30 sec, 61°C for 1 min and 72°C for 1 min, 1 cycle of 72°C 
for 2 min then hold at 4°C ad infinitum. PCR samples were run on a 2% agarose 
gel with SYBER Safe stain (Invitrogen). Gels were visualized under UV light 
using a Fuji LAS-3000 imaging system. Once the line was taken to OGT-loxP 
flanked homozygosity, neonatal mouse cardiac myocytes were isolated and 
cultured as described below. 
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Neonatal mouse cardiac myocyte isolation and culture: Neonatal mouse 
cardiac myocytes (NMCMs) were isolated from 1-2 day old homozygous 10xP-
flanked OGT mice using a modified protocol for NRCM isolation. Mice were 
decapitated, hearts removed, rinsed and minced in calcium- and bicarbonate-free 
Hank's buffer with HEPES. The tissue fragments were digested by stepwise 
trypsin (2 mL) dissociation. The dissociated cells were mixed with 3mL FBS, and 
centrifuged at 180g at room temperature for 5 minutes. The pellet was 
resuspended in 6mL of warm fortified DMEM containing 5% fetal bovine serum, 
penicillin/streptomycin, and vitamin B12, and centrifuged at 180g for 5 minutes. 
Pellet was then resuspended in 10 mL of warm fortified DMEM, and then 
preplated in 100mm dishes for one hour to allow fibroblast to adhere and enrich 
culture with myocytes. The nonadherent myocytes were then plated at a density 
of 0.6-1.0x 106 celis/mL. BrdU (0.1 mmol/L) was added to the medium the first 
four days of culture to inhibit fibroblast growth. The cells were maintained at 37°C 
in the presence of 5% C02 in a humidified incubator. 
Gene transfer: NRCMs were infected with replication-deficient adenoviruses 
carrying OGT gene (AdOGT), O-GlcNAcase (Ad GCA), green fluorescent protein 
(AdGFP), or empty virus (AdNull) for 48 hours as described previously(291). 
Doses used include 0 and 100 multiplicity of infection (MOl). NMCMs were 
infected with replication-deficient adenovirus carrying the CRE recombinase 
gene (0 or 50 Mal AdCRE) for 72 hours to remove the 10xP-flanked OGT gene 
(Fgure 7). Twenty-four hours prior to experimentation, medium was changed to 
49 
serum-free DMEM. An initial aliquot of AdOGT and AdGCA (48) was 
subsequently expanded and purified using cesium chloride gradients, yielding 
adequate concentrations (101°_1011 plaque forming units/milliliter) while AdCRE, 
AdGFP, and AdNull were purchased from Vector Biolabs. Functional expression 
was confirmed by 
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Figure 8. OGT knockout protocol. Neonatal mouse cardiac myocyte (NMCM) 
OGT knockout. Mice carrying 10xP flanked OGT gene were bred to 
homozygousity on the C57 background. NMCMs were isolated and cultured. 
NMCMs were infected with adenovirus carrying the CRE recombinase gene 
(AdCRE) for 72hrs. Because CRE recombinase drives the fusion of lox P sites, 
infecting NMCMs with AdCRE results in deletion of ogt gene. 
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Enzyme inhibition: NRCMs were treated with Vehicle (0.1 % OMSO or 
ethanol), [2H-1, 3-thiazine-6-carboxylic acid, 2-[(4-chlorophenyl) imino] 
tetrahydro-4-oxo-3- (2-tricyclo [3.3.1.13, 7] dec-1-ylethyl-)] (i.e. compound 4 or 
TT04: 1 molll) or 3(2H)-bensoxazolecarboxylic acid, 5-chloro-2-oxo-phenyl ester 
(i.e. compound 5 or TT40: 10 I-Imol/l) dissolved in OMSO (96) prior to 
hypoxia/reoxygenation or two hours before protein harvest for western blotting to 
inhibit OGT. TT04 and TT40 compete with UOP-GlcNAc for binding to OGT 
thereby blocking the addition of GlcNAc to protein (96). TT04 is toxic to cells 
above 1 I-Imol/l during normoxia, thus the reason for short treatment time and 
concentrations used. O-GlcNAcase activity was blocked using O-(2-acetamido-2-
deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate (111, 317) in 0.1 % 
ethanol (i.e., PUGNAc: 200l-lmol/l, overnight) and subjected to 
hypoxia/reoxygenation or total protein isolated for western blotting. Sample size 
was equal to six per group per treatment. 
RNA Interference: Cultured NRCMs were transfected with short interfering (si) 
RNA directed against OGT (30nmol/l, siRNA 10 # 173150; 5'-
GCCUGACAAUACUGGUGGUGUUtt-3'), short interfering (si) RNA directed 
against O-GlcNAcase (60nmol/l, siRNA 10 # 190811; with sense strand 5'-
GCAACUUAUGACUCCAUCtt-3' and antisense strand 3'-
GAUGAGAGUCAUAAGUUGCtc-5') or control sequence fluorescently tagged as 
a non-silencing control (C/M3-labeled negative control, Applied Biosystems). 
Myocytes were transfected with Ambion's SiPORT NeoFX transfection reagent 
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according to manufacturer's instructions. Thirty-six or seventy-two hours 
following transfection, myocytes were subjected to H/R or whole cell Iysates were 
harvested for assessment of OGT protein, O-GlcNAcase and O-GlcNAc levels as 
described below. Sample size is equal to six per group per treatment. 
ER stress induction: Normoxic NRCMs treated as mentioned above were 
subjected to ER stress by treatment with 1 ~g/mL of Brefeldin A (BfA) or 0.5 
~g/mL of Tunicamycin (TM) for 24 hours. TM inhibits N-glycosylation of nascent 
ER proteins by preventing UDP-GlcNAc-dolichol phosphate GlcNAc-phosphate 
transferase activity (72) while BfA interferes with anterograde protein transport 
from the ER to the Golgi apparatus by inhibiting transport in Golgi, which leads 
to proteins accumulating inside the ER (81). 
Reverse Transcription Real-Time peR: DNA-free total RNA was extracted 
with Trizol reagent (Invitrogen) from NRCMs treated with AdGFP (100 Mal, 48 
hours), AdOGT (100 Mal, 48 hours), AdGCA (100 Mal, 48 hours), Vehicle or 
PUGNAc (200~mol/L, overnight). Manufacturer's instructions. Total RNA 
concentration was determined by measuring the absorbance at 260nm (A260). 
The ratios of readings at 260nm and 280nm (A260/A280) or 260nm and 230nm 
(A260/A230) provided an estimated of protein/ phenol and DNA contaminants 
respectively. For purity, the ratio A260/A280 should be above 1.8 and the A260/A230 
ratio should be a close to 2. Total RNA (1 I-Ig) according was subjected to reverse 
transcriptase reaction to synthesize the cDNA using IScripFM cDNA synthesis kit 
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(BioRad). Sequences for GCA, S001, S002, GPX, Cat, 18s, and GAPOH, used 
are shown in Table 3. The relative levels of GCA, S001, S002, GPX, Cat, 18s 
and GAPOH mRNA transcripts were quantified by real-time PCR using SYBR® 
Green (Applied Biosystems). The data generated were normalized to GAPOH or 
18s threshold cycle (CT) values by using the MCT comparative method (194). 
Table 3: Primers for real time peR 
gene Sense (5'-3') Anti-sense (3'-5') 
gca tggaagaccttgggttatgg tgctcagcttcttccactga 
sod1 ccactgcaggacctcatttt caatcacaccacaagccaag 
sod2 ggccaagggagatgttacaa gaaccttggactcccacaga 
gpx tcagttcggacatcaggaga cattcacctcgcacttctca 
catalase gtggttttcaccgacgagat catgtcagggtccttcaggt 
gapdh tgatgacatcaagaaggtggtgaag tccttggaggccatgtgggccat 
18s aaacggctaccacatccaag cctccaatggatcctcgtta 
Protein expression: Total cellular proteins were isolated from NRCMs as 
follows. NRCMs were washed with PBS, harvested in ice-cold lysis buffer 
(containing 68 mmol/L sucrose, 200 mmol/L mannitol, 50 mmol/L KCI, 1 mmol/L 
EGTA, 1 mmol/L OTA and 5 mmol/L HEPES) with freshly added 0.2 j.lmol/L OTT, 
0.1v/v% protease inhibitor stock, 0.4% (v/v) NP-40, 0.4% (v/v) Triton-X and post 
translational modification inhibitor stock. Extracts were sonicated and the 
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resulting Iysates centrifuged at 15000xg for 5 minutes at 4°C to remove cell 
debris. Forty micrograms of protein (according to Bradford assay) was applied to 
each lane of a 6% SOS-PAGE electroblotted onto PVOF membranes for 0-
GlcNAcase, while fifty micrograms of protein was applied to each lane of a 4-
12% or 10% gradient NuPAGE Bis-Tris gel (Invitrogen) or 7% NuPAGE Tris-
acetate gel (Invitrogen) and electroblotted onto nitrocellulose membranes 
(Invitrogen) for OGT, O-GlcNAc levels and a-tubulin. Reagent-grade nonfat milk 
(BioRAO) 5% (w/v) in Tris buffered saline was used for blocking. Blots were 
incubated with anti-OGT (1 :1000, SIGMA), anti-O-GlcNAcase (1 :200, a gift from 
Or Zachara of Johns Hopkins), anti-O-GlcNAc antibodies (1 :1000 CTO 110.6; 
Covance or 1 :2000 RL2; Affinity BioReagents), anti-Grp 94 (1:1000, SCBT), anti-
Grp 78 (1:1000, SCBT), anti-PARP (1:1000, SCBT), anti-CHOP (1:1000, SCBT), 
anti-calreticulin (1: 1 000, SCBT) or anti-a-tubulin (1: 1 000, SCBT), as primary 
antibodies for 12 minutes at 25°C or overnight at 4°C. Blots were then incubated 
for 12 minutes or one hour with 0.051-Jg/mL of appropriate HRP-conjugated 
secondary antibody (goat anti-rat IgG, goat anti-rabbit IgG, goat anti-mouse IgM, 
goat anti-mouse IgG, donkey anti-goat IgG or anti-chicken IgG) and detected 
with an enhanced chemiluminescent detection system (Pierce). 
Glycoprotein staining: Total cellular protein was isolated from NRCMs treated 
with either Vehicle, OGT inhibitor (1l-Jmol/L TT04) or infected with adenovirus 
overexpressing OGT as described above. Following SOS-PAGE, gels were fixed 
by incubation in 50% methanol and 5% glacial acetic acid for 2 hours at 25°C. 
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The fixed gels were then washed by gentle agitation three times with 3% glacial 
acetic acid solution for 10minutes, oxidized with periodic acid for one hour at 
room temperature, stained with Pro-Q emerald for 1 hour in the dark and imaged 
using a 488 laser and S20 /BP 40 emission filter on TYPHOON 9400. 
Enzymatic labeling of O-GlcNAc-modified proteins: O-GlcNAc modified 
proteins were labeled using Invitrogen's Click-iT enzymatic labeling kit according 
to manufacturer's instructions (Figure 8). Detergents were precipitated out of 
200IJg whole cell lysate (n=6/group) or SOIJL of immunoprecipitated protein 
(VDAC or O-GlcNAc modified proteins) using the chloroform/methanol 
precipitation method by adding 600 IJL of methanol, 1S0 IJL of chloroform and 
400 IJL of distilled water and centrifuging at 14000g for Smins at 4°C. The 
interface layer containing the protein precipitate was washed twice with methanol 
and centrifuged at 14000g for Smins at 4°C. The resulting pellet was then 
covered with lint-free paper and allowed to dry for 1Smins in fume hood. The 
dried pellet was resuspended in 40 IJL of 1 % SDS and 20mM HEPES buffer pH 
7.9, boiled at 90°C for Smins, vortexed briefly and allowed to coolon ice for 
3mins. 49 IJL of distilled water, 80 IJL of labeling buffer and 11 IJL of MgCI2 were 
added and the mixture vortexed briefly. 10 IJL of UDP-GaINAz (azide-modified 
UDP-N-Acetylgalactosamine) and 7.S IJL of mutant ~-1-4-galactosyltransferase 
were added. The mixture was vortexed briefly and incubated at 4°C overnight. 
The next day, the GalNAz-labeled O-GlcNAc-modified protein mixture was 
precipitated using the chloroform/methanol precipitation method and 
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resuspended in 50 IJL of buffer containing 1 % SOS, 50mM Tris-HCI, and pH 8. 
The azide-labeled proteins were tagged with a fluorescent dye, TAMRA, by 
adding 100 IJL of TAMRA in 2x click-iT reaction buffer, 10 IJL of distilled water, 10 
IJL of CUS04, 10 IJL of click-iT reaction buffer additive 1 and 20 IJL of Click-iT 
reaction buffer additive 2. The mixture was vortexed for 5secs after the addition 
of each component. The mixture was then rotated for 1 hour at 4°C for the 
conversion of the azide group to a stable triazole conjugate. 25mM DTT was 
added, incubated at 4°C for 15mins to stop the reaction and proteins precipitated 
using the chloroform/methanol precipitation method. The dried-labeled protein 
sample was resuspended in SOS-PAGE buffer for electrophoresis. The gel was 
then imaged by excitation using a 532nm laser on a TYPHOO 9400 imager. 
SYPRO Ruby staining: Gels were stained for total protein using SYPRO ruby 
gel stain according to manufacturer's instructions. Briefly, gels were first washed 
3 times using distilled water, fixed by incubation in 50% methanol and 5% glacial 
acetic acid for 15 minutes at 25°C, and washed by gentle agitation three times 
with distilled water for 10minutes.The fixed gels were then rapid stained with 
SYPRO ruby for 1 hour in the dark by microwaving and agitating for 30 seconds, 
microwaving for 30 seconds and agitating for 5minutes and microwaving for 30 
seconds and agitating for 23 minutes. The stained gels were then destained by 
gentle agitation in 7% glacial acetic acid and 10% methanol solution for 
30minutes, washed by gentle agitation three times with distilled water for 5 
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minutes, and imaged using a 488 laser and 610 IBP 30 emission filter on 
TYPHOON 9400. 
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molecules on modified proteins 
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Figure 9. Enzymatic labeling of O-GlcNAc-modified proteins. Exogenous 
galactosyltransferase (Gal-T1) was used to cap O-GlcNAc molecules on modified 
proteins with azide-modified galactosamine (UDP-GaINAz) overnight. GalNAz 
capped proteins were then incubated with a fluorescently tagged alkyne 
(TAMRA-alkyne) to convert the "azide" group into a stable triazol conjugate. 
Proteins were then separated by SDS-PAGE and imaged on TYPHOON 9400. 
Identification of O-GlcNAc-modified Proteins: Proteins from Vehicle and 
PUGNAc-treated samples were precipitated with 10% trichloroacetic acid (v/v) 
and centrifuged at 14,055 x g for 15 minutes at 4°C. The protein pellets were 
washed with acetone and dried under a gentle stream of nitrogen gas. Two-
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dimensional electrophoresis (20E) sample buffer (20 mmolll Tris, pH 6.8, 
containing 8 molll urea, 2% CHAPS, 1 mmol/l EOTA, and 50 mmol/l OTT) was 
then added and proteins were allowed to solubilize for 2 hours at room 
temperature with gentle vortexing. Samples were again centrifuged at 14,055 x g 
for 15 minutes at 4 °C and the protein concentration in the supernatant was 
assayed by a modified method of Bradford using bovine serum albumin in 8mol/l 
urea as a standard. OTT was added to a final concentration of 50 mmol/l, 
ampholytes were added to 1 %, and 40 IJg of protein from the Vehicle and 
PUGNAc-treated samples were loaded for passive rehydration (12 hours 
incubation) onto 3-10 Nl and 7-10 IPG strips (Bio-Rad). The proteins were 
isoelectrically focused (Figure 9) for 26000 V/hrs at 25°C and strips were then 
equilibrated with base rehydration buffer containing OTT and iodoacetamide, 
respectively. IPG strips were then loaded on a 12% polyacrylamide gel and 
electrophoresed for 90 minutes at 140 V for protein separation in the second 
dimension. Proteins were then transferred to PVOF membranes by 
electroblotting overnight at 30 mA. Parallel gels were silver-stained using the 
EMBl silver-staining protocol. For western analysis, O-GlcNAc-modified proteins 
were probed using 4 IJg/ml anti-O-GlcNAc monoclonal antibodies (CT0110.6) 
followed by 0.1 IJg/ml goat anti-mouse secondary antibodies. Membranes were 
developed using ECl Plus reagents and analyzed with a Typhoon 9400 Variable 
Mode Imager (Amersham Biosciences). To obtain peptides for MS analysis, 
protein spots of interest were excised from parallel silver-stained gels and 
digested with trypsin using a modified version of the method described by Jensen 
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et 81(150). Briefly, the excised gel pieces were incubated for 15 minutes in 100 
mmollL NH4HC03 and 50% acetonitrile and dried by vacuum centrifugation. 
Proteins were then reduced by incubation with 20 mmollL OTT at 56°C for 45 
min, followed by alkylation with 65 mmollL iodoacetamide in the dark at room 
temperature for 30 min. After alkylation, gel pieces were incubated for 15 min in 
50 mmol/L NH4HC03 and 50% acetonitrile and dried by vacuum centrifugation. 
Proteins were hydrolyzed by incubation in 20 ng of modified trypsin (Promega) 
per ml at 3rC overnight. Trypsin-generated peptides were applied on stainless 
steel targets by thin-film spotting using a-cyanohydroxycinnamic acid (Aldrich) as 
a matrix. Mass spectral data were obtained with a TOF-Spec 2E instrument 
(Micromass) and a 337 nm N2 laser at 20 to 35% power in the reflector mode. 
Spectral data were obtained by averaging 10 spectra, each of which was the 
composite of 10 laser firings. Mass axis calibrations were accomplished by using 
peaks from tryptic auto-hydrolysis. Peptide masses obtained by MALOI-TOF/MS 
analysis were analyzed with Protein Probe software (MassLynx) to identify intact 
proteins. Additionally, the National Center for Biotechnology Information (NCBI) 
database was also used for protein identification(238). Peptides displaying 
masses consistent with O-GlcNAc modification (monoisotopic mass = 203.079) 
were ascribed as potentially modified protein fragments. 
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Figure 10. Protocol for identifying O-GlcNAc modified proteins by 2-D gel 
electrophoresis followed by MALDI-TOF. 
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Mitochondrial isolation: C57BLl6 mice were injected (intraperitoneal) with 
Vehicle (0.1 % w/v DMSO or 0.1 % ethanol), 10 mg/kg TT04, or 50mg/kg of 
PUGNAc. After 18 h, the mice were anesthetized with 100 mg/kg pentobarbital. 
Hearts were harvested, immediately rinsed with PBS, and placed in Kontes Duall 
homogenizer containing 4 mL sucrose buffer A (300 mmollL sucrose, 10 mmol/L 
Tris-HCI, 2 mmollL EGTA and 5 mg/mL BSA, pH 7.4) on ice. Hearts were 
homogenized using 12 strokes. The homogenate was centrifuged at 2000 xg for 
2 min at 4 °C to remove cell debris. The supernatant was further centrifuged at 
10,000 xg for 5 min 4 °C to sediment impure mitochondria. Mitochondria were 
washed twice with 1 mL of sucrose buffer A (minus BSA)(92) and purified by 
adding 19% Percoll and centrifuging at 14,000 xg for 10 min at 4 °C. 
Mitochondrial pellet was washed twice with 0.5 mL of sucrose buffer B 
(300 mmollL sucrose, 10 mmollL Tris-HCI, pH 7.4)(103). Purified mitochondrial 
pellet was resuspended in 0.5 mL of sucrose buffer B. 100l-iL of mitochondrial 
stock was used for protein concentration determination using BIO-RAD protein 
assay buffer according to the Bradford method. Adult mouse hearts were used to 
confirm the insights from the neonatal rat cardiomyocytes in the adult 
myocardium, and more importantly, because of the relatively high yield of intact 
mitochondria from the adult mouse heart. 
Co-immunoprecipitation: Co-immunoprecipitation was performed with Protein 
G immunoprecipitation kit (Sigma) according to manufacturer's instructions on 
adult mouse cardiac mitochondrial proteins from DMSO, TT04 (OGT inhibitor), 
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HCI or PUGNAc treated mice as shown on Figure 10. Briefly, 5 ~L of the anti-O-
GlcNAc antibody (RL2) or 1 0 ~L of the anti-VDAC antibody and 245 ~L of 1 x IP 
buffer were added to 50 ~L of sample and rotated in an end-to-end fashion at 
4 °C for 1 h. 50 ~L of washed Protein-G-sepharose beads was added to 
antibody-sample mixture and rotated in a head-to-tail fashion at 4 °C overnight. 
The antibody-sam pie-bead mixture was then washed five times with 300 ~L of 1 x 
IP buffer and once with 0.1x IP buffer centrifuging at 12,000 000 xg at 4 °C for 
30 s between washes. 1 x sample buffer, reducing agent and 1 x TBS were added 
and the mixture was heated at 95 °C for 5 min. Samples were then 
immunoblotted for VDAC using anti-VDAC (1 :2000, Santa Cruz) or O-GlcNAc 
using RL2 (1 :1000, Affinity BioReagents). Standard densitometry was performed 
and the value for the Vehicle (DMSO or HCI) group was set at 100%. All samples 
were normalized to their total VDAC levels (which were not different between the 
two groups). 
Antibody (anti-
VDAC or anti-
O-GlcNAc) 
Antibody binds to 
specific protein 
Proceed w ith W ester n b lotting 
Figure 11. Immunoprecipitation protocol. 
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Densitometry: Densitometry was performed using non-saturated 
chemiluminescent membranes exposed and quantitated using Fuji LAS-3000 
bio-imaging analyzer. Multiple exposures from every experiment were used to 
confirm that the signal was within the linear range. Densitometric analysis of 0-
GlcNAc levels using CTD 110.6 and RL2 antibodies were performed on the 
entire lane. O-GlcNAc levels were normalized to the appropriate control 
(Ponceau stain), and then expressed as a percentage of control (set at 100%). 
In vitro hypoxia-reoxygenation injury in cardiac myocytes: Cardiac myocytes 
were subjected to hypoxia using Esumi lethal ischemic media, pH 6.2 
(containing 117 mmol/L NaCI, 12 mmol/L KCI, 0.9 mmol/L CaCI2, 0.49 mmol/L 
MgCI2, 4 mmol/L HEPES, 20 mmol/L sodium lactate, and 5.6 mmol/L L-glucose) 
by sealing the plated myocytes in humidified hypoxic chambers (Billups-
Rothenberg, Inc) (164), flushing each chamber with a gas mixture consisting of 
5% C02 and 95% N2 for fifteen minutes, and incubating the hypoxic chamber in a 
modular incubator at 37°C for three hours. Following hypoxia, the media was 
changed to 1x Esumi control media (pH 7.4, 137 mmol/L NaCI, 3.8 mmol/L KCI, 
0.9 mmol/L CaCI2, 0.49 mmol/L MgCb, 4 mmol/L HEPES, and 5.6 mmol/L D-
glucose) and culture dishes reoxygenated for one or six hours in the modular 
incubator or on the fluorescent microscope during imaging as appropriate. 
Similarly treated NRCMs were subjected to four or 9 hours of normoxia in 1x 
Esumi control media to serve as normoxic/aerobic controls. 
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Cell death: Cell death was assessed for NRCM treated as mentioned above and 
subjected to hypoxia/reoxygenation by measuring normoxic or post-hypoxic LDH 
release using a commercially available kit (Sigma). Data was expressed as LDH 
release relative total LDH in the cells and normalized to the appropriate controls 
(1 hr reoxygenation data) or normoxic untreated control (for 6hrs reoxygenation 
data). Similarly treated NRCMs were stained with the fluorescent DNA-binding 
dyes Hoechst 33342, 5l-1g/mL and propidium iodide, 51-1g/mL (Invitrogen) during 
the last 30 minutes of reoxygenation(19). The stained nuclei were then 
visualized using a 20x objective on a Nikon-TE2000E2 fluorescence microscope 
and Xcite 120 Fluor light source (level of 12%). Filters used included 350/50 nm 
excitation and 470/40 nm emission filters for Hoechst and 560/40 nm excitation 
and 630/60 nm emission filters for PI. Neutral density filter setting was set at 
ND4 and binning of 2x for all image acquisition. Exposure duration was set at 
100ms for Hoechst and 200ms for PI. Four fields per treatment were counted 
and data were expressed as % PI positive nuclei/total nuclei. Because the 
nuclear stain Hoechst 33342 is membrane permeable, it was used to determine 
total cells in each field and not as an index of apoptosis. Sample size of at least 
four per group was used. 
Apoptosis: Apoptosis was assessed by measuring Caspase 3/7 activity in whole 
cell Iysates using Caspase Glo kit (PROMEGA) according to manufacturer's 
instructions. Briefly, equal volumes of whole cell lysate (50l-lg) and caspase 
reagent were mixed and incubated in the dark for one hour at room temperature. 
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Bioluminescence was measure using Modulus luminometer (Turner Biosystems) 
and expressed in relative luminescent units (RLUs). Sample size is equal to at 
least five per group per treatment. 
Fluorescence Microscopy: NRCMs were imaged in imaging medium 
(Dulbecco's Modified Eagle Medium (with HEPES and minus phenol red and 
pyruvate). Images were captured using a Photometric CoolS NAP ES camera 
attached to a Nikon-TE2000E2 fluorescence microscope with a T-PFS Perfect 
Focus Unit all controlled with MetaMorph 6.3r2 software. The Perfect Focus 
System was used to prevent minute defocusing caused by changes over time 
during time-lapse imaging. Xcite 120 Fluor light source (level of 12%) was used 
and a Plan Apo 60xA/oil (NA=1.4) objective were used for magnification. Neutral 
density filter setting was set at ND4 and binning of 2x for all image acquisition. 
Images were captured every 90 seconds for 60 minutes. Exposure duration was 
set at 100ms for all fluorescent dyes except for rhod-2 which was set at 50ms. 
Excitation and emission filters varied depending on the fluorescent dye as 
mentioned below. 
Assessment of Calcium Overload: NRCMs treated with AdGFP, AdNull, 
AdOGT, AdGCA, vehicle, or PUGNAc were loaded with 2j.JmollL of rhod-2(290, 
291) (used to assess mitochondrial calcium, Invitrogen) and subjected to 3 hours 
of hypoxia. Calcium levels were assessed by following the changes in rhod-2 
fluorescence during reoxygenation using time-lapse fluorescent microscopy. 
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Imaging was initiated during reoxygenation by exciting rhod-2 through 560/28 nm 
and 646/38 nm emission filter. All experimental groups were repeated in six 
separate NRCM cultures. 
Assessment of reactive oxygen species (ROS) production: ROS levels were 
assessed in NRCMs using time-lapse fluorescence microscopy by following the 
changes in 5-(and-6)-carboxy-Z,T-dichlorodihydrofluorescein diacetate (DCF) 
fluorescence(291). NRCMs treated with AdNull, AdOGT, AdGCA, Vehicle, or 
PUGNAc were loaded with 2IJmoi/L DCF and subjected to 3 hours of hypoxia as 
mentioned above. During reoxygenation, imaging was initiated immediately by 
exciting DCF through 470/40 nm bandpass filter and emission through 522/40 
nm bandpass filters. All expmimental groups were repeated in at least four 
separate isolations. 
Assessment of mitochondrial membrane potential: Using time-lapse 
fluorescence microscopy (4, 5, 158, 290, 291), detection of mitochondrial 
membrane potential changes were performed by following changes in 
tetramethylrhodamine methyl ester (TMRM) fluorescence. NRCMs treated with 
AdGFP, AdOGT, AdGCA, vehicle, PUGNAc, Control siRNA or GCA siRNA were 
loaded with 100 nmol/L TMRtvl and subjected to 3 hours of hypoxia. Imaging 
was initiated during reoxygenation by exciting TMRM through a 546/11 nm 
bandpass filter and emission assessed through a 567/15 nm bandpass filter. 
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Exposure duration was set at 100ms and all experimental groups were repeated 
in at least four separate isolations. 
Mitochondrial swelling assay: The mitochondrial swelling assay was 
performed similar to previous reports. Two mg/ml cardiac mitochondria from 
Vehicle- (0.1 % DMSO or 0.1 % ethanol), TT04- (OGT inhibitor), or PUGNAc-
(GCA inhibitor) treated mice in buffer B was loaded on a 96-well plate and 
allowed to warm to room temperature. CaCI2 (100 jJmol/L) was used to induce 
mitochondrial swelling and the change in absorbance measured 
spectrophotometrically at 520 nm. A decrease in absorbance indicated an 
increase in swelling (i.e. mitochondrial permeability transition pore opening). 
Murine in vivo ischemia-reperfusion: Three- to four-month-old male SV129 
(mean body weight 25±1 g) were randomized to PUGNAc or isovolumetric 
Vehicle treatment groups. Mice were subjected to in vivo coronary artery 
ischemia-reperfusion for assessment of O-GlcNAc levels or myocardial infarct 
size according to well characterized protocol (Figure 11 )(156, 158). Mice were 
anesthetized with intraperitoneal injections of ketamine hydrochloride (50 mg/kg) 
and sodium pentobarbital (50 mg/kg). The animals were then attached to a 
surgical board with their ventral side up. The mice were orally intubated with 
polyethylene (PE)-60 tubing connected to a rodent ventilator (Harvard Apparatus) 
with tidal volume and breathing rate set by standard allometric equations. The 
mice were supplemented with 100% oxygen via the ventilator side port. Body 
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temperature was maintained between 36.5 and 37.5 using a rectal probe and a 
heat lamp. A left thoracotomy was performed using a thermal cautery, and the 
proximal left main coronary artery was visualized with the aid of a dissecting 
microscope and completely occluded for 40 minutes with 7-0 silk suture mounted 
on a tapered needle (8V-1, Ethicon). After 40 minutes, the suture was removed 
and reperfusion was initiated and visually confirmed. The chest was closed in 
layers using 4.0 silk suture. The skin was closed using 4-0 nylon suture. 
Ketoprofen was given as analgesia prior to closing the chest. Upon recovery of 
spontaneous breathing, mice were removed from the ventilator, extubated and 
allowed to recover in a warm, clean cage supplemented with 100% oxygen. 
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Figure 12. Murine myocardial ischemia-reperfusion protocol. A - 40mins of left 
anterior descending coronary artery ligation_ B - Suture cut and reperfusion 
initiated. C - Reocclusion of LAD_ D - Injection of Evans blue dye into the right 
carotid artery to delineate the ischemic zone and the non-ischemic zone. E-
Heart cross sections incubated in TTG to delineate viable and non viable tissue. 
NEG: necrotic tissue and NIZ: non-ischemic zone. 
Myocardial ischemic/non-ischemic zone determination: Following 40minutes 
ligation of left anterior descending coronary artery in G57BL6 mice described 
above, reperfusion was initiated. After 0, 1, 4 and 24 h of reperfusion , the mice 
were anesthetized with isoflurane. A tracheotomy was performed and mice were 
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ventilated as described above. A catheter (PE-10 tubing) was placed in the 
common carotid artery to allow for Evans blue dye injection. A median 
sternotomy was performed, and the left main coronary artery was relegated in 
the same location as before. Evans blue dye (1.2 ml of a 2% solution) was 
injected into the carotid artery catheter into the heart to delineate the ischemic 
zone from the non ischemic zone (Figure 11). The heart was rapidly excised and 
serially sectioned along the long axis in 1-mm-thick sections. With the aid of a 
dissecting microscope, the non-ischemic and ischemic zone was separated and 
O-GlcNAc levels were assessed. 
Myocardial infarct size determination: Myocardial infarct size was determined 
according to well characterized protocol (153, 155). After 24 h of reperfusion, the 
mice were anesthetized as with isoflurane and Evans blue dye (1.2 ml of a 2% 
solution) used to delineate the ischemic zone from the non ischemic zone as 
described above. The heart was rapidly excised and serially sectioned along the 
long axis in 1-mm-thick sections, which were then incubated in 1.0% 2,3,5-
triphenyltetrazolium chloride for five minutes at 3rC to demarcate the viable and 
nonviable myocardium within the risk zone (Figure 11). Digital pictures of the 
basal of each section were taken. Each of the five 1-mm-thick myocardial slices 
was weighed. A blinded observer assessed the areas of infarct, risk, and non-
ischemic zone using computer-assisted planimetry (Image J, version 1.38x). 
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Evaluation of blood pressure, heart rate, and left ventricular function: In 
order to assess the closed-chest hemodynamic status, mice were anesthetized 
with ketamine (50 mg/kg, intraperitoneal) and pentobarbital (50 mg/kg, 
intraperitoneal) and supplemented with oxygen via a nasal cone. A fluid-filled 
polyethylene catheter was inserted into the right common carotid artery and 
advanced to the aorta left ventricle via (197). Data were recorded for 10 
seconds. Offline assessment of these data yielded mean arterial blood pressure, 
and heart rate (HR). The catheter was then advanced through the aortic valve 
into the left ventricle (LV). Data were recorded for 10 seconds. In vivo 
transthoracic echocardiography of the left ventricle using a 15 MHz linear array 
transducer (15LBs) interfaced with a Sequoia C512 (Acuson) was performed 
(154, 156). Ventricular parameters were measured according to the leading-
edge technique. M-mode (frame rate=30 Hz; sweep speed=200 mm/s) 
echocardiograms were captured from short-axis views of the LV at the mid-
papillary level. Data for each animal were calculated from at least 10 seconds of 
chart recording. All data were calculated from 10 independent cardiac cycles 
per experiment. Short axis views at the mid papillary level yielded left ventricular 
(LV) end diastolic diameter (ED D), end systolic diameter (ESD), heart rate (HR), 
and fractional shortening (%FS). LV fractional shortening (LVFS) was calculated 
according to the following equation: LVFS= ([LVEDD-LVESD]/ LVEDD)x100. 
Cardiac troponin-I assessement: cardiac Troponin-I release was measured in 
plasma from mice subjected to sham surgery or ischemia-reperfusion protocol 
71 
described above according to manufacturer's instructions. First, a 1:4 dilution of 
plasma samples in plasma diluents was made and loaded on to a 96 well plate in 
triplicate. Diluted plasma samples were allowed to react simultaneously with two 
affinity purified antibodies (one used for solid phase immobilization and the other 
and conjugated to HRP) on the microtiter wells by incubating plate at room 
temperature on a plate shaker. Wells were washed with water to remove any 
unbound HRP-conjuated antibody. HRP substrate, tetramethylbezidine was 
added and plate incubated for 20 minutes at room temperature fordevelopment 
of color. 1 mol/L Hel was added to each well to stop color development and 
absorbance measured on a spectrophotometer at 450nm. cTnl concentration of 
the samples were determined from standard curve and in ng/mL. 
Statistical analysis: Data were analyzed using GraphPad Prism 4 software. 
One-way ANOVA was employed for three or more experimental groups and 
Dunnett's t tests for post hoc analysis. Unpaired student's t test was used to 
analyze data containing two experimental groups. Data are reported as 
mean ± standard error of the mean with differences between treatment groups 
accepted as significant when p < 0.05. 
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CHAPTER V 
RESULTS 
A. O-GlcNAc levels are altered following oxidative stress: O-GlcNAc levels 
were assessed via Western blot analysis in isolated cardiomyocytes treated with 
Vehicle or PUGNAc (a GCA inhibitior) and exposed to various durations of 
hydrogen peroxide (H20 2 , 0.1 mmol/L) in serum-free media. Cardiomyocytes 
experience a significant (p<0.05) decrement in O-GlcNAc levels at about 40 
minutes (Figure 12A). Myocytes treated with PUGNAc showed markedly 
(p<0.05) higher levels of O-GlcNAc throughout the time course compared with 
Vehicle-treated myocytes (Figure 12A). Furthermore, the oxidative stress-
mediated decrement in O-GlcNAc levels was retarded in the PUGNAc- compared 
with the Vehicle-treated group (Figure 12A). To determine whether reversal of 
the decrement in O-GlcNAc levels could attenuate cell death, cardiomyocytes 
were treated with PUGNAc or Vehicle, exposed to H20 2, and coincubated with 
propidium iodide and annexin V. At the end of 150 minutes of H20 2 exposure, 
the percentage of propidium iodide-positive cells was Significantly (p<0.05) 
augmented compared with control (Figure 128). Moreover, exposure to H20 2 
induced a significant (p<0.05) increase in annexin V fluorescence positivity 
compared with control (Figure 12C). PUGNAc treatment significantly (p<0.05) 
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attenuated H20 2-induced cell death according to PI and annexin V positivity. 
Saponin permeabilization was used at the end of the experimental protocol to 
confirm equal numbers of cells per field (Figure 128). 
B) 
A) Vehicle PUGNAc 
Time (mins) 0 15 40 45 5055 60 0 15 40 45 50 55 60 
110 
80 
65 
50~ ________________________ ~ 
IS : O-GlcNAc 
C) 
o 102030 <40 50 eo 70 10 to 100110'120130140150 
(mlinutn po" hydrogen pero ..... 
Time 
Control Vehicle PUGN.Ac 
Figure 13. Effects of augmented O-GlcNAc levels on oxidative stress-induced 
cardiomyocyte death. A) Representative immunoblot (18) of time course of 0-
GlcNAc levels in cardiac myocytes treated with Vehicle or PUGNAc and 
subjected to oxidative stress for 60 minutes (n=4 per group). O-GlcNAc levels 
are significantly elevated in PUGNAc-treated myocytes compared with Vehicle. 
8) After 150 minutes of oxidative stress, most Vehicle-treated myocytes become 
PI positive, a phenomenon inhibited by PUGNAc (n=3/group). Representative 
confocal images of myocytes from each treatment group at the end of the 
experiment (pre-saponin) or after saponin permeabilization, indicating equivalent 
number of cells per field. C) During the time course of oxidative stress, annexin 
V positivity increases in Vehicle-treated myocytes, an effect attenuated by 
PUGNAc. Representative confocal images of myocytes from each treatment 
group at the end of the experiment (n=3/group). 
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B. O-GlcNAc levels are altered following hypoxia-reoxygenation: To 
determine if O-GlcNAc levels change during hypoxia and reoxygenation, isolated 
neonatal rat cardiac myocytes (NRCMs) were subjected to hypoxia and 
reoxygenated for different durations (0, 1 and 6 hours). Hypoxia significantly 
decreased O-GlcNAc levels compared to normoxia (Figure 13A-B). During 
reoxygenation, we observed a time dependent increase in O-GlcNAc levels 
peaking after 6 hours (Figure 13A-B) and falling to minimal levels by 18 hours of 
reoxygenation (data not shown). 
Hypoxia damaged cardiac myocytes as reflected in increased post-
hypoxic LDH release compared to normoxia. Reoxygenation further exacerbated 
the hypoxia-mediated myocytes injury mirrored by the time dependent increase 
in post-hypoxic LDH release for hypoxic myocytes compared to normoxia (Figure 
13C). 
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Figure 14. Effects of hypoxia-reoxygenation on O-GlcNAc levels. Myocytes 
were subjected to hypoxia for three hours and reoxygenated for zero, one or six 
hours. O-GlcNAc levels were assessed on whole cell Iysates or cell injury 
assessed by measuring post-hypoxic LDH release in the media. B) 
Representative immunoblots of time course of O-GlcNAc levels in cardiac 
myocytes. B) Densitometric quantification of O-GlcNAc immunoblots expressed 
as percent of normoxic control. C) Hypoxia induced cell injury according to post-
hypoxic LDH release. 
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C. ROLE OF OGT IN POST -HYPOXIC CARDIOMYOCYTE INJURY 
C.1. OGT overexpression attenuates post-hypoxic cardiac myocyte death: 
Adenovirus carrying the OGT gene was used to study gain-of-function for 0-
GlcNAc transferase (AdOGT). Forty eight hours after infecting isolated neonatal 
rat cardiac myocytes (NRCMs) with AdOGT, total cellular proteins were 
harvested and OGT protein and O-GlcNAc levels assessed via western blot 
analysis. Infection of NRCMs with AdOGT augmented OGT levels (349 ± 86% of 
o MOl, n=3/group, Figure 14A). Assessment of the functional readout, 0-
GlcNAc, showed significant (p < 0.05) increase in O-GlcNAc levels (145 ± 19% of 
o MOl, n>/=6/group, Figure 148). To confirm this finding, two additional 
approaches were used. First, the same samples were evaluated using another 
O-GlcNAc antibody (RL2), which showed a significant (n=5/group, p < 0.05, 
Figure 148) increase in O-GlcNAc levels at 100 MOl compared to 0 MOl AdOGT. 
Second, additional samples were prepared for evaluation using a non-immune 
technique (enzymatic labeling of O-GlcNAc with TAMRA fluorophore; i.e. click-
chemistry based approach). The enzymatic labeling technique also showed a 
significant augmentation of O-GlcNAc levels with 100 MOl AdOGT (155 ± 9%) 
compared to 0 MOl AdOGT (Figure 148). Immunoblots/gels for O-GlcNAc levels 
show multiple positive bands because O-GlcNAc is a post-translational 
modification, not a single protein (Figure 148). In addition to the significant 
increases in O-GlcNAc levels, there was no significant difference in total 
glycoprotein levels following OGT overexpression according proQ emerald 
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staining (Figure 14C). Equal protein loading was confirmed by densitometric 
analysis of Ponceau-stained membranes or SYPRO ruby stained gels. 
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Figure 15. Effects of OGT overexpression (using AdOGT) on post-hypoxic 
cardiomyocyte injury. Myocytes were infected with AdOGT 48 hours prior to 
protein harvest or hypoxia-reoxygenation. A) Summary densitometric analysis 
(n=3/group) and immunoblot of OGT (using SQ17) show significant (p<0.05) 
increase in OGT protein with 100 MOl compare to 0 MOl of AdOGT. B) 
Densitometric analysis (n=5-6/group) and of the functional readout of OGT, 0-
GlcNAc. Significant increase in O-GlcNAc levels (n=6/group) is seen with the 
CTD110.6 and RL2 antibodies as well as TAMRA fluorescence. As expected, 
multiple immunopositive bands appear because the O-GlcNAc modification 
occurs on numerous proteins throughout the cell. C) Representative immunoblot 
show significantly augmented O-GlcNAc levels with AdOGT. D) Representative 
TAMRA-GlcNAc gel showing augmented O-GlcNAc levels despite no change in 
total glycoprotein levels (ProQ gel staining, n=3/group) with AdOGT *p<0.05 vs. 0 
MOl AdOGT. 
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To evaluate the effects of OGT overexpression on post-hypoxic cardiac 
myocyte survival, similarly-treated cardiac myocytes were subjected to hypoxia 
(three hours) and reoxygenation (one hour). Post-hypoxic media were harvested 
and assayed for LDH release and cells were evaluated for PI positivity. A 
significant (p < 0.05) decrease in post-hypoxic LDH release was seen with 100 
Mal (67 ± 15% of 0 Mal) compared with 0 Mal AdOGT treated NRCMs (Figure 
15A). Also, we observed a significant reduction in PI positivity at 100 Mal 
(66 ± 7% of AdGFP) compared with AdGFP treated NRCMs (Figure 158). 
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Figure 16. A) OGT overexpression improved post-hypoxic cardiac myocyte 
survival. LDH release was spectrophotometricallY determined from the media 
following hypoxia-reoxygenation (n=4-6/group). B) OGT overexpression 
attenuated post-hypoxic injury according to propidium iodide staining. *p<0.05 vs. 
o Mal AdOGT or 100 Mal AdGFP. 
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C.2. OGT inhibition exacerbates post-hypoxic cardiac myocyte injury: 
Loss-of-function for OGT was evaluated by incubating cultured NRCMs 
(n = 6/group) with Vehicle (0.1 % DMSO) or OGT inhibitors (1.0 IJmol/L TT04 or 
10 IJmollL TT40) for two hours prior to protein harvest and immunoblotting for 0-
GlcNAc levels. The concentrations of TT04 and TT 40 used were not toxic to the 
cells under normoxic conditions. Significant reductions (65 ± 7%, P < 0.05) in 0-
GlcNAc levels were observed with TT04 treatment compared to Vehicle (Figure 
16A). We observed similar results with RL2, an additional O-GlcNAc antibody as 
shown in bar graph (Figure 16A). A similar phenomenon was observed with a 
related OGT inhibitor, TT40 (Figure 168). There was no significant difference in 
glycoprotein levels following OGT inhibition (100 ± 8% of Vehicle, p = NS) 
compared with Vehicle (100 ± 4%) according to Pro-Q Emerald staining (Figure 
16C) demonstrating that the OGT inhibitor (TT04) does not alter other 
glycosylation processes. As with virtually all known compounds, no absolute and 
exclusive claims can be made regarding potential non-specific effects. 
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Figure 17. Evaluation of effects of OGT inhibition on post-hypoxic cardiac 
myocyte survival. NRCMs were treated with the OGT inhibitor, TT04 or TT40, 
prior to protein harvest or H/R. A) Densitometric analysis and representative 
immunoblots for O-GlcNAc levels following TT04 treatment show significant 
reduction in O-GlcNAc levels. Multiple bands occur because O-GlcNAc is a post-
translational modification occurring on a plethora of intracellular proteins 
(n=6/group). B) Densitometric analysis and representative immunoblots for 0-
GlcNAc levels following TT40 treatment show significant decrease in O-GlcNAc 
levels (n=3/group). C) Densitometric analysis and representative ProQ emerald 
stained gel for glycoprotein levels following TT04 treatment show no change in 
glycoprotein levels (n=4/group). 
To evaluate the effects of OGT inhibition on cardiac myocyte survival post-
hypoxia, cardiac myocytes (n = 6/group) were treated with TT04, subjected to 
hypoxia-reoxygenation, and media harvested to measure LDH release. Inhibition 
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of OGT with TT04 (172 ± 18%, p<0.05) or TT40 (227±30%, p<0.05) significantly 
augmented post-hypoxic LDH release compared to vehicle (Figure 17 A). 
Moreover, PI positivity was significantly more following OGT inhibition with TT04 
(132 ± 10%, P < 0.05) compared to Vehicle (Figure 178). 
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Figure 18. A) OGT inhibition (with TT04 and TT40) significantly exacerbated 
post-hypoxic cardiac myocyte survival. LDH release was spectrophotometrically 
determined from the media following hypoxia-reoxygenation (n=6/group). B) 
OGT inhibition via TT04 worsens post-hypoxic injury reflected by the significant 
increase in PI positive cells (n=4/group). *p<0.05 vs. Vehicle. 
C.3. Knockdown of OGT sensitizes cardiac myocytes to post-hypoxic 
death: NRCMs (n ~ 4/group) were treated with OGT siRNA or Control siRNA for 
36 hours to knockdown OGT expression at the mRNA level. The transfection 
efficiency for the siRNA was estimated to be greater than 90% (Figure 18A). 
Whole cell Iysates immunoblotted for OGT and O-GlcNAc showed significant 
reductions in OGT levels (49 ± 8% of Control, p < 0.05) and O-GlcNAc levels 
(64 ± 5% of Control, p < 0.05) for OGT siRNA-treated NRCMs compared with 
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control siRNA-treated NRCMs (Figure 188-C). There was no difference in 0-
tubulin levels between OGT siRNA- and Control siRNA-treated myocytes 
according to western blot (Figure 188). 
To investigate the effects of OGT gene knockdown on cardiac myocyte 
survival post-hypoxia, cardiac myocytes (n=6/group) were treated with 30 nmol/L 
OGT siRNA or Control siRNA for 36 hours, subjected to hypoxia-reoxygenation, 
and media harvested to measure LOH release. There was a significant 
(120 ± 2% of control p < 0.05) augmentation in post-hypoxic LOH release in OGT 
siRNA-treated NRCMs compared to Control siRNA-treated NRCMs (Figure 180). 
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Figure 19. Effects of OGT gene knockdown on post-hypoxic NRCM survival 
(n=6/group). A) NRCMs transfected with fluorescently tagged control siRNA 
showing a transfection efficiency of more than 90%. B) Knockdown of OGT 
significantly reduces OGT protein levels according to immunoblotting in OGT 
siRNA-treated compared with Control siRNA treated NRCMs. C) Whole cell 
Iysates from OGT siRNA-treated NRCMs showed a significant decrease in 0-
GlcNAc levels compared with those from Control siRNA-treated NRCMs 
according to western blotting. D) NRCMs treated with OGT siRNA were more 
sensitive to hypoxia-induced injury (according to LDH release) compared with 
NRCMs treated with Control siRNA. *p< 0.05 vs. Control siRNA. 
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C.4. Deletion of OGT gene sensitizes cardiac myocytes to hypoxic injury: 
Neonatal mouse cardiac myocytes (NMCMs, n=3/group) carrying only 10xP-
flanked copies of the OGT gene (Figure 19A) were infected with adenovirus 
expressing CRE-recombinase for 72 hours. Whole cell Iysates were 
immunoblotted for CRE-recombinase, OGT, and O-GlcNAc modification. NMCMs 
expressing CRE-recombinase (Figure 19B) showed significant reductions in OGT 
(44 ± 16% of control, Figure 19C) and O-GlcNAc levels (28 ± 5% of control, 
Figure 190). To assess the effect of OGT deletion on cardiac myocyte survival 
following hypoxia, 72 hour post-AdCRE infection, NMCMs were subjected to 3 h 
of hypoxia and 1 h of reoxygenation and media harvested for LOH assay. A 
significant (p < 0.05) elevation in LOH release was observed at 50 MOl 
(122 ± 12% of control) compared with 0 MOl AdCRE (Figure 19E). 
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Figure 20. Effects of OGT deletion on survival following hypoxia in cardiac 
myocytes. NMCMs were infected with AdCRE 72 hours prior to protein harvest 
or H/R. A) Representative genotyping PCR results showing 10xP-fianked or WT 
OGT gene. B) Cardiac myocytes from homozygous litters were exposed to 
AdCRE or no virus. There was a significant (p<0.05) increase in CRE-
recombinase expression (n=4/group) and C) a significant (p<0.05) decrease in 
OGT levels with 50 MOl compared with 0 MOl AdCRE (n=4/group). D) O-GlcNAc 
levels were markedly decreased at 50 MOl compared with 0 MOl AdCRE 
(n=4/group). E) LDH release was significantly (p<0.05) elevated at 50 MOl 
compared with 0 MOl AdCRE following hypoxia-reoxygenation (n=4/group). 
*p<0.05 vs. 0 MOl AdCRE. 
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D. ROLE OF GCA IN HYPOXIA-INDUCED CARDIAC MYOCYTE INJURY 
D.1. GCA (AdGCA) overexpression exacerbates post-hypoxic cardiac 
myocyte death: Forty-eight hours following AdGCA infection of isolated NRCMs 
(n>/=5 per group), total cellular proteins were isolated for GCA protein and 0-
GlcNAc levels (via western blot analysis). Adenoviral overexpression of GCA 
significantly (p<0.05) augmented GCA protein levels (Figure 20A). Such 
elevation corresponded with a significant (p<0.05) reduction in O-GlcNAc levels 
(48±7% of 0 Mal AdGCA) (Figure 208). Similar findings were seen with another 
O-GlcNAc antibody, RL2 (65±8% of 0 Mal AdGCA; Figure 208). Immunoblots for 
O-GlcNAc levels show multiple immunopositive bands because O-GlcNAc is a 
posttranslational modification, not a single protein (Figure 208). Other studies 
have demonstrated similar findings in various cell lines (333) and NRCMs(33, 
34). Equal protein loading was confirmed by densitometric analysis of Ponceau-
stained membranes. 
To evaluate the effects of GCA overexpression on post-hypoxic cardiac 
myocyte survival, similarly treated cardiac myocytes were subjected to hypoxia (3 
h) and reoxygenation (1 or 6 h). Post-hypoxic media was harvested for LDH 
release, and additional post-hypoxic NRCMs were stained with PI to assess cell 
death. Myocytes infected with AdGCA were more sensitive to hypoxia-induced 
injury by the first hour of reoxygenation according to LDH release (150±23% of 0 
Mal AdGCA, p<0.05; Figure 20C). To determine whether the detrimental effect 
of AdGCA on post-hypoxic cardiac myocytes was short-lived, similarly treated 
NRCMs were reoxygenated for 6 hours after 3 hours of hypoxia. The longer 
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duration of reoxygenation (6 hours) still showed exacerbated cellular injury in 
AdGCA NRCMs, according to LOH release (179±14% versus 136±8% for 
AdGFP, p<0.05; Figure 20C). Another index of cell death i.e. PI positivity 
confirmed our one hour (17±2% versus 10±1% for AdGFP; Figure 200) and six 
hour (34±3% versus 24±2% for AdGFP, p<0.05; Figure 200) post-post-hypoxic 
LOH data compared to 0 MOl AdGCA or AdGFP. 
Cell damage was not significantly different among AdGCA, AdGFP, or 
uninfected NRCMs under normoxia according to LOH release (109±3% of control 
versus 93±3% of control, p>0.05) and PI positivity (14±1% for GCA versus 
13±1 % for AdGFP versus 12±1 % for control, p>0.05). Such results confirm that 
viral infection does not affect cell survival or O-GlcNAc levels in this system. 
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Figure 21. Myocytes were infected with AdGFP or AdGCA (0 or 100 Mal) 48 
hours before protein isolation or hypoxia/reoxygenation. A) Bar graph of real 
time PCR showing significantly augmented GCA mRNA levels at 100 Mal 
compared to 0 Mal AdGCA (n=3/group). B) Representative immunoblot of GCA 
protein shows significant elevation in GCA levels following AdGCA infection. C) 
Densitometric analysis and representative immunoblot of O-GlcNAc levels. 
AdGCA significantly reduced O-GlcNAc levels. As expected, multiple 
immunopositive bands appear because the O-GlcNAc modification occurs on 
numerous proteins throughout the cell (n=5/group). D) GCA overexpression 
exacerbated post-hypoxic cardiac myocyte damage according to LDH release 
(n=5/group). E) GCA overexpression aggravated post-hypoxic injury according 
to propidium iodide positivity (n=4-5 /group). *P<0.05 vs. 0 Mal AdGCA or 100 
Mal AdGFP. 
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0.2. GCA inhibition attenuates post-hypoxic cardiac myocyte injury: 
NRCMs (n=61 group) were treated with PUGNAc (GCA inhibitor) overnight before 
protein harvest, then immunoblotted for a-GlcNAc levels. PUGNAc significantly 
increased a-GlcNAc levels (878±215% of control, p<0.05) compared to vehicle 
(Figure 21A). 
Additional NRCMs (n=61 group) were treated with PUGNAc, subjected to 
hypoxia/reoxygenation, and media harvested to measure LDH release. Inhibition 
of GCA (with PUGNAc) (70±10% of Vehicle, p<0.05; Figure 218) significantly 
attenuated post-hypoxic LDH release at the end of the first hour of 
reoxygenation. The protective effect of augmented a-GlcNAc levels (with 
PUGNAc) was still seen at 6 hours of reoxygenation according to LDH release 
(133±11% for PUGNAc, p<0.05 versus 177±14% for Vehicle; Figure 218). 
Similar protective effects were observed using PI positivity as another index of 
cell death at both one (9±1 % versus 13±1 % for vehicle, p<0.05; Figure 21 C) and 
six hour (21±2% versus 36±2% of Vehicle, p<0.05; Figure 21C) reoxygenation 
time points. PI positivity and PI positivity. PUGNAc or Vehicle treatment did not 
significantly alter normoxic/aerobic cellular viability compared with untreated 
NRCMs under normoxia according to LDH release (p>0.05, 90±8% of control 
versus 104±8% of Control) and PI positivity (p>0.05, 12±1 % for PUGNAc versus 
13±1 % for Vehicle versus 13±1 % for Control). 
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Figure 22. NRCMs were subjected to pharmacological repression of GCA 
activity (n=6/group). A) Densitometric analyses of O-GlcNAc Western blots show 
significantly elevated O-GlcNAc levels compared to Vehicle. Representative 
immunoblots for O-GlcNAc levels following PUGNAc treatment show a significant 
increase in O-GlcNAc levels compared to Vehicle. Multiple bands occur because 
O-GlcNAc is a posttranslational modification. B) GCA inhibition with PUGNAc 
diminished post-hypoxic injury in NRCMs (according to LDH release) compared 
with Vehicle. C) GCA inhibition with PUGNAc reduced post-hypoxic injury (per 
PI positivity) compared with Vehicle. *P<O.05 vs. Vehicle. 
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0.3. Knockdown of GCA reduces post-hypoxic cardiac myocyte injury: 
NRCMs (n=6/group) were treated with 60 nmol/L GCA siRNA or Control siRNA 
for 72 h to knockdown GCA expression. GCA knockdown significantly (p<0.05) 
reduced GCA protein levels compared to Control siRNA, despite no change in a-
tubulin levels (Figure 22A). GCA siRNA significantly (p<0.05) augmented 0-
GlcNAc levels (132±12% of Control, P<0.05) compared to Control siRNA (Figure 
22A & 8). 
Additional NRCMs were treated with GCA or Control siRNA, subjected to 
hypoxia/reoxygenation, and media harvested to measure LOH release. GCA 
siRNA significantly (p<0.05) reduced post-hypoxic LOH release after 1 h 
(72±10% of Control siRNA; Figure 22C) and 6 hours (130±4% for GCA siRNA 
versus 170±26% for Control siRNA; Figure 22C) of reoxygenation compared to 
Control siRNA. In addition, GCA siRNA significantly diminished PI positivity at 6 
hours (22±2% for GCA siRNA versus 33±2% for Control siRNA, p<0.05; Figure 
220) compared with Control siRNA. GCA (102±5%) or Control siRNA (97±5%) 
treatment did not cause significant cell damage compared with untreated NRCMs 
under normoxialaerobic conditions. 
92 
Figure 23. A) GCA message knockdown (siRNA) significantly reduced GCA 
protein levels compared with Control siRNA (n=5-6/group). B) Densitometric 
analysis of O-GlcNAc immunoblots showed a significant increase in O-GlcNAc 
levels for GCA siRNA compared with Control siRNA. Representative immunoblot 
for Iysates from GCA siRNA-treated NRCMs showing augmented O-GlcNAc 
levels compared to Control siRNA. C) GCA siRNA-treated NRCMs were more 
resistant to hypoxia-induced injury according to LDH release and D) PI positivity 
compared to Control siRNA. *P<O.05 vs. Control siRNA. 
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E. ROLE OF O~GlcNAc IN ER STRESS~INDUCED CARDIOMYOCYTE DEATH 
E.1. Hypoxia induces ER stress: ER stress markers were evaluated to confirm 
that hypoxia induces ER stress. Cardiac myocytes subjected to six hours of 
hypoxia and six hours of reoxygenation then immunoblotted for ER stress 
proteins showed significantly (p<0.05) augmented UPR-inducible proteins, Grp 
94 (169+/-14% of Normoxia), Grp 78 (136+/-16% of Normoxia), and calreticulin 
(135+/-15% of Normoxia) as shown in Figure 23A and B. Moreover, hypoxia 
induced apoptosis according to significant (p<0.05) PARP cleavage (50+/-16% of 
normoxia) despite no change in o-tubulin protein levels (Figure 23A & B). These 
results indicate that hypoxia induces ER stress in cultured neonatal cardiac 
myocytes and confirms previous findings by other groups (283, 293). Because 
hypoxia/ischemia exact multiple insults on cardiac myocytes, we wanted to 
isolate one such pathology (ER stress) and ask whether O-GlcNAc signaling 
could interfere with this specific pro-death pathway. 
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Figure 24. Cardiac myocytes (n=6/group) were subjected to hypoxia-
reoxygenation and activation of ER stress evaluated. A) Hypoxia activated ER 
stress as reflected by immunoblots showing augmented Grp 94, Grp 78, and 
calreticulin levels. B) Densitometric quantification of immunoblots showed 
significant post-hypoxic upregulation of Grp 94, Grp 78, Calreticulin (Cal), and 
PARP cleavage (expressed as cleaved/uncleaved PARP in bar graph). * p<O.05 
vs. Normoxia. 
E.2. Genetic manipulation of O-GlcNAc signaling alters maladaptive ER 
stress signaling: As shown above and supported by other groups, augmented 
O-GlcNAc levels attenuate post-hypoxic cardiac myocyte death (33, 34), post-
ischemic contractile dysfunction in isolated perfused hearts (189-191), and 
hemorrhagic shock-mediated inflammation (337, 338). Because numerous 
studies have implicated ER stress in the pathogenesis of post-ischemia/hypoxic 
injury(249, 283, 293), we evaluated whether genetic manipulation of O-GlcNAc 
signaling affects ER stress-induced cardiac myocyte death, per se, under 
normoxic conditions. 
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Cardiac myocytes infected with replication deficient adenovirus carrying 
GFP, OGT, or GCA gene for 24 hours, were treated with prototypical ER stress 
inducers, Tunicamycin (TM)(72) or Brefeldin A (BfA)(250), for 24 hours. 0-
GlcNAc levels and the levels of several UPR inducible proteins were assessed 
by immunoblotting. BfA treatment significantly (p<0.05) augmented O-GlcNAc 
levels (206±19% of AdGFP, Figure 24A). OGT overexpression significantly 
(296±32% for AdOGT + BfA vs. 206 ±19% for AdGFP + BfA, p<0.05) increased 
O-GlcNAc levels over the levels already induced by ER stress (Figure 24A). 
Although induction of ER stress in GCA overexpressed cells augmented 0-
GlcNAc levels, it was still less than baseline O-GlcNAc levels (Figure 24A). 
Similar changes in O-GlcNAc signaling were observed following induction of ER 
stress with TM (Figure 24B). 
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Figure 25_ Normoxic cardiac myocytes (n=6/group) were treated with AdGFP, 
AdOGT, or AdGCA, subjected to ER stress with Brefeldin A (BfA, inhibit ER-golgi 
protin transport) or Tunicamycin (TM, inhibits N-glycosylation). Whole ceillysates 
was immunoblotted for O-GlcNAc and a-tubulin. A) BfA treatment augmented 0-
GlcNAc levels. OGT overexpression significantly augmented O-GlcNAc levels 
over that induced by BfA as shown in immunoblot and densitometric 
quantification of immunoblots. B) TM treatment augmented O-GlcNAc levels. 
OGT overexpression significantly augmented O-GlcNAc levels over that induced 
by TM. n=6/group. * p<O.05 vs. AdGFP, ** p<O.05 vs. AGFP + BfA or AdGFP + 
TM. 
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BfA-induced ER stress stimulated significant (p<O.OS) increase in ER 
chaperones, Grp 94 (18S±14% AdGFP), Grp 78 (491±S6% AdGFP), and 
Calreticulin (1SS±34% AdGFP) as shown in Figure 2SA & B. Moreover, BfA 
treatment activated the maladaptive arm of ER stress response according to 
PARP cleavage (231±29% AdGFP) and CHOP activation (839±29% AdGFP) as 
shown in Figure 2SA & B. OGT overexpression significantly reduced BfA-
mediated ER stress reflected by reduced Grp 94 (144±10% for AdOGT + BfA vs. 
18S±14% for AdGFP + BfA) and Grp 78 (303±28% for AdOGT + BfA vs. 
491 ±S6% for AdGFP + BfA) protein levels (Figure 2SA & B). Furthermore, OGT 
overexpression significantly (p<O.OS) attenuated BfA-induced activation of 
maladaptive ER stress response according to diminished CHOP activation 
(400±77% for AdOGT + BfA vs. 839±29% for AdGFP + BfA, Figure 2SA & B). 
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Figure 26. Normoxic cardiac myocytes (n=6/group) were treated with AdGFP, 
AdOGT or AdGCA, subjected to ER stress with BfA and whole cell Iysates 
immunoblotted for Grp 94, Grp 78, Calreticulin, PARP and CHOP. A) Total 
protein was isolated from selected cultures and immunoblotted for ER stress 
indicators. OGT overexpression significantly attenuated, while GCA 
overexpression did not change BfA-induced ER stress according to 
immunoblotting. B) Densitometric quantification of immunoblots showed 
significant reduction in BfA-induced increase in Grp 94, Grp 78, and CHOP levels 
with OGT overexpression. OGT overexpression did not affect Calreticulin 
expression or PARP cleavage (expressed as cleaved PARP/uncleaved PARP). 
GCA overexpression did not significantly change BfA-induced Grp94, grp78, 
Calreticulin, PARP cleavage and CHOP levels. * p<O.05 vs. AdGFP, ** p<O.05 
vs. AGFP + BfA. 
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To confirm the protective effects of augmented O-GlcNAc levels (via OGT 
overexpression) on the activation of maladaptive unfolded protein response, we 
examined whether OGT overexpression affects ER stress induced by 
Tunicamycin (TM), an inhibitor of N-glycosylation of nascent ER proteins. OGT 
overexpression significantly (p<O.05) reduced the TM-induced ER stress 
according to Grp 94 (320±33% for AdOGT + TM vs. 421±18% for AdGFP + TM), 
Grp 78 (322±47% for AdOGT + TM vs. 536±31% for AdGFP + TM), and CHOP 
activation (1549±239% for AdOGT + TM vs. 3065±585% for AdGFP + TM) as 
shown in Figures 26A & B. In both BfA and TM treatments, OGT overexpression 
did not affect ER stress-mediated increase in calreticulin protein level or PARP 
cleavage (Figure 26A-B). GCA overexpression did not alter BfA or TM-mediated 
increases in the ER chaperones: Grp94, Grp78 and calreticulin (Figure 26A-B). 
Finally, AdGCA did not affect ER stress mediated apoptosis according to CHOP 
activation and PARP cleavage (Figures 25 and 26). These results demonstrate 
that known ER stress inducers (BfA and TM) augment protein levels of three 
well-characterized UPR-inducible proteins in cardiomyocytes, consistent with 
other groups(283, 293}. 
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Figure 28. Normoxic cardiac myocytes (n=6/group) were treated with AdGFP, 
AdOGT, or AdGCA, subjected to ER stress with TM and whole cell Iysates 
immunoblotted for O-GlcNAc, Grp 94, Grp 78, Calreticulin, PARP and CHOP. A) 
OGT overexpression significantly mitigated, while GCA overexpression did not 
change TM-induced ER stress according to immunoblotting. B) Densitometric 
quantification of immunoblots showed significant reduction in TM-induction of Grp 
94, Grp 78, and CHOP with OGT overexpression despite no change with GCA 
overexpression. * p<O.05 vs. AdGFP, ** p<O.05 vs. AdGFP + TM. 
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E.3. Genetic manipulation of Q-GlcNAc signaling affects ER stress-
mediated cardiac myocyte death: During prolonged or severe ER stress, the 
cell death pathways can be activated. Therefore, we questioned whether genetic 
manipulation of the two enzymes involved with O-GlcNAc signaling affects ER 
stress-induced cardiac myocyte death. In the absence of ER stress, neither OGT 
overexpression nor GCA overexpression altered cellular viability according to PI 
positivity (Figure 27 A). OGT overexpression significantly (38±3% for AdOGT + 
BfA vs. 47±3% for AdGFP + BfA, p<O.05) attenuated, while GCA overexpression 
exacerbated (60±2% for AdGCA + BfA, p<O.05) BfA-induced cell death according 
to PI positivity (Figure 27 A). Neither OGT nor GCA overexpression significantly 
altered BfA mediated cardiomyocyte apoptosis according to Caspase 3/7 activity 
(Figure 27B). 
Similarly, OGT overexpression significantly mitigated TM-induced 
cardiomyocyte death (21±3% for AdOGT + TM vs. 34±3% for AdGFP + TM, 
p<O.05, Figure 27C). GCA overexpression did not alter TM-mediated 
cardiomyocyte death (Figure 27C). Moreover, both OGT and GCA 
overexpression did not significantly alter TM-mediated cardiomyocyte apoptosis 
according to Caspase 3/7 activity (Figure 270). Taken together, these results 
indicate that augmented O-GlcNAc levels are protective against ER stress-
induced cell death. 
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Figure 28. Normoxic cardiac myocytes ((n=6/group) were treated with AdGFP, 
AdOGT or AdGCA, subjected to ER stress with BfA and cell death evaluated 
using the nuclear stain, PI or measuring caspase activity. A) OGT 
overexpression significantly attenuated, while GCA overexpression exacerbated 
ER stress-induced cardiac myocyte death according to PI positivity. B) OGT or 
GCA overexpression did not change ER stress-induced cardiomyocyte 
apoptosis. C) OGT overexpression also significantly reduced TM-induced cardiac 
myocyte death despite no change with GCA overexpression according to PI 
positivity. D) Neither OGT nor GCA overexpression affected TM-induced 
cardiomyocyte apoptosis. n>/=5/group. * p<O.05 vs. AdGFP, ** p<O.05 vs. 
AdGFP + BfA or TM. 
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E.4. Q-GlcNAcase inhibition reduces pro-death UPR signaling: Next, we 
used a complementary approach to elevate O-GlcNAc levels by inhibiting 0-
GlcNAcase with PUGNAc(111). Cardiac myocytes were treated with PUGNAc or 
Vehicle (0.1 % ethanol) three hours prior to ER stress induction (with TM or BfA, 
24 hours) and whole cell Iysates immunoblotted for O-GlcNAc levels and ER 
stress indicators. Inhibition of O-GlcNAcase significantly augmented O-GlcNAc 
levels above that induced by BfA (Figure 28A) or TM (Figure 28B) alone. 
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Figure 29. Normoxic cardiac myocytes were treated with either Vehicle or 0-
GlcNAcase inhibitor (PUGNAc) and subjected to ER stress (with BfA or TM). A) 
Western blots of whole cell Iysates showed augmented O-GlcNAc levels with 0-
GlcNAcase inhibition compared to Vehicle. O-GlcNAcase inhibition augmented 
O-GlcNAc levels above that induced by BfA. B) O-GlcNAcase inhibition 
significantly increased O-GlcNAc levels above that induced by TM. n=4/group. 
*p<0.05 vs. Vehicle, ** p<0.05 vs. BfA or TM. 
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L 
Moreover, O-GlcNAcase inhibition significantly (p<O.OS) reduced BfA-induced ER 
stress according to Grp 94 (124±12% for PUGNAc + BfA vs. 179±18% for BfA 
alone), Grp 78 (136±7% for PUGNAc + BfA vs. 224±S1% for BfA alone), and 
calreticulin (148±26% PUGNAc + BfA vs. 268±6% for BfA alone) shown in Figure 
29. Additionally, O-GlcNAcase inhibition significantly (p<O.OS) blocked the 
activation of maladaptive ER stress response as reflected by diminished CHOP 
activation (S79±76% for BfA + PUGNAc vs. 1474±216% for BfA alone, Figure 
29). Similar findings were observed with TM. PUGNAc treatment significantly 
attenuated TM-induced ER stress according to Grp 94 (171 ±3% for PUGNAc + 
TM vs. 28S±73% for TM alone, p<O.OS), Grp 78 (164±12% for PUGNAc + TM vs. 
293±40% for TM alone, p<O.OS), Calreticulin (174±1S% PUGNAc + TM vs. 
260±49% for TM alone, p<O.OS) as represented in Figure 30. Finally, 0-
GlcNAcase inhibition reduced TM-induced CHOP activation, but did not affect 
BfA or TM induced PARP cleavage (Figure 30). 
105 
A) 
B. 
Vehicle 
PUGNAc 
Brefeldin A 
Grp94 
Grp78 
Calreticulin 
Uncleaved PARP 
Cleaved PARP 
CHOP 
a-tubulin 
2000 
1750 
Vehicle + + -
Brefeldin A + + 
PUGNAc + 
+ + 
+ 
+ + 
• III • • II 
.. 
.. 
-
.. 
I • • 
Grp 78 Calreticulin 
+ + - + + -
- + + - + + 
- + - - + 
.. 94 
72 
55 
116 
62 
25 
50 
PARP 
+ + -
- + + 
+ 
CHOP 
* 
+ + -
- + + 
- - + 
Figure 30. Normoxic cardiac myocytes ((n=5-6/group) were pre-treated with 
either Vehicle or O-GlcNAcase inhibitor (PUGNAc) and subjected to ER stress 
with BfA. A) Western blots of whole cell Iysates showed significant reduction in 
BfA-mediated activation of Grp 94, Grp 78, Calreticul in and CHOP protein levels 
with O-GlcNAcase inhibition. B) Densitometric quantification of immunoblots 
showed significantly reduced Grp 94, Grp 78, Calreticulin, and CHOP protein 
levels with O-GlcNAcase inhibition. PUGNAc treatment did not affect BfA-
mediated PARP cleavage (expressed as cleaved PARP/uncieaved PARP). * 
p<O.05 vs. Control , ** p<O.05 vs. BfA. 
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Figure 31. Normoxic cardiac myocytes (n=5-6/group) were pre-treated with 
either Vehicle or O-GlcNAcase inhibitor (PUGNAc) and subjected to ER stress 
with TM. Whole ceillysates were immunoblotted for ER chaperones (Grp 94, Grp 
78 and Calreticulin) and pro-apoptotic (CHOP and PARP) proteins. A) 0-
GlcNAcase inhibition showed significant reduction in BfA-mediated activation of 
Grp 94, Grp 78, Calreticulin and protein levels. Moreover, GCA inhibition 
significantly reduced the TM mediated increase in CHOP protein levels despite 
no effect on PARP cleavage compared to TM alone according to representative 
immunoblots and B) densitometric quantification. * p<O.05 vs. Control, ** p<O.05 
vs.TM. 
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E.4. Q·GlcNAcase inhibition mitigates ER stress·induced cardiac myocyte 
death: Like OGT overexpression, O-GlcNAcase inhibition (with PUGNAc) has 
been shown to be cytoprotective during hypoxia, ischemia and oxidative 
stress(190). Here, O-GlcNAcase inhibition with PUGNAc significantly attenuated 
BfA-induced cardiomyocyte death (1B±7% for PUGNAc + BfA vs. 41±7% for BfA 
alone, p<O.OS, Figure 31A). Such results were further supported by significantly 
attenuated TM-induced ER stress with O-GlcNAcase inhibition with PUGNAc 
(1S±3% PUGNAc + TM vs. 33±6% for TM alone, p<O.OS, Figure 31B). Thus, 
shifting the cellular balance in favor of O-GlcNAcylation via genetic or 
pharmacologic means mitigates ER stress-induced cell death. Inhibition of 0-
GlcNAcase did not significantly alter BfA or TM-induced apoptosis according to 
Caspase 3/7 activity (Figure 31 C and D). 
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Figure 32. Normoxic cardiac myocytes were pre-treated with either Vehicle or 0-
GlcNAcase inhibitor (PUGNAc), subjected to ER stress with BfA or TM and cell 
death evaluated via PI or caspase activity. A) O-GlcNAcase inhibition attenuated 
BfA-induced cardiomyocyte death. B) O-GlcNAcase inhibition did not affect BfA-
induced cardiomyocyte apoptosis. C) O-GlcNAcase inhibition attenuated TM-
induced cardiomyocyte death. D) O-GlcNAcase inhibition did not affect TM-
induced cardiomyocyte apoptosis. n=6/group. * p<O.05 vs. Control, ** p<O.05 
vs. BfA or TM. 
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F. PROTEIN MODIFICATION BY O-GlcNAc 
Numerous studies have documented an ever-growing list of proteins modified by 
O-GlcNAc. However, sparse information exists on specific cardiac proteins 
modified by O-GlcNAc. According to the immunoblotting data in Figures above, it 
appears that several proteins are modified by O-GlcNAc in cardiac myocytes. In 
Figure 32, we attempted to specifically identify some of these as potential 
candidates for cardioprotection. Proteins isolated from cultured cardiac myocytes 
treated with vehicle or PUGNAc were harvested as described above. Two-
dimensional gel electrophoresis revealed at least 13 spots on which the 0-
GlcNAc modification (as evidenced by CTD antibody positivity) was augmented 
after PUGNAc treatment (Figure 32A). Analysis of these 13 spots (Table 4) by 
Matrix Assisted Laser Desorption Iionization- Time Of Flight (MALDI-TOF) mass 
spectrometry revealed several proteins involved in metabolism and one (VDAC) 
that piqued our interest because of its participation in the mitochondrial 
permeability transition pore (mPTP). Next, we performed an immunoprecipitation 
experiments to confirm that VDAC was modified by pulling down the O-GlcNAc-
modified proteins and performing an immunoblot against VDAC. Indeed, the 
band corresponding to ==30 kDa was also augmented in the PUGNAc sample 
compared with vehicle (Figure 328). 
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Table 4: List of MALOI-TOF protein 10 
Spot Protein Accession Molecular Isoelectric Sequence 
No. Identity No. Weight, Point Coverage, Oa % 
1 HSP60 CAA38564 60965 6.1 32 
2 HSP60 CAA38564 60965 6.1 39 
3 Desmin P48675 53325 5.3 39 
4 -Actin Q61264 37729 5.4 24 
5 HSP27 NP 114176 22865 6.1 28 
6 VOAC AAH60558 32060 8.4 54 
7 Malate AAH63165 36117 8.9 35 dehydrogenase 
8 Malate P04636 35655 9.1 34 dehydrogenase 
Glyceraldehyde 
9 3-phosphate P04797 35705 8.6 28 
dehyd rogenase 
Glyceraldehyde 
10 3-phosphate P04797 35705 8.6 27 
dehydrogenase 
Fructose-
11 bisphosphate NP 036627 39220 8.5 40 
aldolase 
Fructose-
12 bisphosphate NP 036627 39220 8.5 28 
aldolase 
13 Pyruvate kinase P11980 57649 7.6 21 
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Figure 33. Cardiomyocytes were treated with Vehicle or PUGNAc, whole cell 
lysate isolated and O-GlcNAc-modified proteins identified via two-dimensional 
immunoblotting and MALDI-TOF. A) 2D immunoblotting for O-GlcNAc identified 
several proteins with enhanced immunoreactivity, which was subsequently 
submitted for mass spectrometry analysis via para"el silver-stained gels. Several 
proteins displayed augmented O-GlcNAc modification after PUGNAc treatment, 
including VDAC (spot 6); n=2. See the Table 4 for protein identities. pi indicates 
isoelectric point. B) Additional samples separated on narrower isoelectric point 
and molecular weight ranges to enhance the ability to identify the VDAC spot. C) 
Additional protein isolates were subjected to immunoprecipitation (IP) with an 
antibody against O-GlcNAc, then immunoblotted (18) for VDAC. 
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F.1. VDAC is a mitochondrial target of O-GlcNAc: Our focus on VDAC is 
based on its identity as a putative element in formation of the mPTP, which 
represents a significant and proximal event in the commitment to cell death. 
Although this serves only as an initial foray into the likely numerous proteomic 
changes associated with O-GlcNAc in this system, this singular finding is 
intriguing and consistent with the in vitro evidence for O-GlcNAc-mediated 
cardioprotection. It is important to note that lower-molecular-weight proteins are 
not shown in the 1-dimensional gels earlier in this study because the Western 
blots were not optimized for lower-molecular-weight ranges. Nevertheless, the 
appearance of the lower-molecular-weight bands appeared after the saturation of 
some of the higher-molecular-weight bands (by which time the exposure was 
stopped for the analyses shown in the earlier Figures). 
Because our MALDI-TOF data identified VDAC as a target of O-GlcNAc 
modification, we assessed O-GlcNAc-modified VDAC levels following inhibition 
OGT (with TT04) or GCA (via PUGNAc) as a possible mechanistic link between 
O-GlcNAc signaling and the mitochondria. Adult wild-type mice were treated with 
TT04 (10mg/kg), PUGNAc (50 mg/kg IP) or isovolumic Vehicle (0.1 % DMSO or 
0.1 % Ethanol) intraperitoneally, and cardiac mitochondrial proteins were 
evaluated to ascertain whether such changes in VDAC modification suggested 
by the 2-dimensional gels (Figure 32) also occurred in the adult myocardium. 
Fractionation of hearts from Vehicle-, TT04- and PUGNAc-treated mice yielded 
clean, largely intact mitochondria (Figure 33A). Further examination of the 
mitochondrial fraction revealed that cardiac mitochondria from TT04-treated mice 
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contained reduced O-GlcNAc-modified-VOAC compared with those from Vehicle-
treated mice (Figure 338). Moreover, an immune-independent technique further 
confirmed the co-IP findings showing reduction in O-GlcNAc modification of 
VOAC with OGT inhibition (Figure 33C). Conversely, more VOAC was O-GlcNAc 
modified after PUGNAc treatment compared with Vehicle and such change 
occurred without a difference in total VOAC according to immunoblotting (Figure 
330). Again, VOAC is not the only O-GlcNAc modified protein. 
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Figure 34. Adult mice were treated with vehicle (V; n=4), TT04 (n=4) or 
PUGNAc (P; n=4), and cardiac mitochondria were isolated. A) Total protein was 
isolated from mitochondrial and non-mitochondrial aliquots. Immoblotting for 
cytochrome c oxidase subunit 4 (COX IV) and a-tubulin in the mitochondrial non-
mitochondrial Iysates confirmed sound mitochondrial isolation. B) OGT inhibition 
(via TT04) reduced O-GlcNAc levels on at least one mitochondrial protein 
(VDAC). Co-immunoprecipitation for O-GlcNAc-modified-VDAC showed a 
reduction in O-GlcNAc-modified-VDAC in adult cardiac mitochondria from TT04-
treated mice compared with Vehicle-treated mice, despite no difference in total 
VDAC levels from both groups (n = 4/group). C) GCA inhibition (via PUGNAc) 
augmented O-GlcNAc levels on at least one mitochondrial protein (VDAC). Co-
immunoprecipitation for O-GlcNAc-modified-VDAC showed an increase in 0-
GlcNAc-modified-VDAC in adult cardiac mitochondria from PUGNAc-treated 
mice compared with Vehicle-treated mice, despite no difference in total VDAC 
levels from both groups (n = 4/group). D) Immunoprecipitation for VDAC and 
enzymatic labeling of O-GlcNAc-modified proteins confirmed the reduction in 0-
GlcNAc-modified-VDAC in cardiac mitochondria from TT04-treated compared 
with Vehicle-treated mice. There was no difference in protein loading according 
to SYPRO ruby staining. *p < 0.05 vs. Vehicle . 
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F.2. Effects of manipulation of O-GlcNAc levels on expression of mPTP 
components: To determine if baseline manipulation of O-GlcNAc levels altered 
the protein levels of mPTP components, whole cell Iysates from normoxic 
NRCMs treated with AdGFP, AdGCA, Vehicle, PUGNAc, Control siRNA or GCA 
siRNA were immunoblotted for CyP 0, ANT and VDAC. Neither augmented 0-
GlcNAc levels (PUGNAc or GCA siRNA) nor diminished O-GlcNAc levels 
(AdGCA) significantly (p>O.05) changed CyP 0, ANT and VDAC protein levels 
(Figure 34). 
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Figure 35. Expression of putative molecular components of mitochondrial 
permeability transition pore (mPTP). Expression of CypD, ANT, and VDAC were 
not significantly affected by A) genetic overexpression (n=4/group), B) 
pharmacological inhibition (n=4/group), or C) siRNA knockdown of GCA 
according to western blotting (n=4/group). P=NS for all comparisons. 
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G. O-GlcNAc MODIFICATION AND MITOCHONDRIAL-MEDIATED DEATH 
PATHWAY 
G.1. Effects of altered O-GlcNAc levels on hypoxia-induced Ca2+ overload 
G.1.i. Effects of OGT overexpression on hypoxia-induced Ca2+ overload: 
Several studies have implicated Ca2+ overload as a key contributor to 
mitochondrial permeability transition leading to ischemia-reperfusion injury and 
interventions that reduce or delay the rise in [Ca2+] block or delay myocardial 
death (219, 244, 276, 277). In addition, inhibiting the rise in mitochondrial [Ca2+] 
has been shown to confer cardioprotection following acute MI or IRI (94, 218). 
Moreover, dysregulation of mitochondrial Ca2+ is known to induce mPTP 
formation (63, 141). Accordingly, we assessed whether OGT overexpression 
affects Ca2+ overload following hypoxia in NRCMs. OGT overexpression did not 
alter baseline mitochondrial Ca2+ levels but Significantly attenuated hypoxia-
induced mitochondrial Ca2+ overload according to rhod-2 fluorescence 
(n=5/group, Figure 35). 
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Figure 36. Evaluation of calcium overload in post-hypoxic cardiac myocytes 
using Rhod-2AM (n=5/group). Myocytes were treated with AdNull or AdOGT. 
Following hypoxia, myocytes undergo progressive calcium overload. Genetic 
overexpression of OGT attenuates post-hypoxic calcium overload according A) 
representative montage B) reoxygenation time-lapse graph and C) bar graph 
representation of the change in rhod-2 fluorescence. 
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G.1.ii. Effects of GCA manipulation on hypoxia-mediated Ca2+ overload: To 
determine if manipulation of GCA levels affects hypoxia-induced Ca2+ overload, 
cardiac myocytes were treated with either AdGFP (48 hours, 100 MOls), AdGCA 
(48 hours, 100 Mal), Vehicle (overnight), or PUGNAc (overnight, 200 ~mol/L), 
loaded with the mitochondrial calcium indicator rhod-2 (2 ~mol/L) and subjected 
to three hours of hypoxia and one of reoxygenation. Time-lapse fluorescence 
microscopy was initiated at the beginning of reoxygenation for changes in 
mitochondrial Ca2+ levels. Augmentation of Ca2+ levels is reflected by an 
increase in rhod-2 fluorescence. Hypoxia sensitized myocytes to Ca2+ overload. 
GCA overexpression (AdGCA) exacerbated hypoxia-induced calcium overload 
during reoxygenation reflected by a significant increase in rhod-2 fluorescence 
(Figure 36A-8), whereas GCA inhibition (PUGNAc) attenuated hypoxia-induced 
calcium overload compared to Vehicle (Figure 36A & C). 
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Figure 37. Assessment of calcium overload in post-hypoxic cardiac myocytes 
using Rhod-2AM (n>/=4/ group). Myocytes were treated with AdGFP or AdGCA 
(A and B) or vehicle or PUGNAc (A · and C). Following hypoxia, myocytes 
undergo progressive calcium overload. Genetic overexpression of GCA 
exaggerates, whereas pharmacological inhibition of GCA attenuates, post-
hypoxic calcium overload. *P<O.05 vs. AdGFP or Vehicle. 
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G.2. Effects of altered O-GlcNAc levels on hypoxia-induced ROS generation 
G.2.i. Effects of OGT overexpression on hypoxia-induced ROS production: 
Reactive oxygen species (ROS) are important contributors to ischemia-
reperfusion injury. In fact, studies have shown that addition of antioxidants or 
ROS scavengers delay the onset or attenuate ischemia-reperfusion injury (7,43, 
168). Therefore, I evaluated the effects of overexpressing OGT to augment 0-
GlcNAc levels on hypoxia-induced ROS generation. NRCMs infected with 100 
MOl of AdNull or AdOGT for 48h were loaded with DCF (2 IJmol/L) and subjected 
to hypoxia for three hours. Time-lapse fluorescence microscopy was initiated at 
the beginning of reoxygenation for changes in ROS levels. Augmentation of ROS 
levels is reflected by an increase in DCF fluorescence. Hypoxia augmented 
myocytes ROS generation which was significantly attenuated by OGT 
overexpression. OGT ovexpression did not change baseline ROS levels (Figure 
37). 
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Figure 38. Evaluation of post-hypoxic ROS production in NRCMs treated with 
AdNull or AdOGT using DCF (n=4 per group). Subjecting myocytes to hypoxia 
augmented ROS production. An effect attenuated by genetic overexpression of 
OGT. A) Representative montage showing DCF fluorescence. B) Quantitative 
changes in mean DCF fluorescence (expressed as %) in NRCMs using time-
lapse fluorescent microscopy. C) Bar graph showing the change in DCF 
fluorescent intensity between 1 minute and 61 minutes. *P<O.05 vs. AdNu11. 
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G.2.ii. Effects of GCA manipulation on hypoxia~mediated ROS production: 
To determine the effect of GCA manipulation on post-hypoxic ROS generation, 
NRCMs treated with AdGFP, AdGCA, Vehicle or PUGNAc, were loaded with 
DCF, and then subjected to hypoxia (3h) and reoxygenation (one hour). Imaging 
was initiated at the beginning of reoxygenation for changes in ROS levels. GCA 
overexpression (AdGCA) exacerbated hypoxia-induced ROS production during 
reoxygenation reflected by a significant (p<O.05) increase in DCF fluorescence 
(Figure 38A-C), whereas GCA inhibition (PUGNAc) attenuated hypoxia-induced 
ROS generation compared to Vehicle (Figure 38A, D-E). 
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Figure 39. Evaluation of post-hypoxic ROS production in NRCMs treated with 
AdNull , AdGCA, Vehicle or PUGNAc using DCF (n=4 per group). Hypoxia 
induced ROS production. Genetic overexpression of GCA exaggerated, while 
pharmacologic inhibition of GCA (PUGNAc) mitigated post-hypoxic ROS 
production. A) Representative montage showing DCF fluorescence. B) 
Quantitative changes in mean DCF fluorescence (expressed as %) in NRCMs 
infected with AdNull or AdGCA using time-lapse fluorescent microscopy C. Bar 
graph showing the change in DCF fluorescent intensity between 1 and 61 
minutes in NRCMs infected with AdNull or AdGCA. D) Quantitative changes in 
mean DCF fluorescence (expressed as %) in NRCMs treated with Vehicle or 
PUGNAc using time-lapse fluorescent microscopy E) Bar graph showing the 
change in DCF fluorescent intensity between 1 and 61 minutes in NRCMs 
infected with Vehicle or PUGNAc. *P<O.05 vs. AdNull or Vehicle, **p<O.05 vs. 
AdNull + Hypoxia or Vehicle + hypoxia. 
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G.2.iii. Effects of O-GlcNAc manipulation on catalase, SOD and GPX 
expression: To determine if alteration in the expression of oxidative stress 
response enzymes, glutathione peroxidase, superoxide dismutase and catalase 
was responsible for the O-GlcNAc mediated decrease in post-hypoxic ROS 
generation, real time PCR for Cat, GPX, and SOD mRNA levels was performed 
on RNA from normoxic NRCMs treated with AdGFP, AdGCA, Vehicle or 
PUGNAc. OGT overexpression (AdOGT) did not significantly altered (p>O.05) 
GPX, SOD, and Cat expression (Figure 39A). Moreover, neither overexpression 
of GCA (AdGCA) nor inhibition of GCA (PUGNAc) significantly changed GPX 
and SOD expression (Figure 39A & B). GCA overexpression (AdGCA) 
significantly diminished while GCA (Figure 39A) inhibition significantly 
augmented Cat expression despite no change in protein levels (Figure 39B). 
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Figure 40. Expression of antioxidant enzymes: superoxide dismutase (S001 & 
S002). glutathione peroxidase (GPX) and Catalase (Cat), evaluated via real time 
PCR in NRCMs treated AdGFP, AdOGT, AdGCA, Vehicle or PUGNAc 
(n=4/group). A) Genetic overexpression of OGT did not affect S001, S002, 
GPX and Cat expression. Even though S001, S002, and GPX expression were 
not significantly affected by overexpression of GCA, Cat expression was 
significantly reduced. B) Pharmacological inhibition of GCA activity did not affect 
S002 expression but significantly augmented Cat expression. 
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G.3. Effects of Q-GlcNAc manipulation on Ca2+ -induced mPTP formation 
Because a hallmark of mPTP is the massive swelling of the mitochondria, 
we assessed sensitivity to calcium-induced mitochondrial swelling following 
manipulation of O-GlcNAc levels. To test the potential link between O-GlcNAc 
modification and a functional biochemical assessment of mitochondrial function 
within the mechanistic context of cell survival, cardiac mitochondria isolated from 
TT04-, PUGNAc- and Vehicle-treated adult mouse hearts were subjected to 
calcium-induced mitochondrial swelling. Exposure of isolated mitochondria to 
supra-physiological concentrations of Ca2+ permeabilizes the mitochondrial inner 
membrane to small solutes « 1.5 kDa) (108). Mitochondria isolated from 
vehicle- PUGNAc- and TT04-treated mice were intact (Figure 40A), were free of 
cellular debris (Figure 40B), and maintained stable, calcium-free absorbance 
levels throughout the assay (Figure 40C). Cardiac mitochondria from TT04-, 
PUGNAc or Vehicle-treated mice were challenged with 0.1 mmollL calcium 
chloride and the change in absorbance measured at 520 nm every 2 s. The 
mPTP inhibitors, Cyclosporine A and Sanglifehrin A, significantly inhibited 
calcium-induced swelling in mitochondria from Vehicle- treated mice (Figure 40C) 
showing that the swelling was mPTP dependent. Similar results were observed 
with mitochondria from TT04- or PUGNAc-treated mice (data not shown). 
Adult cardiac mitochondria from TT04-treated mice were significantly 
(178 ± 10% of Vehicle) more sensitive to CaCh induced swelling compared with 
Vehicle (Figure 40D). Conversely, cardiac mitochondria isolated from PUGNAc-
treated mice revealed resistance to the induction of mPTP. The rate of swelling 
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in Figure 400 was calculated as a simple change in absorbance with respect to 
time and normalized to the Vehicle group. Such functional data complement the 
biochemical data in Figure 32. These data provide a novel molecular link 
between the identity of an O-GlcNAc-modified protein and a potential direct 
mechanism of cytoprotection. 
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Figure 41. Assessment of sensitivity to mPTP formation according to calcium-
induced mitochondrial swelling. Adult mouse cardiac mitochondria were 
subjected to time control or challenged with 100 IJmollL CaCb. Change in 
absorbance (at 520 nm) was measured over time every two seconds using a 
spectrophotometer. A) Gross transmitted light evaluation of Percoll-purified 
cardiac mitochondria from vehicle-, TT04- and PUGNAc-treated hearts 
(respectively) demonstrating structures of ==1 IJm in diameter, with no apparent 
cellular debris (image size 100x75 IJm). B) Challenge with 0.1 mmol/L calcium 
chloride significantly reduced absorbance (520 nm) in the cardiac mitochondria. 
An effect significantly inhibited by mPTP inhibitors; CsA or Sf A C). Cardiac 
mitochondria from TT04-treated mice were significantly more sensitive to 
calcium-induced swelling compared with those from Vehicle-treated mice 
(n=4/group). 0) Cardiac mitochondria from PUGNAc-treated mice were 
significantly less sensitive to calcium-induced swelling compared with those from 
Vehicle-treated mice (n=4/group). *p< 0.05 vs. Vehicle. 
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G.4. Effects of OGT manipulation on post-hypoxia ~lIJm recovery 
Specifically motivated by the importance of maintaining mitochondrial integrity to 
enhance cell survival, we ascertained whether hypoxia-induced loss of 
mitochondrial membrane potential was affected by alterations in O-GlcNAc 
levels. Such an avenue is particularly attractive given the early decline in 0-
GlcNAc levels shown above. 
G.4.i Effects of OGT manipulation on post-hypoxia ~lIJm recovery: Because 
mitochondria are arbiters of cell fate and the present data support the role of 
OGT as a pro-survival enzyme, we assessed the effects of blocking endogenous 
OGT activity on post-hypoxic mitochondrial membrane potential. NRCMs were 
treated with AdGFP (100 Mal, 48 hour), AdOGT (100 Mal 48 hour), TT04 (OGT 
inhibitor; prior to H/R, 1 IJmollL) or equal volume of DMSO, and loaded with the 
mitochondrial membrane potential indicator, tetramethylrhodamine methylester 
(TMRM; 50 nmoI/L). Cardiac myocytes were then subjected to three hours of 
hypoxia and one hour of reoxygenation. During the reoxygenation period, 
myocytes were evaluated for changes in mitochondrial membrane potential using 
time-lapse fluorescence microscopy. Dissipation of mitochondrial membrane 
potential is reflected by a loss of TMRM fluorescence. For reference purposes, 
the normoxic group averaged between 205 and 225 AU. Thus, the mitochondria 
are not 'increasing' their fluorescence, more precisely, they are 'recovering'. 
AdGFP-infected NRCMs loaded with TMRM maintained mitochondrial 
membrane potential under normoxia and showed no significant difference in 
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mitochondrial membrane potential over time (Figure 41 B). Overexpression of 
OGT (AdOGT) attenuated the loss of mitochondrial membrane potential 
compared to AdGFP as shown by increased TMRM fluorescence and thus 
protected myocytes from cell death following hypoxia (Figure 41A, B & D). 
Inhibition of OGT (via TT04) exacerbated the loss of mitochondrial membrane 
potential compared to H/R alone as shown by a further reduction in TMRM 
fluorescence and thus sensitized myocytes to mitochondrial damage (Figure 
41A, C-D). Such findings support a role for OGT at the level of the mitochondrial 
permeability transition pore. 
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Figure 42. Assessment of post-hypoxic mitochondrial membrane potential 
recovery in NRCMs following manipulation of OGT. TMRM fluorescence was 
used to indicate mitochondrial membrane potential (n=6/group) beginning at 
post-hypoxic reoxygenation and continuing through the first hour of 
reoxygenation. OGT overexpression improved the recovery of mitochondrial 
membrane potential compared to AdGFP while OGT inhibition (via TT04) 
repressed the recovery of mitochondrial membrane potential compared to 
Vehicle. A) Representative montages of post-hypoxic TMRM fluorescence in 
cardiomyocytes. B) Graph showing average TMRM fluorescence for AdGFP and 
AdOGT infected myocytes over 60 minutes of reoxygenation as index of recovery 
of mitochondrial membrane potential. C) Graph showing average TMRM 
fluorescence for Vehicle and TT04 treated myocytes over 60 minutes of 
reoxygenation. D) Quantification of the change in relative fluorescent intensity 
for AdGFP, AdOGT, Vehicle and TT04 treated myocytes. *P<0.05 vs. AdGFP or 
Vehicle 
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G.4.ii. Effects of GCA manipulation on post-hypoxia ~lIJm preservation: Loss 
of mitochondrial membrane potential (Ll4Jm) commits cells to death pathways (4, 
175). Consequently, we examined the effects of GCA knockdown on hypoxia-
induced loss of mitochondrial membrane potential using TMRM. We assessed 
the effects of altered GCA activity on post-hypoxic mitochondrial membrane 
potential. NRCMs were treated with either AdGFP (48 hours, 100 MOl), AdGCA 
(48 hours, 100 MOl), Vehicle (overnight), PUGNAc (overnight, 200 jJmollL), 
Control siRNA (72 hours, 60 nmollL), or GCA siRNA (72 hours, 60 nmol/L) and 
loaded with the mitochondrial membrane potential indicator TMRM (100 nmol/L). 
Cardiac myocytes were then subjected to either three hours of normoxia, or, 
three hours of hypoxia and one hour of reoxygenation. During the reoxygenation 
period, myocytes were evaluated for changes in mitochondrial membrane 
potential using time-lapse fluorescence microscopy. Dissipation of mitochondrial 
membrane potential is reflected by a loss of TMRM fluorescence. For reference 
purposes, the normoxic group averaged between 198 and 215 A.U. Thus, the 
mitochondria are not 'increasing' their fluorescence, more precisely, they are 
'recovering'. Hypoxia/reoxygenation induced mitochondrial membrane potential 
loss. GCA overexpression attenuated the post-hypoxic mitochondrial membrane 
potential recovery during reoxygenation, shown by impaired recovery of TMRM 
fluorescence (Figure 42A-8 & E). Conversely, inhibition of GCA (via PUGNAc or 
GCA siRNA) attenuated the loss of mitochondrial membrane potential compared 
to vehicle or Control siRNA, as shown by the significant restoration of TMRM 
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fluorescence toward that of the normoxic control, and protected cells from post-
hypoxic mitochondrial dysfunction (Figure 42A, C-E). 
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Figure 43. Assessment of post-hypoxic mitochondrial membrane potential 
recovery in NRCMs following manipulation of GCA. TMRM fluorescence was 
used to indicate mitochondrial membrane potential (n=6/group). GCA 
overexpression attenuated, while GCA inhibition (via PUGNAc or via GCA 
siRNA) enhanced mitochondrial membrane potential recovery compared to 
AdGFP, Vehicle or control siRNA respectively A) Representative montages of 
post-hypoxic TMRM fluorescence in cardiomyocytes. B) Graph showing average 
TMRM fluorescence for AdGFP and AdGCA infected myocytes over 60 minutes 
of reoxygenation as index of recovery of mitochondrial membrane potential. C) 
Graph showing average TMRM fluorescence for Vehicle and PUGNAc treated 
myocytes over 60 minutes of reoxygenation. D) Graph showing average TMRM 
fluorescence for Control and GCA siRNA transfected myocytes over 60 minutes 
of reoxygenation. E) Quantification of the change in relative fluorescent intensity 
for AdGFP, AdGCA, Vehicle, PUGNAc, Control siRNA and GCA siRNA treated 
myocytes. *P<0.05 vs. AdNull or Vehicle or Control siRNA. 
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H. TRANSLATION TO IN VIVO MODEL 
H.1. O-GlcNAc levels change following myocardial ischemia-reperfusion: 
We used the exogenous enzymatic labeling of O-GlcNAc modified proteins, Click 
chemistry technique to assess changes in O-GlcNAc levels in the ischemic (area 
at risk, n>/=4/group) and nOh-ischemic zones (n>/=4/group) of mice subjected to 
40 minutes of myocardial ischemia (MI) via left anterior descendinf coronary 
artery ligation or Sham surgery and reperfused for zero, one, four or twenty four 
hours. O-GlcNAc levels decreased after 40 minutes of myocardial ischemia in 
the ischemic zone for MI group compared to sham group (Figure 43A and 8). 
Upon reperfusion, O-GlcNAc levels were :::::1.6-fold higher than sham after 1 hr, 
and dropped to baseline after 4hrs and 24 hrs of reperfusion (Figure 43A and 8). 
Despite changes in O-GlcNAc levels in the ischemic zone of hearts of the MI 
group, there was no significant change in O-GlcNAc levels in the non-ischemic 
zone from both the MI and Sham groups following ischemia and during the 
different durations of reperfusion i.e. zero, one, four or twenty four hours(Figure 
43C). Moreover, myocardial ischemia induced cellular injury which was 
exacerbated by reperfusion compared to Sham surgery as reflected in cardiac 
troponin I release (cTnl, Figure 430). There was no significant difference in cTnl 
release in the Sham group at the different time points (Figure 430). 
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Figure 44. Effects of ischemia-reperfusion injury on O-GlcNAc levels. Adult C57 
(n=4-6 per group) mice were subjected to 40 minutes of ischemia and reperfused 
for 0-24 hours. Evans blue dye was used to delineate ischemic zone (IZ) from 
non-ischemic (nIZ) zone. O-GlcNAc levels were assessed via click chemistry for 
the non-ischemic and ischemic zones while ischemia-reperfusion injury was 
assessed via serum cardiac troponin I (cTnl) levels. A) Representative TAMRA-
GlcNAc gels for ischemic zone for time points with significant changes in 0-
GlcNAc levels. Ischemia induced significant decrement, while reperfusion for one 
hour augmented O-GlcNAc levels. B) Densitometric quantification of TAMRA-
GlcNAc gels expressed as percent of sham for ischemic zones show significant 
reduction in O-GlcNAc levels following ischemia (zero hour of reperfusion), 
augmented O-GlcNAc levels by 1 hour of reperfusion and no change in 0-
GlcNAc levels by four and twenty four hours of reperfusion compared to Sham. 
C) There was no significant difference in O-GlcNAc levels in the Non-ischemic 
zones of MI hearts compared with sham hearts. D) Ischemia induced troponin I 
(cTnl) release. Reperfusion exacerbated ischemia-induced cTnl release. *P<0.05 
vs. Sham 
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H.2. Reduction of myocardial infarct size by PUGNAc in vivo: Infarct size is a 
major determinant of mortality following myocardial infarction (28, 86). Reducing 
infarct size is therefore critical for improving survival following MI. Indeed, 
studies have shown that interventions that reduce infarct size reduce injury in MI 
(223, 243). Therefore, we ascertained whether augmentation of O-GlcNAc levels 
is sufficient to reduce infarct size in vivo. We intraperitoneally injected mice with 
50 mg/kg of PUGNAc (O-GlcNAcase inhibitor) or isovolumic Vehicle eighteen 
hours before surgery. Several mice (n=3/group) not undergoing surgery were 
also euthanized to determine whether the dosing regimen of PUGNAc was 
sufficient to increase cardiac O-GlcNAc levels. As shown in Figure 44A, such 
treatment significantly augmented myocardial O-GlcNAc levels compared with 
Vehicle treatement. Additional mice (n>/=8/group) were treated similarly and 
subjected to 40 minutes of ischemia via left anterior descending coronary artery 
ligation and 24 hours of reperfusion. At the end of reperfusion, Evans blue dye 
and 2,3,5-triphenyltetrazolium chloride were used to define the area at risk 
(ischemic zone) and infarct size, respectively (Figure 448). There was no 
difference in ratio of the area at risk (AAR) to left ventricle (LV) for PUGNAc-
treated mice compared to the Vehicle-treated mice indicating that the occlusion 
point was same for both group (Figure 44C). PUGNAc treatment significantly 
reduced infarct size when normalized to the area at risk or left ventricukar area 
compared with Vehicle (Figure 44D). 
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Figure 45. Mice were treated with 50 mg/kg PUGNAc or saline Vehicle for 
eighteen hours. A) To one group (n=3 per group) of PUGNAc or Vehicle-treated 
mice, total cellular protein was isolated from the hearts and western blotting for 
O-GlcNAc performed to confirm the ability of PUGNAc to augment O-GlcNAc 
levels in the hearts. PUGNAc treatment significantly augmented O-GlcNAc 
levels in the heart. B) Representative photomicrographs of mouse hearts 
treated with Vehicle or PUGNAc, subjected to 40 minutes of left coronary artery 
occlusion, 24 hours of reperfusion and infarct staining. The amount of dead 
tissue (white) in the representative PUGNAc heart is reduced compared with 
Vehicle. C) Summary data of hearts exposed to the myocardial 
ischemia/reperfusion protocol. LV indicates left ventricle. Infarct (INF) size with 
respect to the area at risk (AAR) was significantly reduced in the PUGNAc (n=8) 
group compared with Vehicle (n=12). *P<0.05 vs. Vehicle. 
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H.3. Effects of manipulaiton of Q-GlcNAc levels on cardiovascular 
hemodynamics: One potential explanation for the cardioprotective effects may 
be that PUGNAc favorably affects cardiovascular hemodynamics, thereby 
reducing oxygen demand and by extension, infarct size. Accordingly, we 
measured blood pressure in mice treated with Vehicle (n=3) or PUGNAc (n=3) 
and found no significant differences in mean arterial blood pressure (Table 5). 
Furthermore, we evaluated LV end diastolic diameter, LV end systolic diameter, 
LV fractional shortening, and heart rate and found no differences between the 
two groups (Table 5). Similarly, PUGNAc did not alter blood glucose levels in the 
mice (143 ± 18 mg/dL) compared to Vehicle treatment (147 ± 20 mg/dL). Such 
data indicate that there were no gross reductions in myocardial work or 
circulating glucose levels that would explain the salubrious effects of PUGNAc 
during myocardial ischemia. Collectively, these findings provide a clinically-
relevant counterpart to our more detailed and mechanistic in vitro studies. 
Table 5: Cardiovascular hemodynamiCS data 
Index Vehicle (n=3) PUGNAc (n=3) 
Mean arterial blood Pressure 80 ± 3 78 ± 2 (mmHg) 
LV end diastolic diameter 3.33 ± 0.03 3.34 ± 0.24 (LVEDD, mm) 
LV end systolic diameter 2.30 ± 0.06 2.30 ± 0.20 (LVESD, mm) 
LV fractional shortening (LVFS, 30.1 ± 2.4 31.0 ± 2.6 %) 
Heart rate (HR, bpm) 360 ± 23 421 ± 33 
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CHAPTER VI 
DISCUSSION 
The purpose of this study was to determine whether the post-translational 
sugar modification, O-GlcNAc, plays a role in the pathogenesis of myocardial 
ischemia-reperfusion injury. 
First, we determined if O-GlcNAc signaling changes following in vitro 
oxidative stress, hypoxia-reoxygenation, or ER stress, and in vivo myocardial 
ischemia. Oxidative stress and ER stress transiently augmented O-GlcNAc 
signaling, while hypoxia alone and ischemia alone reduced O-GlcNAc signaling. 
Characterizing O-GlcNAc profiles following short-term oxidative stress induction 
revealed that O-GlcNAc levels increased early and start decreasing 40 minutes 
post-oxidative stress. Hypoxia reduced O-GlcNAc levels, while reperfusion 
induced time dependent augmentation of O-GlcNAc levels peaking after six 
hours of reoxygenation. Our present characterization of the changes in 0-
GlcNAc signaling following hypoxia-reoxygenation in cardiomyocytes differs from 
that described by Champattanachai et a/ (33, 34). These studies revealed that 
O-GlcNAc levels rise following four hours of hypoxia and early reoxygenation (33, 
34). Such disparity raises the possibility that changes in O-GlcNAc levels 
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following hypoxia might be dependent on the severity of hypoxia (anoxia vs. 
hypoxia) and the composition of the hypoxic medium. In the intact myocardium, 
we show that myocardial ischemia caused decrement in GlcNAc levels; while 
upon reperfusion, O-GlcNAc levels increased after 1 hour and were back at 
baseline by four and by 24 hours of reperfusion in the ischemic zone. 
Interestingly, O-GlcNAc signaling did not change in the non-ischemic zone of the 
mice subjected to myocardial ischemia-reperfusion injury. Such changes in 0-
GlcNAc levels in vivo support our in vitro hypoxia-reoxygenation findings. The 
decrement in O-GlcNAc levels observed following hypoxia/ischemia could be due 
to decreased substrate (glucose) availability. Moreover, hypoxic or ischemic 
stress could lead to decreased OGT activity and/or augmented GCA activity. 
Studies in isolated perfused rat hearts from Chatham's group reveal that 
simulated ischemia alone augments UDP-GlcNAc and O-GlcNAc levels early in 
the low-flow phase and then decline by the end of low flow and during reflow(83, 
191). The changes in O-GlcNAc signaling following oxidative, hypoxic, ER stress 
or ischemic stress highlight the role of O-GlcNAc as a stress response in the 
heart. Moreover, these data support previous findings by Zachara et al. showing 
that O-GlcNAc signaling acts as a stress signal (333). 
Next, we determined whether manipulation of O-GlcNAc levels affects 
oxidative stress, ER stress, hypoxia and ischemia-mediated cell death. In 
oxidative stress, enhanced O-GlcNAc signaling with PUGNAc (GCA inhibitor) 
delayed oxidative stress-induced decrease in O-GlcNAc signaling as well as 
attenuated the severity of the oxidative stress-mediated cardiomyocyte death. 
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Moreover, during ER stress, augmented O-GlcNAc levels via elevating OGT 
levels and O-GlcNAcase inhibition (with PUGNAc), attenuated ER stress-
mediated cardiomyocyte death even though decrement of O-GlcNAc levels via 
elevation of GCA levels did not affect ER stress-mediated cardiomyocyte death. 
Additionally, during hypoxia-reoxygenation, elevated O-GlcNAc levels via OGT 
overexpression and O-GlcNAcase inhibition (siRNA or pharmacologically with 
PUGNAc) favored O-GlcNAc modification and mitigated cardiomyocyte death 
following hypoxia. Conversely, reducing global O-GlcNAc modification via OGT 
inhibition (using siRNA, cre-Iox, or pharmacologically with TT04 and TT40) and 
O-GlcNAcase overexpression reduced O-GlcNAc levels and exacerbated post-
hypoxic cardiac myocyte death. Therefore, this project provides evidence that 
pharmacologic or genetic manipulation of OGT and O-GlcNAcase affects cardiac 
myocyte survival following oxidative stress, ER stress, and hypoxia. Moreover, 
the present data suggest that OGT is a critical survival protein, while 0-
GlcNAcase antagonizes cardiac myocyte survival. Such pro-survival effects of 
enhanced O-GlcNAc modification are supported by data from Champathanachi 
et al. in which adenoviral (Ad) overexpression of OGT reduced post-hypoxic 
H20 2-induced cardiac myocyte death (34), while short interfering RNA against 
OGT sensitized NRCMs to hypoxia-induced apoptosis (34). On the other hand, 
evidence supporting the antagonistic role O-GlcNAcase on cardiomyocyte 
survival following lethal stress is seen several studies by Champattanachai et al. 
showing that O-GlcNAcase inhibition (with PUGNAc or NButGT) attenuated 
cardiac myocyte death following hypoxia and oxidative stress (33, 34, 190). 
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Better still, PUGNAc administration early in the reflow phase has been shown to 
improve cardiac functional recovery, reduce troponin release and calpain-
mediated proteolysis of a-fodrin and Ca2+/calmodulin-dependent protein kinase II 
compared to untreated Controls in isolated perfused hearts(190). Here, we 
show that the cytoprotective effects of enhanced O-GlcNAc signaling seen in 
NRCMs and isolated perfused heart, are relevant in an in vivo setting. Enhanced 
O-GlcNAc levels reduced infarct size in mice subjected to ischemia-reperfusion 
injury. Thus, enhanced O-GlcNAcylation of proteins seems essential in the 
ability of the cardiac myocytes, and hence the intact myocardium to withstand 
lethal stressors. Such collective insights during oxidant stress, ER stress, 
hypoxia, and ischemia are reminiscent of original findings by Zachara et al. of 
augmented O-GlcNAc signaling during cell stress (333). 
Outside the common connections between cellular stress and O-GlcNAc 
levels, there is a body of data indicating that flux through the hexosamine 
biosynthetic pathway can augment O-GlcNAc levels and exert cytoprotection in 
vitro (33, 34, 82, 189-191) and in vivo (322, 337). In one in vitro study, 
hyperglycemia or treatment of cells with glucosamine (to increase HBP flux), 
augmented O-GlcNAcylation of proteins and was associated with increased 
cellular viability(33). Because the hyperglycemia-mediated increase in post-
hypoxic O-GlcNAc levels was blocked by azerserine (a GFAT inhibitor), it 
seemed that the protective effect required HBP flux and subsequent O-GlcNAc 
modification of proteins. In addition, in vivo augmentation of O-GlcNAc levels 
using glucosamine after severe injury such as hemorrhagic shock has been 
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shown to improve cardiac function and peripheral organ perfusion in rats. Thus, 
the myocardium, like various tissues and cell lines, possesses the ability to 
recruit O-GlcNAc signaling system in times of stress. Such a conserved and 
stress-responsive system suggests an endogenous self-defense system 
operative in the heart. 
To determine how O-GlcNAc confers cardioprotection, we first identified 
candidate proteins modified by O-GlcNAc in the heart. Based on the list of 13 
proteins identified (table 3), voltage dependent anionic channel (VDAC) was 
most interesting because it is an outer mitochondrial membrane protein and a 
putative member of the mPTP. On this premise, we hypothesized that 
enhanced O-GlcNAc protein modification may act (at least partially) on the 
mitochondria to effect protection. Ca2+ accumulation in the mitochondrial matrix 
and increased ROS generation are prominent features of post-ischemic and 
hypoxic injury, and favor mPTP formation. Hence, it was logical to determine 
whether manipulation of O-GlcNAc signaling affect post-hypoxic Ca2+ overload 
and ROS generation. Genetic (AdOGT) and pharmacologic (O-GlcNAcase 
inhibition with PUGNAc) augmentation of O-GlcNAc levels attenuated hypoxia-
induced Ca2+ overload compared to Vehicle. Conversely, diminished O-GlcNAc 
levels (AdGCA) exacerbated hypoxia-induced Ca2+ overload. These data 
supports previous findings by Nagy et al. showing that enhanced O-GlcNAc 
signaling via increased HBP flux or inhibition of GCA (PUGNAc) in neonatal 
cardiomyocytes, blocked angiotensin II-induced cytosolic Ca2+ elevation (222). 
On the other hand, inhibition of OGT (with alloxan) abrogated the glucosamine 
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mediated inhibition of angiotensin II-induced cytosolic Ca2+ overload(222). How 
O-GlcNAc attenuates Ca2+ overload in acute stress is unknown. Since the 
primary source for the rise in intracellular Ca2+ during/following ischemia or 
hypoxia might be via reverse functioning NCX(143), it is possible that enhanced 
O-GlcNAc levels mitigate hypoxia-induced Ca2+ overload via glycosylation of 
NCX. Another possible mechanism may be enhanced SERCA2a activity and/or 
decreased phospholamban binding to SERCA2a. Such hypothesis is supported 
by several studies from Dillmann's group showing that hyperglycemic 
cardiomyocytes and hearts from STZ-induced diabetic mice with elevated 0-
GlcNAc levels exhibited prolonged Ca2+ transients. In addition, these 
hyperglycemic myocytes and diabetic hearts showed diminished SERCA2a 
expression and phosphorylated phospholamban (PLB)(48, 135). Interestingly, 
overexpression of GCA (AdGCA) improved Ca2+ transients and augmented 
SERCA2a expression(48, 135), hence raising the possibility that O-GlcNAc 
signaling might infere with calcium handling by affecting SERCA2a expression 
and/or activity. If this is true, it is likely that O-GlcNAc signaling acts directly via 
glyocsylation of SERCA2a or indirectly by modifying an upstream kinase. 
Another question is whether manipulation of O-GlcNAc signaling affects 
SERCA2a expression and PLB phosphorylation at baseline (non-pathological 
conditions) in the heart. We also show that manipulation of O-GlcNAc signaling 
affects mitochondrial Ca2+ overload. Ca2+ likely enters the mitochondria via 
mitochondrial uniporter. Because there exist a mitochondrial OGT isoform 
(mOGT)(198) which is thought to be membrane bound(115), it is possible that 
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mOGT interacts with mitochondrial Ca2+ uniporter preventing Ca2+ uptake into the 
mitochondria. Such a hypothesis remains to be tested. 
In addition to its roles in signal transduction and in regulation of redox cell 
signaling, ROS generation contributes to myocardial ischemia-reperfusion injury 
(183). Therefore, we ascertained whether manipulation of O-GlcNAc levels 
attenuated post-hypoxic ROS generation. Enhanced O-GlcNAc levels (AdOGT 
and PUGNAc) blocked hypoxia-mediated ROS generation while GCA 
overexpression (AdGCA) exacerbated hypoxia-induced ROS generation. One 
might hypothesize that O-GlcNAc signaling attenuates hypoxia-induced ROS 
generation by upregulating the expression and/or activity of antioxidant enzymes: 
catalase (Cat), glutathione peroxidase (GPX), and superoxide dismutase (SOD). 
Transcription of oxidative stress responsive enzymes, catalase and MnSOO 
(S002) is regulated by forkhead box 01 (Fox01). Fox01 is a nutrient and stress 
sensor known to playa regulatory role in diabetes. Recently, Fox01 was shown 
to be O-GlcNAc modified. O-GlcNAc modification of Fox01 activates Fox01 and 
can in turn lead to activation of transcription of oxidative stress response 
enzymes Cat and MnSOO. Therefore, we evaluated whether manipulation of 0-
GlcNAc levels alter mRNA expression of catalase, superoxide dismutase or 
glutathione peroxidase in normoxia. Neither augmented O-GlcNAc (AdOGT and 
PUGNAc) nor diminished (AdGCA) O-GlcNAc levels significantly altered baseline 
mRNA levels of superoxide dismutase and glutathione peroxidase. However, 
inhibition of GCA (PUGNAc) augmented, while overexpression of GCA, reduced 
baseline catalase mRNA levels despite no change in catalase protein levels. 
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Because our hypoxia-reoxygenation studies last less than twenty four hours we 
do not believe the reduction in post-hypoxic ROS generation seen with 
augmented O-GlcNAc levels involves de novo synthesis of antioxidant enzymes. 
Instead, if O-GlcNAc signaling affects antioxidant enzymes SOD and GPX, we 
expect it to be at the level of the enzyme activity. The alteration in Cat expression 
with GCA manipulation partially explains the exacerbated post-hypoxic ROS 
generation with GCA expression and reduced ROS generation with GCA 
inhibition. Another possible hypothesis could be that O-GlcNAc signaling 
enhances oxidative phosphorylation. Studies show that augmenting glucose flux 
improves ischemic tolerance of the heart, potentially through an elevation in 
glycolytic ATP production and reduction of fatty acid oxidation (65, 274). The 
present data involve alterations in a glucose-derived metabolic signal, O-GlcNAc, 
leading one to question whether its manipulation would affect ATP levels. Such 
questions might be justified because of the present data indicating mitochondrial 
(including VDAC) and metabolic (e.g. glyceraldehyde-3-phosphate 
dehydrogenase, fructose-bisphosphate aldolase, pyruvate kinase as an 0-
GlcNAc target) proteins are O-GlcNAc modified. If alteration in O-GlcNAc 
modification of these enzymes affects their function, then it might be reasonable 
to expect changes in cellular ATP levels. Moreover, one of VDAC's physiological 
functions is to facilitate ATP transport across the outer mitochondrial membrane. 
However, because the HBP normally uses less than 5% cellular glucose, minimal 
changes in glycolytic ATP (via fructose-6-phosphate) should occur, assuming 0-
GlcNAc modification of such enzymes would not affect their activity. We show 
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that inhibition of OGT (via TT04) did not affect ATP levels in cardiac myocytes [0 
IJM TT04 (26.3 ± 15.3 nmol/Llmg protein) vs. 2.5 IJM TT04 dose (26.3 ± 11.9 
nmoI/Llmg)]. In agreement with this notion, Champattanachai et a/. found that 
glucosamine treatment in cardiac myocytes did not significantly affect ATP 
levels(33}. The effects of altered O-GlcNAc signaling on post-hypoxic cardiac 
mitochondrial respiration remain to be tested. Though the present data suggest 
that decrement of OGlcNAc levels did not affect cellular ATP levels, Hu et a/. 
recently identified components of mitochondrial respiratory chain complex I, III 
and IV to be O-GlcNAc modified (137). Moreover, Hu et a/. showed that 
hyperglycemia augmented O-GlcNAcylation of components of mitochondrial 
respiratory chain complex I, III and IV, reduced their activity and decreased 
cellular ATP content in neonatal cardiomyocytes (137). Overexpression of GCA 
restored the activity of these complexes as well as the cellular ATP content 
(137). Therefore, determining whether such findings in chronic stress are similar 
in acute myocardial stress is critical. In addition, addressing whether baseline 
manipulation of OGT and GCA alter the activity of mitochondrial ETC complexes 
is critical. Since mitochondrial ROS is generated during electron transport in 
complex I and III, and components of complex I and III are known to be 0-
GlcNAc modified, it is possible that during myocardial ischemia/hypoxia, there is 
reduced O-GlcNAcylation of complex I and III components leading to augment 
ROS generation. Therefore, elevated O-GlcNAc signaling might diminish post-
ischemic or post-hypoxic ROS generation via enhanced O-GlcNAcylation of 
components of complex I and III. 
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Mitochondria are key mediators and regulators of cell death in myocardial 
ischemia-reperfusion injury. The mPTP in particular appears to be a critical for 
the transition from reversible to irreversible myocardial ischemia-reperfusion 
injury(62). The mPTP is activated by ROS and Ca2+, and both of these are 
elevated during myocardial ischemia and reperfusion. Numerous 
cardioprotective pathways work primarily by inhibition of mPTP formation directly 
or by preventing the conditions that promote mPTP formation. Consequently, we 
tested the hypothesis that O-GlcNAc signaling mitigated hypoxia/ischemia 
mediated mPTP formation. Augmented O-GlcNAc signaling (PUGNAc) 
attenuated Ca2+ -induced mitochondrial swelling while diminished O-GlcNAc 
levels sensitized cardiac mitochondria to Ca2+-induced swelling. Because 
mitochondrial Ca2+ overload and ROS production favor mPTP (63, 141), it is 
possible that O-GlcNAc signaling might mitigate mPTP formation indirectly by 
attenuated Ca2+ overload and/or ROS generation. Because, VDAC, a putative 
component of mPTP is O-GlcNAc modified, we hypothesized that GlcNAcylation 
of VDAC would prevent its interaction with other mPTP components and hence 
block mPTP formation. One might dispute such a hypothesis based on recent 
findings by Baines et al. showing that mitochondria for VDAC null mice undergo 
mPTP (11). However, there is no evidence that cardiac mitochondria deficient of 
all three VDAC isoforms undergo mPTP. 
Several models of mPTP have been proposed by different groups. In the 
model proposed by Halestrap's group, CyP-D when activated by augmented 
mitochondrial Ca2+ binds to ANT and undergoes conformational changes to form 
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mPTP (57, 58, 318). CsA blocks mPTP formation by inhibiting the peptidyl-prolyl 
cis-trans isomerase (PPlase) activity of CyP-D and also preventing the binding of 
CyP-D to ANT(58, 93, 105, 106). Based on this model, O-GlcNAc might mitigate 
mPTP formation by GlcNAcylation of CyP-D, inhibiting the PPlase activity of 
CyP-D and/or inhibition of the binding of CyP-D to ANT. In the model proposed 
by Lemaster's group(128), mPTP could be formed by aggregation of misfolded 
integral membrane proteins damaged by oxidant and other stressors and is 
blocked by CsA. In this model, CyP-D prevented protein aggregation normally by 
binding these proteins (as chaperone) but when activated by augmented 
mitochondrial Ca2+, dissociated from these proteins. Hence, O-GlcNAc signaling 
might attenuate mPTP formation by enhanced CyP-D chaperone function. 
Whether CyP-D and ANT are O-GlcNAc modified is unknown. 
Opening of mPTP is characterized by the loss of ~ljJm, massive 
mitochondrial swelling, rupture of outer mitochondrial membrane, and the release 
of intermembrane components such as cytochrome c(62). Dissipation of ~4Jm is 
a critical event early in the process of cell death(175), hence, we tested the 
hypothesis that manipulation of O-GlcNAc signaling affects post-hypoxic 
recovery ~ljJm. The present data reveals that augmented O-GlcNAc levels 
enhanced post-hypoxic ~ljJm recovery, while reduced O-GlcNAc signaling 
diminished ~ljJm recovery. Therefore, inhibition of ~ljJm loss by O-GlcNAc 
signaling may be mediated by prevention of Ca2+ overload or ROS production in 
mitochondria, such that PTP never opens. 
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In addition to Ca2+ overload and increased ROS generation, endoplasmic 
reticulum (ER) stress has emerged as a potentially critical element of 
ischemia/hypoxia -induced injury. Consequently, we focused on the potential 
ability of O-GlcNAc signaling to directly attenuate ER stress-induced cell death 
(in the absence of the confounding condition of hypoxia). Here, we show that 
augmented O-GlcNAc levels (via overexpression of OGT or inhibition of 0-
GlcNAcase) attenuated the activation of maladaptive ER stress response and 
mitigated ER stress-induced cardiac myocyte death. On the otherhand, 
overexpression of GCA did not alter BfA or TM-mediated activation of 
maladaptive ER stress response. A notable finding in the present study is the 
augmentation of O-GlcNAc signaling during ER stress. It will be interesting to 
ascertain the cause for augmented O-GlcNAcylation during ER stress. One 
might conjecture that augmented O-GlcNAc levels may be due to elevated OGT 
and/or reduced O-GlcNAcase activities. Regardless of the mechanism, we 
hypothesized that such a response was a pro-adaptive but insufficient response 
to the induction of ER stress. The induction of O-GlcNAc signaling during ER 
stress might be predicted from the significant literature supporting the role of 0-
GlcNAc as an acute stress or alarm signal (228, 333). The present 
demonstration of O-GlcNAc signaling may reflect a partially pro-adaptive 
response during ER stress. Clearly, augmentation of O-GlcNAc signaling 
rescued cardiomyocytes from ER stress-induced cell death. The new question 
relates to the mechanism operative during O-GlcNAc signaling-mediated rescue 
of cells undergoing the UPR. The data related to OGT overexpression and 0-
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GlcNAcase inhibition (via PUGNAc) are clear in that there is robust attenuation of 
ER stress-mediated cell death (with either BfA or TM). In addition, it also 
appears that such maneuvers designed to augment O-GlcNAc signaling might 
limit the severity of the induction of ER stress, as indicated by the general 
limitation of the markers of ER stress activation. In this regard, augmented 0-
GlcNAc signaling might function as a regulator of the initiation/propagation of ER 
stress and indirectly attenuate cell death. In addition, enhanced O-GlcNAc 
signaling may directly attenuate cell death, which may be independent of ER 
stress mitigation. Conversely, the data from O-GlcNAcase could initially be 
viewed as ambiguous. Overexpression of O-GlcNAcase (AdGCA) did not 
exaggerate any of the ER stress indicators. Interestingly, AdGCA exacerbated 
ER stress-mediated cell death when BfA, but not TM, was used as the inducer of 
ER stress. Although the precise reason for the apparently discrepant response is 
not clear, we hypothesize that the dose of TM used in our system produces 
somewhat greater induction of ER stress (as evidenced by the larger increase in 
the ER stress markers in the TM experiments) and that AdGCA is unable to 
exacerbate this response. 
The UPR initially attempts to support restoration of ER homoeostasis and 
protect cells from stress. In fact, Vitadello et al. first demonstrated that 
overexpression of Grp94 reduces ischemia-induced cardiomyocyte death(305). 
Moreover, Thuerauf et al. showed that subjecting cardiac myocytes to hypoxia 
activated XBP1 and XBP1 contributed to protecting post-hypoxic cardiomyocytes 
(293). However, prolonged ER stress activates cell death. Induction of the pro-
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apoptotic transcription factor CHOP is a hallmark of ER stress-mediated cell 
death. Here, BfA or TM-induced CHOP expression was attenuated by 
genetic/pharmacologic elevation of O-GlcNAc levels (via OGT overexpression 
and O-GlcNAcase inhibition). The exact mechanism through which O-GlcNAc 
signaling blocks CHOP activation is unknown. It is known that p38 MAPK 
phosphorylates CHOP, which increases its activity(284). Accordingly, O-GlcNAc 
signaling may block CHOP phosphorylation, independent of absolute reductions 
in protein expression, thereby reducing its activity and subsequent cardiomyocyte 
death. Targeting eukaryotic initiation factor-2 (eIF-2) represents another 
potential mechanism in the context of ER stress. Its activity is regulated by 
phosphorylation and indirectly by O-GlcNAcylation. A 67kDa polypeptide (p67) 
binds to e1F-2 blocking its phosphorylation and subsequently inhibits protein 
synthesis(32). It is plausible that enhanced p67 glycosylation (Le. with AdOGT) 
binds to and blocks e1F-2 phosphorylation by e1F-2 kinase. Although transient 
reduction in protein synthesis may be pro-adaptive during the early stages of ER 
stress, prolonged blockade of protein synthesis is not viable. Therefore, one 
might predict that augmenting O-GlcNAc levels promotes p67 glycosylation and 
subsequent blockade of e1F-2 phosphorylation, as one potential mechanism in 
the present study. Such possibilities remain to be evaluated. 
Although the present study focuses on the acute effects of altered 0-
GlcNAc signaling, other studies interrogated the role of chronic elevation of 0-
GlcNAc levels and its possible role in diabetes. Several groups have shown that 
prolonged elevation of O-GlcNAc levels attenuates insulin signaling(307, 313), 
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though this issue is far from reconciled (29). In the heart, several studies have 
linked chronic elevation of O-GlcNAc levels to abnormal cardiomyocyte function. 
Clark et al. reported that in neonatal cardiomyocytes enhancing O-GlcNAc 
signaling with hyperglycemia, glucosamine, or OGT overexpression prolonged 
Ca2+ transient decays whereas diminishing O-GlcNAc signaling via 
overexpression of GCA, improved Ca2+ transients in cells subjected to 
hyperglycemia. Moreover, hyperglycemia decreased SERCA mRNA and protein 
expression and this was prevented by GCA overexpression(48}. Subsequently, 
Hu et al. showed that hearts from STZ-induced diabetic mice have increased 
OGT expression and O-GlcNAc levels, accompanied by cardiomyocytes 
dysfunction. GCA overexpression significantly reduced O-GlcNAc levels, 
increased SERCA expression, and improved function in both isolated 
cardiomyocyte and intact hearts compared to diabetic controls(135}. More 
recently, Hu et al. showed that several proteins of the mitochondrial ETC are 0-
GlcNAc modified (138). Moreover, hyperglycemia augmented glycosylation of 
mitochondrial ETC proteins and impaired mitochondrial function while 
overexpression of O-GlcNAcase reduced glycosylation of ETC proteins and 
reversed the hyperglycemia-mediated mitochondrial dysfunction(138}. Such 
efforts support the emerging notion that O-GlcNAc signaling participates in the 
pathogenesis of diabetes. Thus, acute and chronic effects of altered O-GlcNAc 
levels may have significantly different implications in the heart. One explanation 
for these potentially contradictory effects of enhanced O-GlcNAc signaling in the 
acute and chronic settings in the heart may be that acute increases in O-GlcNAc 
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signaling may be protective while chronic activation of O-GlcNAc signaling may 
produce adverse effects. Moreover, target proteins for O-GlcNAcylation in 
response to short-term increase in O-GlcNAc levels may be different from that 
due to sustained increases in O-GlcNAc signaling. Another possible explanation 
is based on the concept of allostasis. The theory of allostasis suggests that the 
initial biological response to an acute stress is the activation of processes that 
are protective and improve survival, however, as the allostatic load is increased; 
the stress becomes more frequent and/or continuous such that activation of the 
same pathways results in the development of pathology. Therefore, if 
augmented O-GlcNAc signaling is an acute survival response, the development 
of path physiology in chronic diseases like diabetes may be partially due to 
chronic activation of O-GlcNAc signaling. 
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CHAPTER VII 
SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
Summary of Findings 
Prior to this study, very few studies addressed the role of O-GlcNAc in the 
heart in general, and more so, no literature was available on its role in acute 
myocardial ischemia. The few studies that examined the role of O-GlcNAc in the 
heart were focused on its contribution to the development of diabetic 
card iomyopathy. 
Our study provides evidence that the heart recruits O-GlcNAc signaling 
system in times of stress (Figure 45). Oxidative and ER stress induced transient 
increases in O-GlcNAc signaling, while hypoxic/ ischemic stress trigger an initial 
decrease in O-GlcNAc signaling. This notion supports recent findings by 
several other groups showing that O-GlcNAc is a stress response signal. 
Moreover, we show that pharmacologic or genetic enhancement of O-GlcNAc 
signaling attenuated stress induced cellular damage while pharmacologic or 
genetic decrement exacerbated stress-mediated cell death. Therefore, acute 
increases in O-GlcNAc signaling in the heart promote resistance to stress, while 
short-term reduction in O-GlcNAc signaling sensitizes cells to stress-induced 
death. 
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We identified potential mechanisms through which enhanced O-GlcNAc 
confers cardioprotection. We show that O-GlcNAc mitigates components of 
mitochondrial mediated death pathway. As show in Figures 35 and 36, 
augmented O-GlcNAc signaling attenuates Ca2+ overload, ROS generation and 
subsequent mitochondrial permeability transition pore formation and loss of 
mitochondrial trans inner membrane potential. Besides mitigating mitochondrial 
induced death pathway, we show that O-GlcNAc signaling may confer 
cardioprotection via attenuating the activation of maladaptive unfolded protein 
response (Figure 45). Our proposed mechanisms are not the only likely 
mechanisms through which O-GlcNAc cardioprotects because numerous 
proteins are O-GlcNAc modified in the heart. 
Finally, we show that in vivo enhancement of O-GlcNAc levels reduce 
infarct size after ischemia-reperfusion in mice. Such data provide strong 
evidence that the protective effect seen associated with increasing O-GlcNAc 
levels at the cellular level and supported in isolated organ studies by Chatham's 
group can be translated to the in vivo environment. 
Although one limitation of this project is the use of young, healthy, isolated 
cardiomyocytes, such a reductionist approach was necessary to identify the role 
of the key enzymes that regulate O-GlcNAc modification, OGT and GCA, per se, 
and maintain the ability to elevate and reduce OGT and GCA activity. 
In conclusion, complete understanding of the protective role of O-GlcNAc 
in the heart may yield viable therapeutic options to combat post-ischemic 
myocardial injury. Moreover, the present study lays the groundwork for 
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understanding the role of O-GlcNAc in more complex cardiovascular phenotypes 
such as diabetes, hypertension, obesity, and other pathologies that predispose 
patients to heart disease. 
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Future Directions 
Further investigation is necessary to elucidate more fully how O-GlcNAc 
signaling confers cardioprotection at the level of the mitochondria and ER. 
For mitochondrial-mediated cardioprotective mechanism, future studies 
will focus on understanding the potential interaction between O-GlcNAc 
signaling, ROS generation, and mitochondria. Moreover, identifying specific 
proteins that are involved with O-GlcNAc-mediated reductions in Ca2+ overload is 
critical for the complete understanding of O-GlcNAc mediated cardioprotection. 
We will also determine if other components of the mPTP are O-GlcNAc modified. 
With respect to cardioprotection at the level of the ER, future studies will 
be geared towards identifying proteins involved with UPR that are O-GlcNAc 
modified. In addition, we will determine the mechanism through which O-GlcNAc 
attenuates ER stress. 
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Professional Memberships 
• American Heart Association (Basic Sciences Council) 
• American Physiological Society (Cardiovascular) 
• American Society of Pharmacology & Experimental Therapeutics 
(Cardiovascular) 
Invited Presentations (includes abstract oral presentations) 
10109/2008: Presented "O-GlcNAc Signaling: Novel Cardioprotective Signal" at 
the Research Seminar Series, Department of Physiology and 
Biophysics, University of Louisville School of Medicine, Louisville, 
KY. 
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04/09/2008: Presented "Q-GlcNAc Signaling Attenuates Mitochondrial 
Permeability Transition" at the "Mitochondria in Life and Death: 
From Biogenesis to Autophagy" symposium. Experimental Biology 
Meeting. San Diego, CA. 
04/08/2008: Presented "Q-GlcNAc Signaling Attenuates Mitochondrial 
Permeability Transition" at the 2008 ASPET Cardiovascular 
Division Graduate Student Best Abstract Competition. 
Experimental Biology Meeting. San Diego, CA 
01/22/2008: Presented "The Role of Q-GlcNAc Signaling in Acute Myocardial 
Ischemia" at the Research Seminar Series, Department of 
Physiology and Biophysics, University of Louisville School of 
Medicine, Louisville, KY. 
09/01/2009: Presented "Glycosylation and Myocardial Ischemia-Reperfusion 
Injury" at the Research Seminar Series, Department of Physiology 
and Biophysics, University of Louisville School of Medicine, 
Louisville, KY. 
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